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ABSTRACT OF THE DISSERTATION
Tumor Antigens Revealed By Exome Sequencing Drive Editing of Tumor
Immunogenicity
by
Matthew David Vesely
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2013
Professor Robert D. Schreiber, Chairperson

Accumulated data from animal models and human cancer patients strongly
support the concept that immunity cannot only function as an extrinsic tumor suppressor,
but also shape tumor immunogenicity. These observations led to the development of the
cancer immunoediting hypothesis that stresses the dual host-protective and tumorsculpting actions of immunity on developing cancers. We previously demonstrated
important roles for lymphocytes and type I (IFN-α/β) and type II (IFN-γ) interferons in
cancer immunoediting. In the present work, we confirmed the role of IFN-γ in sculpting
tumor immunogenicity and provide evidence that antigens expressed by tumors drive the
destructive or sculpting actions of immunity on cancers.
Initial studies confirmed the finding that IFN-γ is a critical mediator of cancer
immunoediting. Wild type mice treated with antibodies that neutralize IFN-γ developed
more sarcomas than control mice. Furthermore, a subset of sarcomas generated in IFN-γ
neutralized mice spontaneously reject when transplanted into wild type mice. Finally,
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these unedited tumors had differential requirements for IFN-γ responsiveness at the level
of the host and the tumor to mediate tumor rejection.
Although many immune components that participate in cancer immunoediting are
known (e.g. IFN-γ), its underlying mechanisms remain poorly defined. We used
massively parallel sequencing to characterize the expressed mutations in a highly
immunogenic sarcoma, d42m1, and identified mutant spectrin-β2 as the major rejection
antigen. Moreover, we demonstrate that editing of d42m1 tumor cells occurs via a T celldependent immunoselection process that promotes outgrowth of variants lacking mutant
spectrin-β2. Thus, the strongly immunogenic characteristic of an unedited tumor can be
ascribed to expression of a highly antigenic mutant protein.
Subsequent studies established that antigen loss variants of d42m1 and edited
sarcomas from wild type mice exhibit residual immunogenicity and respond to
checkpoint blockade immunotherapy (anti-CTLA-4). Exome sequencing of these tumors
has laid the groundwork for the eventual identification of the antigens targeted for
destruction by this form of cancer immunotherapy. Taken together, these studies
demonstrate that antigens drive the cancer immunoediting process and point to the future
potential that cancer genome sequencing may have on the fields of tumor immunology
and cancer immunotherapy.
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CHAPTER 1

Introduction to Cancer Immunoediting
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AN INTRODUCTION TO CANCER AND GENERAL MECHANISMS OF
CANCER SUPPRESSION

The fundamental mechanisms of cellular division and DNA replication carry the
inherent danger that the replication machinery will inevitably make mistakes, which
could compromise the integrity of the genome and potentially results in cancer formation.
Extensive research over the last half-century has revealed cancer to be a genetic disease
that arises by an evolutionary process where somatic cells acquire multiple mutations
overwhelming the barriers that normally restrain their uncontrolled expansion. The
devastation wreaked by cancer cells can be lethal, but fortunately, a number of intrinsic
and extrinsic tumor suppressor mechanisms exist to prevent their development.
A variety of intrinsic tumor-suppressor mechanisms attempt to repair genetic
mutations and will trigger senescence or apoptosis should repairs fail and cellular
proliferation become aberrant. Cellular senescence, a state characterized by permanent
cell-cycle arrest with specific changes in morphology and gene expression that
distinguish it from quiescence (reversible cell-cycle arrest), is induced by a number of
cellular proteins (e.g., p53) that sense genomic disturbances caused by mutagenic insults
(1). In addition, cellular senescence is also triggered by activated oncogenes and it is now
becoming more evident that escape from oncogene-induced senescence is a prerequisite
for cellular transformation such that cancer cells must acquire cooperating lesions that
uncouple mitogenic Ras signaling from senescence to proliferate indefinitely (2). Other
intrinsic tumor suppressor mechanisms, including p53, sense the activity of oncogenes
and initiate the programmed cell-death machinery. In response to cellular stress, injury
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or lack of survival signals, alterations in mitochondria integrity results in the release of
pro-apoptotic effectors that trigger cell death by terminal activation of executioner
caspases (3). In contrast, a second cell-death pathway is activated through ligation of cellsurface death receptors such as tumor necrosis factor receptor (TNFR), tumor necrosis
factor apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2, DR5), and Fas/CD95
(4) with their corresponding ligands of the TNF superfamily to induce the formation of a
signaling complex that activates the apical caspase 8 to initiate apoptosis. Additionally,
increasing attention is being placed on alternative cell death pathways such as necrosis,
autophagy and mitotic catastrophe that may halt the transformation process (3). In
general terms, both senescence and apoptosis prevent the acquired capability of cells to
proliferate without environmental cues and act as a potent barrier to the further
development of any pre-neoplastic cell. These cell-intrinsic prerequisite steps for the
transformation of normal cells into cancer cells were graphically illustrated and included
along with sustained angiogenesis, limitless replicative potential and tissue invasion and
metastasis by Hanahan and Weinberg in their landmark review “The Hallmarks of
Cancer” (5).
Since this famous review, at least three general extrinsic tumor suppressor
mechanisms have been identified by which cells and their adjacent tissues 'sense' the
presence of cancerous cells. All of these, to some extent, can be included under the
umbrella of mechanisms that prevent cancer cells from invading and spreading to other
tissues in the host. The first rests upon the mandatory dependency of cells for specific
trophic signals in the microenvironment that quell their innate suicidal tendencies such as
the epithelial cell – extracellular matrix association that when disrupted results in cell
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death (6). A second appears to involve key links between cell polarity genes that control
cellular junctions and proliferation, preventing cell cycle progression in the face of
dysregulated junctional complexes (7). A third extrinsic tumor suppressor mechanism
involves the limitation of transformation or tumor cell growth by effector leukocytes of
the immune system.
The immune system has three primary roles in the prevention of tumors. First, it
can protect the host from virus-induced tumors by eliminating or suppressing viral
infections. Second, the timely elimination of pathogens and prompt resolution of
inflammation can prevent the establishment of an inflammatory environment conducive
to tumorigenesis. Finally, the immune system can specifically identify and eliminate
tumor cells in certain tissues on the basis of their expression of tumor-specific antigens.
This third process, referred to as cancer immunosurveillance, occurs when the immune
system identifies transformed cells that have escaped cell-intrinsic tumor suppressor
mechanisms and eliminates them before they can establish malignancy. These effector
immune cells employ extremely diverse mechanisms to control tumor targets including
the induction of tumor cell death by mitochondrial and cell death receptor pathways and
thus, evasion of immunosurveillance is acknowledged to be an additional hallmark of
cancer (8-11). However, the immune system not only acts as an extrinsic tumor
suppressor, but paradoxically, also promotes cancer outgrowth. Together, the dual hostprotective and tumor-promoting actions of immunity are referred to as cancer
immunoediting.
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A MODERN HISTORY OF CANCER IMMUNOSURVEILLANCE AND
CANCER IMMUNOEDITING

The idea that the immune system, which so effectively protects the host from
microbial pathogens, might also recognize and destroy tumor cells was conceived 50-100
years ago (12-14). For over a century, the concept of cancer immunosurveillance has
been wrought with controversy (reviewed in detail in (8)) and by the early 1990s, little
attention was paid to the idea that natural immunity could eliminate tumors de novo.
However, interest in this aspect of tumor immunology was rekindled in the mid-1990s by
the observations that transplanted tumors grew more robustly in mice treated with
neutralizing monoclonal antibodies specific for interferon-γ (IFN-γ) (15) and that
immunodeficient mice which lacked either IFN-γ responsiveness (IFNGR1, a component
of the IFN-γ receptor) or an intact T cell compartment were more susceptible to 3’methylcholanthrene (MCA)-induced sarcoma formation (16-18).
In the last decade, work from many laboratories including our own have validated
the concept of cancer immunosurveillance, demonstrating, unequivocally, that the
immune system can indeed protect mice from outgrowth of many different types of
primary and transplantable tumors (15, 16, 19-25). An important study in 2001 provided
evidence that the immune system not only controlled tumor quantity but also tumor
quality (i.e., immunogenicity) (19). Immunodeficient mice lacking either IFN-γ
responsiveness or recombination activating gene-2 (RAG2) (the latter fail to generate T,
B, and natural killer T lymphocytes) develop more spontaneous neoplasia upon aging and
are more susceptible to MCA carcinogen-induced sarcomas compared to wild-type mice.
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In addition, a significant portion (40%) of MCA sarcomas derived from immunodeficient
Rag2-/- mice were spontaneously rejected when transplanted into naïve syngeneic WT
mice, while all MCA sarcomas derived from immunocompetent WT mice grew
progressively when transplanted into naïve syngeneic WT hosts (19). Thus, tumors
formed in the absence of an intact immune system are, as a group, more immunogenic
than tumors that arise in immunocompetent hosts. These results show that the immune
system not only protects the host against tumor formation, but also “edits” tumor
immunogenicity. These new data prompted a refinement of the cancer
immunosurveillance concept and led to the formulation of the cancer immunoediting
hypothesis, which stresses the dual host-protective and tumor-sculpting actions of
immunity on developing tumors.
We now view cancer immunoediting as a dynamic process comprised of three
distinct phases: elimination, equilibrium and escape (8, 26-32). Elimination is a
modernized view of cancer immunosurveillance where molecules and cells of both innate
and adaptive immunity work together to detect the presence of a developing tumor and
destroy it long before it becomes clinically apparent. In some instances, where tumor cell
destruction goes to completion, the elimination phase represents an endpoint of cancer
immunoediting. However, tumor cell variants may sometimes not be completely
eliminated but rather enter into an equilibrium phase where the immune system controls
net tumor cell outgrowth. In this equilibrium phase, tumor cells can become functionally
dormant and remain clinically unapparent for the life of the host. Thus, equilibrium also
represents a potential second stable endpoint of cancer immunoediting. Finally, either as
a result of changes occurring (a) in the tumor cell population due to an active
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immunoediting process or (b) in the host immune system, resulting from increases in
cancer-induced immunosuppression or immune system breakdown due to the natural
aging process, the functional dormancy of the tumor cell population may be broken,
leading to progression of these cells into the escape phase, where they begin to grow in
an immunologically unrestricted manner and emerge as clinically apparent disease. The
concept of cancer immunoediting is thus, a comprehensive interpretation of previous and
current clinical and experimental data, which integrates the immune system’s capacity to
both protect the host from cancer and promote cancer outgrowth through a multitude of
mechanisms. The observations that have led to the concept of cancer immunoediting are
reviewed here, with a particular focus on experimental data from various mouse models
of cancer and clinical data from human cancer patients.

THE ELIMINATION PHASE: CANCER IMMUNOSURVEILLANCE

Immune-mediated Cancer Elimination in Mice
In the first phase of the cancer immunoediting process, the elimination phase,
immune cells locate, recognize and destroy nascent transformed cells and prevent the
development of malignancy. This process has never been visualized in vivo, but rather
has been inferred from the earlier onset or greater penetrance of neoplasia in mice
defective for certain immune cell subsets, recognition molecules, effector pathways or
cytokines. Predominantly through the use of gene-targeted mice or by employing
neutralizing monoclonal antibodies (mAbs) in wild-type mice, this approach has
demonstrated that a number of immune effector cells and pathways are important for the
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suppression of tumor development. For the purposes of this introduction we will not
discuss a large literature where such mice have been challenged by transplanting a bolus
of tumor cells derived from wild-type (WT) mice, since these tumor cells originated by
escaping host immunity and therefore have already undergone cancer immunoediting.
There are three basic mouse models of cancer that are relevant to the discussion of cancer
immunoediting that illustrate the important role of immunity in eliminating developing
tumors: 1) carcinogen-induced tumors; 2) spontaneous tumors that arise upon aging; and
3) tumor development in mice genetically predisposed to cancer.

Carcinogen-induced Tumors in Immunodeficient Mice
Historically, the concepts of cancer immunosurveillance and immunoediting have
predominantly been demonstrated by exposing WT and immunodeficient mice to
carcinogens and comparing their relative tumor incidences. The advantages of regulating
tumor penetrance, tissue involvement and location in carcinogen-induced tumor models
is one reason why these models are widely employed by researchers and in some cases
they represent good mouse models of human cancer (e.g., asbestosis). The two most
commonly employed carcinogen-induced tumor models are sarcomas induced using 3’methylcholanthrene (MCA) and skin papillomas induced by a combination of 7,12-dimethylbenz[a]-anthracene (DMBA) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA).
To date, a number of mice with defined immunodeficiencies have been tested for their
susceptibility to carcinogens (31).
Cells of both the innate and adaptive immune system have been shown to be critical
for the elimination (i.e., cancer immunosurveillance) of primary MCA-induced sarcomas.
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Lymphocyte-deficient Rag1-/-, Rag2-/-, severe combined immunodeficient (SCID) and
nude mice all display an increased susceptibility to tumor induction after MCA exposure
(17-19, 33). Interestingly, 40% of tumors derived from Rag2-/- mice are rejected when
transplanted into WT recipients, but grow progressively in either Rag2-/- hosts or WT
hosts depleted of CD4+ and CD8+ T cells, whereas tumors derived from WT mice grow
readily when transplanted into either WT or Rag2-/- hosts. These observations
demonstrate that carcinogen-induced sarcomas derived from immunodeficient mice are
more immunogenic than those arising in mice with a functional immune system and
formed the basis for the cancer immunoediting concept (19). Subsequent studies found
that mice deficient for either αβ or γδ T cells display increased susceptibility to tumor
induction, indicating that	
  both lymphocyte populations are important in suppressing
MCA-induced tumors (23, 34). In addition, the innate-like lymphocytes are also critical
players in eliminating transformed cells. For example, mice lacking CD1d-restricted T
cells (Cd1d-/-) are more susceptible to MCA-induced sarcomas (35) suggesting that these
cells, which bridge the innate and adaptive arms of the immune system, also have a role
in suppressing MCA-induced sarcomas. Furthermore, mice lacking the Jα18 T cell
receptor (TCR) component are unable to generate the semi-invariant Vα14-Jα18–
containing TCR expressed by natural killer T (NKT) cells, resulting in the absence of
NKT cells, and rendering these mice more susceptible to MCA-sarcoma induction (36).
Consistent with a role for the innate immune cells in cancer immunosurveillance, mice
chronically depleted of NK cells displayed increased tumor incidence (37). One striking
study revealed that CD8α+ dendritic cells (DCs) of the innate immune compartment are
absolutely required for antitumor immunity and mice lacking these cells (Batf3-/-)
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displayed similar antitumor deficiencies as Rag2-/- mice (38). This may be explained in
part, due the role of CD8α+ DCs in cross-presenting antigens to lymphocytes. Even
eosinophils, whose role is more clearly defined in host-defense against helminths, can
protect the host from tumor development. Mice deficient in eosinophils (more
specifically eotaxin-, CCL11- and/or IL-5-deficient or ΔdblGATA) were more susceptible
to MCA-induced sarcoma formation than WT mice in both C57BL/6 and BALB/c
backgrounds (39). Remarkably, mice transgenic for IL-5 have greater circulating
numbers of eosinophils and were more resistant to MCA-sarcomas compared to WT
mice, strongly suggesting an immunosurveillance role for these innate immune cells (39).
A number of mice deficient for specific immune effector molecules and recognition
pathways have also been examined in the context of MCA-induced tumor susceptibility,
including mice lacking perforin (40), IFN-γ (40), IFNGR1 (16, 19), IFNAR1 or IFNAR2
(components of the type I IFN receptor) (24, 41, 42), TRAIL (43, 44), IL-12 (45), TNF-α
(42), and (DNAX accessory molecule-1) DNAM-1 (46). Each of these mouse strains
demonstrated enhanced susceptibility to sarcoma induction after MCA treatment,
suggesting that interferons and cytotoxic lymphocytes suppress tumor initiation in vivo.
Although WT mice treated with blocking antibodies specific for NKG2D (an activating
receptor expressed by CD8+ T cells, γδ T cells and NK cells) was reported to increase the
incidence of MCA-induced sarcomas	
  in two different mouse strains (47), C57BL/6
NKG2D-deficient mice had comparable numbers of MCA-induced sarcomas to WT mice
(48). In addition, although the rate of MCA-induced tumor formation was similar in the
presence or absence of the NK cell natural cytotoxicity receptor NKp46, the expression
of its unknown ligands was NKp46-dependent, suggesting some level of immunoediting
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by cells expressing this receptor (49).
Interferons can contribute to antitumor effects in a number of ways. IFN-γ can exert
direct effects on tumor cells (16) and a major effect of IFN-γ on these cells is to enhance
MHC class I expression, rendering them better targets for tumor-specific CD8+ T cells
(19, 50). In addition, IFN-γ signaling in host immune cells (51) and host stroma cells (52)
also plays an important role in the elimination of tumor cells, indicating that IFN-γ’s
effects in multiple cellular compartments generates antitumor immunity. Others have
proposed that IFN-γ contributes to an inflammatory foreign body reaction that results in
the encapsulation of injected MCA, limiting its spread and thereby reducing its
carcinogenic effects (53). However, this mechanism does not explain the findings of IFNγ preventing the formation of lymphomas induced by the soluble carcinogen N-methyl-Nnitrosourea (54), where encapsulation of the carcinogen is not possible. Furthermore, a
recent report demonstrated that MCA exposure induced more squamous cell carcinomas
(SCC) in the skin of IFN-γ-deficient mice than WT controls (55), indicating that MCA
delivery in a different tissue type than the previous subcutaneous injections also supports
a role for IFN-γ in mediating cancer immunosurveillance. In contrast to the antitumor
effects of IFN-γ occurring at both the level of the tumor and the host, the antitumor
effects of type I IFNs (IFN-α/β) are mediated only at the level of the host’s
hematopoietic system (24, 25, 56). Specifically, CD8α+ DCs of the innate immune
compartment are critical responders of type I IFNs such that selective deletion of
IFNAR1 in CD8α+ DCs results in tumor outgrowth of highly immunogenic sarcomas
(25). These results suggest that the ability of type I IFNs to induce antitumor activity in
immune cells might be the critical mode of action for this cytokine family and that IFN-γ
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and IFN-α/β have distinct, potentially non-overlapping mechanisms of action in
antitumor immunity.
As will be discussed later in this introduction, recent studies reveal that initiation of
MCA-induced sarcomas requires an inflammatory event. Along similar lines, skin
carcinomas induced by the topical application of DMBA (tumor initiator) followed by
repetitive doses of TPA (tumor promoter) are known to require inflammatory
components for tumor initiation and promotion. For example, the induction of
DMBA/TPA skin carcinomas is MyD88- (42), mitogen-activated protein kinase-activated
protein kinase-2 (MK2)- (57), TNF-α−	
  (58), receptor for advanced glycation endproducts (RAGE)- (59), and IDO-dependent (60). Lesions progress from benign
papillomas to metastatic SCC, and both the number of lesions and extant of tumor
progression is dependent on the mouse strain. Despite an inflammatory component,
DMBA/TPA induced tumors are also detected and destroyed by effector cells and
molecules of innate and adaptive immunity. For example, γδ T cells and CD8+ T cells
confer protection from DMBA/TPA-induced papillomas (23, 61). In contrast, CD4+ T
cells promote tumor progression, implying opposite roles for αβ T cell subsets in the
protection or promotion of DMBA/TPA skin carcinogenesis (61). One mechanism by
which γδ T cells and activated CD8+ T cells might regulate tumor development is through
recognition by NKG2D of the stress ligand retinoic acid early transcript 1 (RAE1) that is
induced in the skin after DMBA/TPA treatment and has been found to be upregulated in
transformed cells by the DNA damage pathway (23, 62). NKG2D-expressing dendritic
epidermal γδ T cells can kill RAE1-expressing targets in vitro (23), but in transgenic
mice expressing RAE1 in the skin, NKG2D expression is down modulated on
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lymphocytes and consequently these mice are more susceptible to papilloma induction
than WT mice (63). A follow up study using inducible RAE1 transgenic mice have
provided further insight into the previous observation, where acute upregulation of
NKG2D ligands triggered a swift reorganization of the local skin immune compartment,
resulting in local Vγ5Vδ1+ T cells limiting carcinogenesis, but unexpectedly Langerhans
cells promoted DMBA/TPA carcinogenesis	
  (64). Another innate recognition receptor,
DNAM-1 also protects tumor formation as Dnam1-/- mice develop more papillomas than
their WT counterparts (46).
In addition to cellular subsets and recognition receptors, effector molecules and
cytokines also have a critical function in controlling DMBA/TPA-induced skin tumors.
For example, although DMBA/TPA-treated TRAIL-R-deficient mice did not show an
increase in the number of benign papillomas or the rate of progression to squamous cell
carcinoma when compared to WT mice, metastasis to lymph nodes was significantly
enhanced, indicating a role for TRAIL-R specifically in the suppression of metastasis	
  
(65). One cytokine, IL-12, has been shown to protect mice against DMBA/TPA-induced
tumors, where mice that lack functional IL-12 (Il12a-/-) develop increased numbers of
papillomas compared to WT mice (66, 67).	
  Interestingly, mice that lack functional IL-23
(Il23a-/-) are resistant to tumor development (66, 67), however, the mechanism by which
IL-23 suppresses innate immunity and promotes tumor growth requires further
clarification since it was unexpectedly IL-17A-independent (67). Nevertheless, IL-17Adeficient mice also develop fewer skin papillomas than WT mice after DMBA/TPA
exposure, suggesting a tumor-promoting role for this cytokine (67). One peculiarity of
the DMBA/TPA model is that a loss of IFN-γ or IFNGR1 unexpectedly results in reduced
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tumorigenesis, hence playing and opposite role than in the MCA tumor model (68).
These observations demonstrate the pleiotropic effects that a single immune cell or
molecule can have during carcinogenesis and stress the importance of a multimodal
analysis. The interplay between antitumor immunity and cancer-promoting inflammation
suggested by the above studies is discussed at greater length below.
In addition to the demonstration of cancer immunosurveillance by immune effector
cells and molecules against tumors induced by chemical carcinogens, tumors induced by
physical carcinogens such as ultraviolet (UV) radiation also seem to be controlled by the
immune system (69). Interestingly, UV-induced immune suppression is an important
factor in the development of UV-induced tumors, and these tumors are often
immunogenic when transplanted into naïve hosts but grow in immunosuppressed or
CD8+ T cell-depleted (70). These data show that immunoediting can also be observed in
the UV radiation tumor model as well as the MCA chemical carcinogen model.

Spontaneous Tumor Development In Immunodeficient Mice
An elegant approach to examine the role of the immune system in controlling
tumor development is to simply remove specific components of the murine immune
system and monitor mice as they age for the development of spontaneous tumors. Mice
have long telomeres and display a very low incidence of spontaneous tumor
development. For example, we observe incidences of cancer in a variety of inbred WT
mouse strains that range from only 0-20% over a two-year period. While many
immunodeficient mice also do not develop cancers over a two-year observation period,
ageing studies have clearly demonstrated a critical role for certain cytotoxic pathways,
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lymphocyte cellular subsets, and cytokines in the prevention of spontaneous tumor
development. One striking example is the penetrance of immunogenic B cell lymphomas
in aged mice (>1 yr) on either C57BL/6 or BALB/c backgrounds that increases from 06% in wild-type mice to 40-60% in perforin-deficient mice (20, 22). Mice lacking this
key T cell and NK cell cytotoxic effector pathway develop an even greater prevalence of
B cell lymphomas with an earlier onset when they additionally lack the MHC class I
accessory molecule β2-microglobulin (β2m) or IFN-γ compared with perforin alone (22,
71). The absence of other lymphocyte cytotoxic pathways such as TRAIL or FasL also
increased the susceptibility of mice to spontaneous lymphomas (72, 73). Collectively,
these data provide very strong evidence that critical cytotoxic molecules in lymphocytes
protect the host from spontaneous tumor development. Intriguingly, human patients with
specific mutations in perforin that develop adult onset familial hemophagocytic
lymphohistocytosis (FHL) have recently been identified to also develop leukemia and
lymphoma, suggesting the possibility that perforin may protect against hematological
malignancies in humans (74).
Ageing experiments have also been performed in mice that lack one or more
lymphocyte subsets. Although, early studies in athymic nude mice did not document an
increase in spontaneous tumor development (75), one later study suggested that germ-free
nude mice did develop a low frequency of B cell lymphoma compared with heterozygote
littermates (76). Unlike other genetic models of immunodeficiency (e.g., SCID mice), the
absence of RAG-2 does not affect DNA damage repair pathways in non-immune cells
undergoing transformation. Helicobacter-negative 129/Sv Rag2-/- mice aged in a specific
pathogen-free mouse facility and maintained on broad-spectrum antibiotics developed
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significantly more spontaneous epithelial tumors (35% gastrointestinal and 15% lung of
all mice analyzed at 15–16 months of age) than their WT counterparts (19). Consistent
with these observations, 129/Sv RAG-2-deficient mice that also lack STAT1 (an
important mediator of signaling induced by both type I and type II IFNs) showed an
earlier onset and broader spectrum of malignancy, including the development of colon
and mammary adenocarcinomas (19). The role of specific lymphocyte subsets in the
prevention spontaneous tumor development has yet to be reported in mice lacking NKT
cells, γδ+ T cells or NK cells, but C57BL/6 β2m-deficient mice that lack NKT cells and
many CD8+ T cells did not have elevated tumor formation upon aging (71), suggesting
that distinct lymphocyte populations may play distinct roles, if any, during cancer
immunosurveillance of spontaneous tumors.
Similar to chemical carcinogen models of tumor induction, cytokines are critical
for the activation of immune effector mechanisms that limit spontaneous tumor
development. In one study, a small proportion (<15%) of BALB/c IFN-γ deficient mice
developed lung adenocarcinomas whereas almost half the IFN-γ-deficient mice on a
C57BL/6 background developed a spectrum of various T cell lymphomas, indicating
strain-specific differences in the contribution of IFN-γ to prevent spontaneous tumors
from occurring (22). In addition, C57BL/6 mice deficient for both perforin and IFN-γ
develop more B cell lymphomas with earlier onset than Pfp-/- mice, suggesting that in the
absence of perforin, IFN-γ can play a role in controlling lymphomas (22). Finally, female
mice deficient for the IFN-γ-inducible immunoproteasome subunit LMP2 develop
spontaneous uterine neoplasms with a disease prevalence of approximately 36% by 12
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months of age	
  (77). This observation suggests that IFN-γ inducible proteasome function
may be essential for MHC class I-mediated tumor rejection.
In addition to the role of cytokines in cancer immunosurveillance of spontaneous
tumors, a possible link between tumor immunity and autoimmune or infection-induced
inflammation has been raised by several studies. For example, 50% of mice lacking the
β2 subunit of the IL-12 receptor (IL-12Rβ2) develop plasmacytomas or lung carcinoma
concurrently with immune complex mesangial glomerulonephritis	
  upon aging (78). It is
presently unclear why IL-12p40–deficient mice on the same genetic background as the
IL-12Rβ2–deficient mice do not display either autoimmunity or spontaneous tumor
development	
  (22). Furthermore, mice deficient for both IFN-γ and GM-CSF have been
found to develop spontaneous tumors in a variety of tissues with age and, in this case,
tumor development is associated with acute or chronic inflammatory lesions (79).
Maintaining Gmcsf-/-Ifng-/- mice on a regimen of antibiotics delays tumor onset	
  
suggesting that in addition to potentially eliminating tumor cells directly, the immune
system might also prevent tumor growth by the timely elimination of infections, thereby
limiting inflammation, which is known to facilitate tumor development (80). However,
this finding cannot be generalized to all immunodeficient mice that develop spontaneous
malignancies since heightened tumor incidence was observed in Rag2-/- and Rag2-/-Stat1-/mice maintained on the same antibiotics regimen (as mentioned above).

Genetic Tumor Models in Immunodeficient Mice
Data supporting the ability of the immune system to suppress tumor development in
genetic models of mouse cancer are accumulating rapidly. Mice heterozygous for the
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tumor suppressor p53 (Trp53+/–) are genetically predisposed to tumor development, but in
the additional absence of IFNGR1 (16), perforin (20), TRAIL (72), or NKT cells (35),
more aggressive tumors develop with an earlier onset, providing very strong evidence
that these immune components participate in the elimination of nascent transformed cells.
More recently, a key role for perforin in immunosurveillance of B cell malignancies has
been validated in three different genetic models of B cell malignancies in C57BL/6 mice.
Similar to Pfp-/-Trp53+/- mice, perforin-deficient mice also heterozygous the tumorsuppressor Mlh1 developed more B cell lymphomas with faster kinetics than mice
lacking perforin alone (81).	
  Additionally, perforin protects against the development of
oncogene-driven tumors on a transgenic background, including v-abl-driven
plasmacytomas, and bcl2-driven follicular lymphomas (81).
Other transgenic mice that express oncogenes under the control of tissue-specific
promoters have also revealed immune-mediated protection from tumor formation. In one
example, IFN-γ suppresses tumor development in mice expressing the human T cell
leukemia virus (HTLV) type 1–derived oncogene Tax under the control of a granzyme B
promoter (HTLV-Tax transgenic mice) (82). Loss of a single TRAIL-R allele on the
lymphoma-prone Eµ-myc genetic background significantly reduced median lymphomafree survival corroborating an extrinsic tumor suppressor role for this cell death pathway
(83). The conclusion that NKG2D plays a critical role in cancer immunosurveillance is
further supported by the fact that mice defective in NKG2D are more susceptible to Eµmyc driven pre-B cell lymphomas (48). More recently, in a study using transgenic
adenocarcinoma of the mouse prostate (TRAMP) mice, investigators assessed whether
NKG2D controlled the growth of spontaneous oncogene-driven prostate cancer. NKG2D	
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deficient mice developed more aggressive tumors than WT mice and interestingly, these
aggressive tumors arising in NKG2D-deficient mice expressed higher amounts of
NKG2D ligands than did similar tumors in wild-type mice, suggesting an NKG2Ddependent immunoediting mechanism (48). Also in the same prostate cancer model, the
lack of NKT cells in TRAMP Jα18-/- mice correlated with more aggressive
adenocarcinoma development (84). Despite the presence of a traceable tumor antigenspecific T cell response in these mice, no evidence was found to support a correlation
between the presence of NKT cells and the efficacy of CTL responses in this setting.
Nevertheless, this study extends the list of spontaneously arising tumors in mice in which
NKT cells are critical for natural immune surveillance.
In summary, various cell types including αβ T cells, γδ T cells, NKT cells and NK
cells have all been implicated in the processes of elimination and immunoediting, along
with a number of effector molecules, including perforin and TRAIL, as well as the
cytokines IFN-γ, type I IFNs, and IL-12. More is known about the physiologically
relevant targets of IFN-γ's actions than the other effector molecules or cells during cancer
immunosurveillance. Both host and tumor cells are important targets of IFN-γ during the
development of protective antitumor immune responses and the data substantiating this
conclusion has already been extensively reviewed (8, 26, 27). It is important to note that
the effector cells and cytokines thought to be involved in elimination and immunoediting
differ among models, demonstrating that the success of immunoediting and the evidence
of its occurrence varies among experimental systems. Indeed, there are models in which
the immune system seems to have little influence on the rate of tumor onset or
progression	
  (85) and models in which the immune system has a distinct protective role,
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such as the carcinogen-induced and genetically-predisposed tumor models outlined
above. The level of immune regulation and tolerance (a state of non-responsiveness to
specific antigens) imparted by the tumors in each of these models might explain, at least
in part, why in some cases the effect of subtracting immune elements on tumor
progression is less overt. Blocking these tolerance mechanisms might reveal the true
mechanisms of tumor suppressor immunity. Moreover, recent studies have lent great
support for the cancer immunoediting hypothesis by validating the existence of the
equilibrium phase in multiple models and demonstrating that the immune sculpting
actions on tumor immunogenicity occur during this phase.

THE EQUILIBRIUM PHASE: IMMUNE-MEDIATED TUMOR DORMANCY

Historically, tumor dormancy is the term used to describe latent tumors present in
patients for decades that may eventually recur as local lesions or form distant metastases
(86). Tumors in the equilibrium phase are a subset of dormant tumors that are specifically
controlled by components of the immune system. In the equilibrium phase, the host
immune system and tumor cells enter a dynamic balance, wherein powerful antitumor
immunity contains, but does not fully eradicate, a heterogeneous population of tumor
cells, some of which have acquired means of evading immune-mediated recognition and
destruction. The equilibrium phase was originally hypothesized to exist in order to
explain the long latency period from the initial transformation event to the escape phase
and emergence of malignant disease. In this manner, equilibrium may be the longest of
the immunoediting phases where sculpting forces of immunity select for the tumor cells
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acquiring the most immunoevasive mutations, potentially leading to clinically detectable
disease.
Using a low-dose regimen of the carcinogen MCA, we reported the first
experimental demonstration that immunity maintains primary occult cancer lesions in an
equilibrium state (87). Treatment of naïve WT mice with low doses of MCA led to overt
tumors in only a low proportion of mice. When the remaining carcinogen-treated mice
were rendered immunodeficient via depletion of CD4+ and CD8+ cells and/or
neutralization of IFN-γ, sarcomas rapidly grew out at the original carcinogen injection
site in approximately 50% of the group. Strikingly, tumor outgrowth was not observed to
any significant extent (<10%) in similar MCA treated WT or RAG2-deficient mice
injected weekly with control mAb starting at day 200. Subsequent analyses revealed that
mAbs that depleted cells of adaptive immunity (such as CD4+ and CD8+ T cells) or
blocked cytokines that promote adaptive immunity (such as IFN-γ and IL-12) caused
dormant tumor cells to grow out. In contrast, mAbs that deplete NK cells (anti-NK1.1),
block NK cell recognition (anti-NKG2D) or inhibit NK cell effector function (antiTRAIL) failed to cause the emergence of progressively growing tumors (87). These
results support the conclusion that adaptive immunity, but not innate immunity, is
responsible for maintaining the equilibrium phase. They also help to mechanistically
distinguish this phase from elimination, where both innate and adaptive immunity are
required. Histological examination of occult tumors revealed the presence of atypical
fibroblasts surrounded by a dense infiltration of leukocytes. These atypical fibroblasts
were truly transformed since they formed progressively growing tumors when
transplanted into immunodeficient Rag2-/- mice. Moreover, occult tumors controlled by
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immunity displayed fewer Ki67+ atypical fibroblasts and more terminal deoxynucleotidyl
transferase dUTP end nick labeling (TUNEL) staining cells than progressively growing
sarcomas. The visualization of fewer proliferating tumor cells accompanied by more
cells undergoing apoptosis is supportive of an active immune response controlling
equilibrium tumors. Occult tumors arising after immunodepletion were, on the whole,
highly immunogenic with 40% of the cell lines rejecting after transplantation into WT
mice. In contrast, the rare spontaneous tumors that grew out of mice treated with control
mAbs were poorly immunogenic and grew progressively when transplanted into WT
recipients. Thus, tumor cells held in equilibrium by adaptive immunity remained highly
immunogenic and displayed an unedited phenotype while dormant sarcoma cells that
spontaneously escaped immune control to become actively growing tumors displayed
reduced immunogenicity, indicating that they had undergone editing.
In hindsight, these findings explain previously reported models of immunemediated tumor dormancy. In the past, most experimental models of tumor dormancy
relied heavily on a vaccination-and-challenge strategy with tumor cell lines to induce
latent tumor cells. For example, in the BALB/c B cell leukemia/lymphoma 1 (BCL1)
model of tumor dormancy, mice were immunized with BCL1-derived Ig to create an antiidiotype vaccine against the B cell Receptor (BCR) expressed by the lymphoma cells.
Naïve, non-immunized mice injected with BCL1 tumor cells succumbed to malignancy
within 30 days. In contrast, mice initially immunized with BCL1-derived Ig and
subsequently challenged with BCL1 tumor cells did not develop malignancy although
tumor cells could be detected in the circulation of cancer-free mice hundreds of days after
transplantation (88). Over an extended period of time, vaccinated mice challenged with
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live BCL1 tumor cells spontaneously developed malignancy, suggesting an escape from
dormancy. Interestingly, when mice harboring dormant BCL1 tumor cells were depleted
of CD8+ T cells or IFN-γ using mAbs, the incidence and duration of dormancy were
reduced, suggesting that the immune system plays an important role in controlling these
dormant tumor cells (88).
Using a BCR-ABL mouse model of leukemia, dormancy was also achieved via a
vaccination-and-challenge strategy. The longer the DA1-3b tumor cells remained
dormant within the vaccinated host, the greater the expression of programmed cell death
1 ligand 1 (PD-L1) on the tumor cells, which acted to confer resistance to cytotoxic T
lymphocyte (CTL)-mediated killing (89). Consistent with the concept of the equilibrium
phase, DA1-3b tumor cells acquired advantageous changes over time such that those cells
which remained dormant longer were more resistant to attack by CD8+ T cells.
Recently, two additional studies using different mouse models of cancer
corroborated our findings for the existence of the equilibrium phase by additionally
demonstrating that immunity can control primary carcinomas and metastases for
extended periods of time. The first study involved a new mouse model of cancer
immunosurveillance and equilibrium using ultraviolet B (UVB)-radiation to induce
squamous cell carcinomas of the skin. Here, the authors used mice genetically deficient
in E3 ligase Casitas B-lineage lymphoma b (Cbl-b), which is known to limit the effector
functions of CTLs (90). Thus, mice lacking Cbl-b exposed to UVB-radiation developed
fewer spontaneous squamous cell carcinomas compared to WT mice due to the enhanced
antitumor activity of CD8+ T cells that lack the Cbl-b regulator. Cblb-/- mice that failed
to form carcinomas 400 days after UVB treatment were then divided into two
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experimental groups. One group received mAbs that depleted CD8+ T cells, while the
other group received control mAbs. Only 10 days after starting mAb treatment, nearly
50% of mice depleted of CD8+ T cells developed rapidly growing tumors whereas none
of the mice receiving control mAb developed detectable tumors (90). It will be interesting
to determine in the future whether WT CD8+ T cells can also maintain occult UVBinduced carcinomas in an equilibrium state.
A second study demonstrates that immunity can prevent the outgrowth of
micrometastases for an extended period of time in an oncogene-driven model of
melanoma. In this model, transgenic mice that express the human RET oncogene and a
chimeric mouse/human MHC antigen (91) specifically in melanocytes were found to
develop extensive disseminated metastases (92). Depletion of CD8+ T cells in RET.AAD
mice significantly accelerated the outgrowth of metastatic lesions to visceral organs,
indicating that immunity is one significant barrier disseminated tumor cells must
overcome in order to establish metastatic disease (92). Interestingly, these CD8+ T cells
did not seem to directly kill the tumor cells, but rather mediated cytostatic effects on the
disseminated tumor cells. One likely mechanism underlying control of disseminated
tumor cell outgrowth may be via IFN-γ produced by tumor antigen-specific T cells,
which has been shown in other systems to inhibit cellular proliferation and curtail
angiogenesis (93-95). For example, in a pre-clinical model of pancreatic cancer using
RIP-Tag2 mice, the transfer of IFN-γ producing TNFR1+ CD4+ T cells specific for Tag
prevented the progression of pancreatic islet cancer (95). In this study, transferred Tagspecific T cells arrested tumor cell proliferation and prevented angiogenesis, curtailing
tumor growth and resulting in the inhibition of multistage carcinogenesis and induction of
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a period of extended tumor dormancy. In the absence of either TNFR1 signaling or IFN-γ
receptor signaling, the same T cells paradoxically promoted angiogenesis and multistage
carcinogenesis. Currently, the adoptive transfer of cancer-reactive T cells into human
cancer patients is an experimental therapy with promising results (96) and it will be
interesting to see if these therapies can be optimized as a viable therapeutic endpoint to
induce an equilibrium state in some patients.

THE ESCAPE PHASE: FAILURE OF CANCER IMMUNOSURVEILLANCE

While the processes of cancer elimination and equilibrium largely occur “behind
the scenes”, a more dramatic result of cancer immunoediting can occur when tumors
escape immune control, leading to the appearance of overt cancer. Thus, the escape phase
represents the failure of the immune system to either eliminate or control transformed
cells, allowing surviving tumor cell variants to grow in an immunologically unrestricted
manner. Cancer cells undergoing stochastic genetic and epigenetic changes generate the
critical modifications necessary to circumvent both innate and adaptive immunological
defenses. Moreover, the immune system contributes to tumor progression by selecting
more aggressive tumor variants, suppressing the antitumor immune response, or
promoting tumor cell proliferation. The interaction between a heterogeneous population
of cancer cells undergoing rapid genetic modifications and the constant immunological
pressure exerted by immune cells allows for the Darwinian selection of the most fit tumor
variants to survive and form overt cancer in immunocompetent hosts. Thus, nearly all
human cancers and experimental cancer cell lines are those that have evaded
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immunological control. The focus of this section on tumor escape is not to provide an
exhaustive list of escape mechanisms that have been extensively reviewed elsewhere (8,
9, 26, 27, 29, 97) but rather to shape the framework of how tumor cells achieve
immunological escape. Although, the mechanisms for tumor escape are varied, they can
be categorized generally as cell-autonomous modifications at the level of the tumor cell
that directly evade immune detection and destruction or modifications in immune cells
effected by tumor cells to generate an immunosuppressive network.

Tumor Cell Modifications to Evade Immune Detection or Destruction
Tumor escape can result from changes that occur at the level of the tumor by
directly inhibiting tumor recognition or cytolysis by immune effector cells. In some
cases, immune evasion by tumors is absolute and the immune system has little impact on
tumor progression, while in other cases tumor growth is delayed before the immune
system is overwhelmed, leading to tumor progression. In its simplest form, tumor cells
that express very weak antigens can evade detection due to the induction of central or
peripheral tolerance. Central tolerance is a process whereby self-reactive T cells are
eliminated or converted to a regulatory phenotype in the thymus (98). In this case, and in
the absence of neoantigen expression, tumors may remain “invisible” to the adaptive
immune system and are free to grow unhindered. Peripheral tolerance is an important
process whereby T cells reactive with self-antigens not expressed in the thymus are
deleted or rendered non-responsive in the periphery. In this case, some level of antitumor
immune response may be initiated transiently before tolerance is induced leading to
tumor progression (85, 99).
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In addition to tolerance induction, tumor cells can acquire defects in antigen
processing and presentation pathways that facilitate evasion from adaptive immune
recognition. Specifically, loss of TAP1, MHC class I molecules, β2-microglobulin,
LMP2, LMP7 and the development of IFN-γ or IFN-α/β insensitivity by tumor cells
prevents T cell-mediated elimination, resulting in tumor progression (28, 100-102). An
extreme version of this escape process occurs when tumors lose the ability to respond to
IFN-γ either through mutation or epigenetic silencing of genes encoding the IFN-γ
receptor signaling components (IFNGR1, IFNGR2, JAK1, JAK2 and STAT1) (103). In
this case, the affected tumor cells not only fail to upregulate MHC class I proteins but
also are unable to produce the intracellular machinery that facilitate antigen processing
and presentation (i.e., TAP1, TAP2 and components of the immunoproteasome). In
addition, genomic instability within tumor cells may result in the loss of tumor-specific
antigens creating antigen loss variants that are no longer detectable by antigen-specific
CD8+ T cells. Similarly, tumors can become unrecognizable to cells of the innate immune
system through loss of ligands for the NK cell effector molecule, NKG2D (104), or
suppressing the production of proinflammatory danger signals to impair dendritic cell
maturation (105). Thus, tumors cells may avoid recognition by adaptive or innate
immune cells by multiple mechanisms.
Additionally, tumor cells that are unable to avoid immune cell detection may
develop mechanisms to evade immune-mediated killing. Even when antigens continue to
be expressed, tumors can evade effector lymphocytes by upregulating expression of antiapoptotic molecules such as FLIP and BCL-XL (106, 107). Alternatively, resistance to
lysis by immune cells can be acquired through expression by tumors of mutated inactive
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forms of death receptors including the TRAIL receptor, DR5 (108), and Fas (109).
The above strategies of immune escape can be viewed as passive, involving the loss
of recognition or reduced sensitivity to apoptosis. However, tumor cells can take a more
active and direct role in subduing immunity through expression of immune-inhibitory
ligands on their surface that inhibit the cytotoxic actions of immune cells after tumor cell
recognition in a cell-contact mediated manner. The expression of B7-H1 (PD-L1) (110),
HLA-G (111), and HLA-E (112) on the cell surface of tumor cells interacts with
receptors on the cell surface of T cells to dampen the cytotoxic actions of T cells or
induce apoptosis within the T cell itself. In addition, tumor cell expression of HLA-E or
HLA-G can modify the actions of innate immune cells by inducing tolerance in antigenpresenting cells and inhibiting NK cell-mediated killing (111). The actions of tumor cells
to impede the development of antitumor immune responses is not limited to changes that
occur directly at the level of the tumor, but also result from the elaboration of cytokines
and molecules that act at a distance to generate an extensive immunosuppressive network
that facilitates tumor progression.

Generating an Immunosuppressive Tumor Microenvironment
The development of an immunosuppressive environment concomitantly with tumor
development is evidenced by observations in which protective responses against
transplantable tumors can be generated when immunotherapies are delivered prior to
tumor challenge, but fail against established tumors (113). Importantly, failure of therapy
against established tumors seems to be due to local immunosuppression in the tumor
microenvironment since tumor-bearing mice can often respond normally to other antigens
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(114). The development of an immunosuppressive state is achieved by tumor cells that
inhibit the function of effector immune cells or recruit the efforts of regulatory immune
cells to evade immunological elimination in a paracrine or endocrine manner.
Tumor cells secrete factors to directly inhibit the function of sentinel immune cells
of both the innate and adaptive arms of immunity. For example, tumor cells can block T
cell and NK cell function through secretion of soluble forms of ligands for effector
molecules, as has been reported for shed ligands of NKG2D (115). In addition, antitumor
immunity can be subverted at an early stage by tumor-derived factors that inhibit
dendritic cell (DC) function. In response to danger signals and cellular stress, DCs are
stimulated to mature, migrate, and carry tumor antigens to lymph nodes to alert the
adaptive arm of immunity to the presence of transformed cells. To inhibit this initial
immune priming event, tumor cells secrete sterol metabolites to suppress the expression
of CCR7 on the cell surface of DCs, thereby disrupting DC migration to the lymph nodes
(116). A recent study demonstrates that unknown tumor-derived factors induce the
expression of scavenger receptor A on DCs, resulting in excessive uptake of extracellular
lipids that reduces their capacity to process antigens (117). Furthermore, many tumors
produce VEGF, which is critical for the establishment of one of the hallmarks of cancer
development, angiogenesis, but also prevents endogenous DC function. Targeted
monoclonal antibodies against VEGF improve DC function in vivo and improve the
efficacy of cancer immunotherapies (118).
Simultaneous inhibition of multiple stages in the development of antitumor
immunity can be achieved through the liberation of immunosuppressive cytokines by
tumor cells. For example, TGF-β secretion by tumor cells leads to inhibition of DC
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activation as well as direct inhibition of T cell and NK cell function (119). Similarly, IL10 present within tumors can suppress DC function and skew T cell responses toward a
type 2 immune response that is less effective against malignant cells (120). However, the
role of IL-10 in tumor immunity remains somewhat obscure because it has also been
shown to enhance immune destruction of tumors (121).
Other tumor-derived factors can be more selective in inhibiting particular
components of immune responses but can still effectively suppress immunity. For
example, production of galectin can impede T cell activity and survival, and blocking this
factor can aid tumor rejection in mice (122). In addition to using cytokines and lectins to
down-regulate immune responses, tumors can secrete enzymes that metabolize amino
acids within the tumor microenvironment. Specifically, expression of indoleamine 2,3dioxygenase (IDO) by tumor cells metabolizes tryptophan to generate kynurenines and
inhibits CD8+ T cell proliferation and promotes CD4+ T cell apoptosis (123). Two
potential mechanisms of immune inhibition include starvation, where depletion of this
important amino acid weakens T cells, and metabolite cytotoxicity, where metabolic
products of tryptophan degradation inhibit T cell function (124).
In addition to the mechanism described above, a variety of immunosuppressive
regulatory leukocytes can suppress immune function leading to tumor escape. Regulatory
T cells (Tregs), largely expressing CD4, CD25 and Foxp3 and have been demonstrated to
inhibit CTL function in a number of ways including IL-10 and TGF-β production,
CTLA-4 and PD-L1 expression and IL-2 consumption (125). This regulatory lymphocyte
is the critical mediator of peripheral tolerance under physiological settings, but is often
recruited to the tumor site where it suppresses antitumor immunity. Furthermore, TGF-β
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production by tumor cells can induce effector T cells into regulatory T cells that now
suppress other effector T cells infiltrating the tumor mass (126). Experimental tumor
models that eliminate regulatory T cells, results in robust antitumor immune responses
and the rejection of transplanted or primary tumors (127). In addition to Tregs, other
regulatory lymphocyte populations can be found in subsets of natural killer T cells and B
cells that inhibit effector responses against transformed cells (128, 129).
The production and elaboration of GM-CSF, IL-1β, VEGF, and PGE2 by tumors
leads to expansion of myeloid-derived suppressor cells (MDSCs) and their accumulation
within the tumor mass (130). MDSCs are a heterogeneous group of myeloid progenitor
cells and immature myeloid cells that can inhibit lymphocyte function by a number of
mechanisms including the production of immunosuppressive cytokines (TGF-β) (131),
the depletion or sequestration of amino acids arginine or cysteine that are required for T
cell function (132), the inhibition of T cell activation by TCR nitrosylation (133) and the
induction of regulatory T cells (134). The multiplicity of mechanisms that inhibit
lymphocytes in either an antigen-specific or antigen-nonspecific manner most likely
reflects distinct cellular subsets within the MDSC heterogeneous population (135).
In addition to MDSCs, plasmacytoid dendritic cells (pDCs) are recruited to the
tumor mass and become key players in the immunosuppressive network. Ovarian cancer
cell products activate pDCs, which in turn, induce the expansion of IL-10 producing
CD8+ regulatory T cells (136). A potentially novel subset of DCs, sometimes referred to
as vascular leukocyte cells (VLCs) or Tie2+ monocytes, is recruited to the tumor bed by
β-defensins and induce their endothelial-like specialization, where they in enhance
vasculogenesis and suppress conventional DC function through the secretion of VEGF
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and other pro-inflammatory cytokines (137). A recent study by Shields et al. identified
lymphoid tissue inducer (LTi) cells that are recruited by CCL21-secreting melanomas
and contribute to the development of an immunosuppressive tertiary lymphoid structure
within the tumor mass that recruits MDSCs, regulatory T cells, and polarizes monocytes
to M2 macrophages (138). Many tumors attract tumor-associated macrophages (TAMs)
by IL-4 and IL-13. M2 macrophages can inhibit antitumor immunity through the
production of TGF-β and IL-10, and can promote stromal development and angiogenesis
through secretion of platelet-derived growth factor (PDGF) (139).
Together, these examples demonstrate that, in addition to central and peripheral
tolerance, failure of antitumor immunity can be due to the development of an
immunosuppressive microenvironment. Any one, or combination of several, of the above
cellular and molecular mechanisms can contribute to suppression of tumor immunity. The
balance between these inhibitory mechanisms and immune stimulating conditions
determines whether or not tumors escape immune responses and the rate of tumor
progression. In human cancer patients, immunosuppression of lymphocytes within the
tumor microenvironment has also been widely observed for a variety of cancer types
(140). In the next section we will discuss the evidence for cancer immunoediting in
humans, with particular emphasis on the elimination and equilibrium phases.

EVIDENCE FOR CANCER IMMUNOEDITING IN HUMANS

The extensive studies discussed above clearly demonstrate that the immune
system not only protects against tumor development, but also shapes tumor
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immunogenicity in mouse models of cancer. The question therefore naturally arises
whether cancer immunoediting occurs in humans. Humans are not clean models of
immune deficiency such as those that exist in experimental mice that live in controlled
environments. Nevertheless, compelling clinical data support the existence of cancer
immunoediting in humans. Here, we will not discuss the mechanisms of tumor escape in
humans since they greatly overlap with those observed in mice (discussed above) and
have been extensively reviewed elsewhere (8, 9, 26, 27, 29, 97), but rather we will review
data supporting an active immune response eliminating or controlling cancer in humans.

Acquired Immunodeficiency and Cancer Risk
While severely immunodeficient humans succumb to infections relatively early,
advances in the management of acquired immunodeficiencies have led to extended
survival of patients with partly compromised immune systems. Evidence for
immunosurveillance can be found in patients with AIDS who have an increased
frequency of malignancies (141). Most often, these malignancies are virus-associated and
initiated by viral oncogenes, including lymphomas (Epstein-Barr virus), Kaposi’s
sarcoma (herpesviruses) and urogenital cancers such as cervical cancer (human papilloma
viruses) (142). While the antigenic targets of the above malignancies are not fully
characterized, viral antigens can certainly be expressed, and an argument can be made
that the increased frequency of virus-associated cancers reflects a breakdown in anti-viral
immunity rather than reduced immunosurveillance of cancer. However, support for
immunosurveillance can be found in malignancies of non-viral origin.
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The incidence of non-virally-induced tumors in AIDS patients is less well
documented, but, there is evidence of an increased incidence of solid cancers in AIDS
patients, particularly lung adenocarcinomas (143). While a large proportion of HIVinfected individuals may be exposed to other lifestyle risk factors, including smoking, the
association of lung cancer in AIDS patients has been demonstrated to be independent of
smoking (144), with a 3.5-fold elevated risk of lung cancer for AIDS patients compared
to the wider population.

Immunosuppressed Organ Transplant Recipients and Cancer Risk
Some level of immunodeficiency can be induced in humans by the use of
immunosuppressants following organ transplantation, and an increase in the incidence of
malignancies in these patients suggests a role for immunosurveillance in humans. Greater
cancer prevalence among transplant recipients has been observed in a range of transplant
situations using a variety of immunosuppressants. For example, patients receiving kidney
transplants display a 3-fold increase over the general population in the overall incidence
of malignancy. While virus-associated malignancies predominate, there was also an
increased risk for developing non-infectious cancers of the colon, lung, pancreas, kidney
and endocrine system (145). Additionally, a dramatic increase in risk (200-fold) of nonmelanoma skin cancers has been demonstrated in renal transplant patients, suggesting a
particularly important role for cancer immunosurveillance at this site exposed to
ultraviolet irradiation (146). Finally, melanomas have also been observed to increase in
frequency in these renal transplant patients, but to a lesser degree (2-10 fold) than other
skin cancers (146, 147).
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Interestingly, incidences of some cancers including breast, prostate, ovarian, brain
and testicular have not been observed to increase in the context of pharmacologicallyinduced immunosuppression, but it is not clear if these malignancies are less
immunogenic or simply take longer to develop. These data support the notion that de
novo malignancies arise due to the permissive environment created by
immunosuppressive regimens, which inhibit cancer immunosurveillance mechanisms.
Further supporting the link between immunosuppression and malignancy are
observations of spontaneous remissions of lymphomas after cessation of
immunosuppression (148).

Spontaneous Immune Responses to Cancer
The spontaneous recognition and destruction of human cancers by cells of the
adaptive immune system substantiates the occurrence of cancer immunosurveillance in
humans. As early as the 1970s, screening cancer cell lines with autologous patient serum
identified spontaneous antibody responses to autologous cancers in a subset of patients
(149, 150). Antibody responses in patient serum have been reported for over 100 tumorassociated antigens, although only 8 antigens have been identified in multiple reports
suggesting that many immunogenic mutations might be unique for each individual cancer
(reviewed in (151)). Among the shared antibody responses were those against the cancertestis antigen NY-ESO-1 and the mutant forms of tumor suppressor p53, which are often
overexpressed in many different types of human malignancies (152, 153). The high
frequency of antibodies specific for tumor-associated antigens in cancer patients
compared to healthy individuals suggests that immunity has been induced in response to
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malignancy. The reasons for spontaneous antibody responses in cancer patients are not
known, but may include an over-abundance of antigen or its enhanced presentation to
generate immunogenicity in the malignant setting.
The phenomenon of spontaneously regressing melanoma lesions accompanied by
the clonal expansion of T cells is arguably the strongest evidence for the elimination
phase of cancer immunoediting in humans	
  (154-156). These responses, observed in the
absence of specific immunotherapy, support the ability of the immune system to
spontaneously recognize antigens on/in tumors. Specific CD4+ and CD8+ T cell activity
against tumor-associated antigens, including NY-ESO-1, are known to develop
spontaneously in human cancer patients (157, 158). However, spontaneous T cell
responses specific for some tumor-associated antigens (TAA) such as the MAGE family
are very rare (159), while those specific for the melanocyte differentiation antigen
MART-1/Melan-A have been found in a relatively high percentage (>50%) of healthy
individuals (160). Thus, there is a strong correlation between spontaneous T cell
responses and some tumor-associated antigens but not others, and it is not clear whether
the presence of TAA-specific T cells in healthy individuals reflects past exposure to
transformed cells expressing the antigen. More studies are needed to identify tumorassociated and tumor-specific antigens in a variety of cancers to determine the relative
abundance and uniqueness of tumor antigens.
Other spontaneous immune responses against malignant cells have been
demonstrated in patients with paraneoplastic autoimmune disorders (PND) caused by
cross-reactivity between the antitumor immune response and neurologic antigens (161).
In addition to antibody responses, tumor-specific T cells have also been identified in
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patients with PND (162). Nearly all patients with PND die from cancer or neurologic
disease; however, the few surviving patients have complete tumor remission in response
to therapy and no longer manifest any neurological impairment. These dramatic clinical
cases demonstrate that the tumor antigens are the driver of both beneficial immune
responses against neoplastic tissues and pathological immune responses against normal
tissues (i.e., neurons). Interestingly, PND symptoms can precede tumor diagnosis by a
number of years (163), indicating that antitumor responses might be primed by
undetectable, microscopic tumors early in their evolution. It remains to be determined
whether the antitumor immune response substantially delays tumor growth in patients
with PND and such analysis is likely to be confounded by the lethality of the neurologic
complications. Nevertheless, the presence of anti-neuronal antibodies has been reported
to correlate with improved prognosis at least for some neurological malignancies (164),
and there are some case reports of spontaneous complete remission in the absence of
specific treatment (165). Spontaneous tumor regression accompanied by lymphocyte
infiltration has also been noted for a number of other tumor types (reviewed in (30))
however, the role of the lymphocyte infiltrate in tumor regression has not been
established in these cases due to their rarity. Even in the absence of spontaneous tumor
regression, tumor-infiltrating lymphocytes (TILs) appear to be controlling tumor
outgrowth and enhancing patient survival, as discussed below.

Tumor-Infiltrating Lymphocytes as a Prognostic Indicator
Further support for cancer immunoediting can be found in reports that correlate the
frequency of tumor-infiltrating lymphocytes (TILs) with patient survival. Tumor
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infiltration by T cells, NK cells, or NKT cells have been associated with an improved
prognosis for a number of different tumor types (91, 166-172). However, tumor
infiltration by some leukocytes, such as macrophages and regulatory T cells, has a
detrimental impact on patient survival (173). The initial association between favorable
patient prognosis and TILs was first observed in patients with melanoma (166, 167),
where it was reported that patients with high levels of CD8+ T cell infiltration survive
longer than those whose tumors contain low numbers of lymphocytes. Since then,
various melanoma-specific antigens have been identified in addition to melanomaspecific T cells in patients with melanoma (reviewed in (174)).
In a landmark study in ovarian cancer, the presence of TILs in ovarian cancer tissue
specimens correlated with better prognosis. Specifically, 38% of patients with high
numbers of TILs survived over 5 years as compared to 4.5% of patients with low
numbers of TILs (168). These findings have been confirmed in subsequent studies for
ovarian cancer (169) and for other malignancies including melanoma (175) and colon
cancer (170-172). Particularly elegant studies on colon and lung cancers reveal a tight
correlation between the quality and quantity of intratumor immune responses and patient
survival (171, 172). Remarkably, the type and density of lymphocytes infiltrating these
cancers was a more powerful prognostic indicator than previous pathological criteria for
tumor staging, underscoring the need for clinical pathologists to consider infiltrating
immune cells when determining a patient’s prognosis. In fact, the results of these studies
provide strong evidence for the equilibrium phase of cancer immunoediting in humans.
Enhanced survival of some cancer patients is associated with particular subsets of T cells
such as the intratumor localization of CD8+ T cells and Tregs (91, 169, 170). A
	
  

38

particularly interesting disagreement concerns the significance of Tregs in tumors, where
some groups find a correlation between the presence of Foxp3+ Tregs in tumors with a
poor prognosis (176, 177), while other studies report better prognosis if Tregs are present
in tumor tissue samples (178, 179). Reasons for these different outcomes are not clear,
but may be related to the type of malignancy involved.

Immunogenicity of Cancers with Microsatellite Instability
All cancers are inherently genetically unstable and this instability seems to be a
contributing factor in the capacity of immune cells to detect and control tumor cells. For
example, the infiltration of colorectal cancer by CD8+ T cells is associated with a
favorable prognosis (170-172), as discussed above, and this association is further
strengthened in cases where tumors exhibit high levels of a particular type of genetic
instability referred to as microsatellite instability (MSI), where defects in DNA mismatch
repair mechanisms lead to the duplication or deletion of short repeated sequences of
DNA known as microsatellites (180, 181). Strikingly, MSI-high (MSI-H) tumors are
often strongly infiltrated with lymphocytes, including activated CD8+ T cells (181), and
contain tertiary-lymphoid follicles (180) indicative of a potent local immune response.
The high rate of mutation in MSI-H tumors has been shown to result in the generation of
a number of novel tumor antigens that can be recognized by B cells, CD4+ T cells, and
CD8+ T cells. Together, these findings suggest that the generation of antigenic peptides
as a result of genomic instability might result in the priming of a protective CD8+ T cell–
mediated immune response in patients with MSI-H colorectal cancers. An interesting
possibility is that these findings are not unique to colorectal cancers, but apply to other
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human cancers as well (182).

Cancer Equilibrium in Human Patients
A plethora of clinical evidence suggests that occult cancers can lay dormant in
patients for many years, sometimes exceeding 20 years, before malignant disease
progresses to clinically detectable levels (183). For example, 20-45% of patients with
breast or prostate cancer will relapse years or even decades later (184-186). Such a
lengthy and protracted period from initial cancer remission to cancer recurrence may, in
part, be explained by immunological constraints placed on the remaining cancer cells. In
some cases, circulating disseminated cancer cells exist for decades after treatment
without the re-establishment of clinical disease from these persistent cancer cells (187).
This is known as minimal residual disease and it appears to be a common reservoir of
cancer cells for most cancer types after the initial therapeutic intervention, but whose
mechanisms for maintenance are poorly understood. Minimal residual disease is of
critical importance since the vast majority of morbidity and mortality associated with
cancer is due to metastatic lesions that are presumed to be seeded by these persistent
cancer cells. There is evidence that immunosuppressive intervention for various
conditions can be associated with a greatly increased risk of cancer relapse even after
long periods of time. In one study, three out of eight patients (37%) experienced cancer
relapse following immunosuppression after more than 10 years of remission while cancer
patients in remission for 10 years or more that had not undergone immunosuppressive
treatment had only a 2% relapse rate (183).

	
  

40

One remarkable clinical scenario that suggests immunity can prevent the
outgrowth of occult lesions is the unintentional transplantation of cancer cells from organ
donor to immunosuppressed recipient. In these scenarios, organs were harvested from
deceased donors, who either had no previous clinical history of malignancy or were in
cancer remission and had no overt signs of disease at the time of organ donation and
transplantation into recipients. The recipient patients undergoing immunosuppression for
organ engraftment later developed clinically detectable cancers of donor origin (188,
189). A subset of these donor-derived malignancies were from donors with no previous
history of cancer, suggesting a state of equilibrium operating between cancer cells in the
primary lesion and the donor’s immune system that subsequently broke down after
transplantation into immunosuppressed recipients.
Clinicians have long-observed that the immune system mounts a response against
pre-neoplastic cells in monoclonal gammopathy of unknown significance (MGUS) but
does not eliminate them, eventually allowing MGUS to progress to multiple myeloma
(190). The ability to detect this premalignant phase of disease allows for immunologic
monitoring throughout disease progression	
  and such monitoring has revealed that T cells
derived from the bone marrow of patients with MGUS mount strong responses to
autologous premalignant cells, but these responses are absent in patients with multiple
myeloma (191). These findings are consistent with the idea that T cells may hold premalignant cells in check for an extended period of time (i.e., equilibrium) but eventually
fail to control some abnormal plasma cell clones that ultimately give rise to multiple
myeloma (i.e., escape). Additionally, treatment of low-grade B cell lymphoma by
administering antibodies specific for the idiotype expressed by the malignant cells results
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in remission of disease without entirely eliminating the tumor cells and that these
circulating lymphoma cells are detected up to 8 years after treatment without any other
signs of progressive disease (192). These results suggest that equilibrium may be a viable
therapeutic endpoint for the treatment of cancer, and in such a case, interventions may be
necessary to stabilize the equilibrium phase indefinitely and prevent the immunoselection
of tumor cell variants possessing novel mutations that eventuate in resistance to immune
attack.

Summary of Human Cancer Immunoediting
As discussed above, there is considerable clinical evidence for the cancer
immunoediting process in humans even though cancer patients are a genetically and
immunologically diverse population. The confluence of these very complex factors may
explain why spontaneous immune responses occur in only a proportion of individuals and
why some patients respond better to certain immunotherapies. The differences in an
individual’s immune repertoire, the capacity to process and present antigens, the quality
and quantity of tumor antigens generated as well as the ability of cancer to suppress
antitumor immunity all help to determine the overall outcome. Future advances in gene
expression and proteomics of human cancers and their antigens will provide greater
insight into the mechanism of cancer immunoediting in humans, which may be critical in
determining which patients benefit from particular treatments.
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CANCER-RELATED INFLAMMATION AND CANCER IMMUNOEDITING:
INTERDEPENDENT PROCESSES

Inflammation is a broad and complex physiological process that maintains tissue
homeostasis in response to tissue stressors such as infection or tissue damage (193).
Rudolph Virchow, who established the cellular basis of pathology, was the first to
propose the link between inflammation and cancer in the 1860s when he observed
leukocytes infiltrating neoplastic tissues (194). We now appreciate that chronic
inflammation can contribute to cancer initiation by generating genotoxic stress, cancer
promotion by inducing cellular proliferation, and cancer progression by enhancing
angiogenesis and tissue invasion. On the other hand, there is overwhelming evidence that
immunity against transformed cells can develop to protect the host from cancer formation
as discussed above. Each of the six cell-intrinsic hallmarks of cancer can influence the
immune system (9) and the cancer immunoediting process attempts to describe the varied
outcomes of tumor-immune system interactions including immunosurveillance (antitumor), immunoselection (pro-tumor) and immunosubversion (pro-tumor). We maintain
that cancer immunoediting and tumor-promoting inflammation are not mutually
exclusive processes, but rather potentially overlapping immune algorithms (195).
This overlap was most clearly demonstrated in the MCA model where sarcoma
induction was shown to depend on immune cells and molecules that promote
inflammation including MyD88, IL-1β, IL-10, IL-23 and regulatory T cells (42, 67, 127,
196, 197), but then led to the development of host-protective immune responses that
resulted in tumor destruction (e.g., IFN-γ, IFN-α/β, T cells, etc.). For example, the
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functionally related heterodimeric cytokines, IL-23 and IL-12, both contain the IL-12p40
subunit but activate distinct receptors that share the IL-12Rβ1 subunit and play different
roles in response to transformed cells. Specifically, loss of IL-23 reduced the incidence of
MCA-induced sarcomas, while IL-12-deficient mice developed more sarcomas when
compared to WT mice (67).
Similarly, the DMBA/TPA model of skin carcinogenesis is known to have a major
inflammatory component contributing to tumor development, however, γδ T cells, IL-12
and DNAM-1 all participate in immunosurveillance and prevent skin carcinoma
formation (23, 46, 66). Therefore, tumor-promoting inflammation and cancer
immunosurveillance can co-exist within the same tumor models at the same tissue site,
although they may be temporally distinct. For example, both MyD88 and IL-1β have
been shown to promote tumorigenesis in a number of primary carcinogen models (42,
196, 198, 199), but MyD88 and IL-1β are also critical in the development of antitumor
immunity against established tumors through the recognition of dying tumor cells
undergoing ‘immunological death’ (200-202). Furthermore, the same component of the
immune system may promote or prevent tumor formation depending on the biological
context in which it acts. For example, mice genetically-deficient for TNF-α develop more
sarcomas than WT mice after exposure to MCA (42), indicating a host-protective role for
this cytokine, while TNF-α-deficient mice develop fewer skin carcinomas than wild-type
mice after exposure to DMBA/TPA (58), indicating a tumor-promoting role for TNF-α.
One mechanism for TNF-α’s ability to protect the host against tumor formation is the
priming, proliferation, and recruitment of tumor-specific T cells that was observed in an
oncogene-driven pancreatic cancer model (203).
	
  

44

Finally, inflammation participates in the cancer immunoediting process during the
tumor escape phase, where inflammatory cells and regulatory immune cells are recruited
and activated by cancer-derived products to dampen antitumor immunity and subvert
immune cells to promote cancer progression. To develop more effective
immunotherapies, immunologists must identify the cellular and molecular players that
either eliminate or promote cancer development and what conditions influence that fate.
For this reason, inhibitors of the pro-inflammatory transcription factors NF-κB and
STAT3 may be therapeutically useful in switching the nature of the tumor
microenvironment from one of tumor-promoting inflammation to that of tumoreliminating immunity (204, 205).

LESSONS FROM CANCER IMMUNOEDITING

As our molecular understanding of cancer immunoediting increases, strategies can
be developed to harness the power of immunity to protect against cancer development.
Targets for therapeutic intervention can be found at each stage of the immunoediting
process from elimination to equilibrium to escape. The identification of key immune
molecules and cells important in the elimination of nascent transformed cells may
provide opportunities to boost specific aspects of immunity to induce tumor regression.
Furthermore, development of therapeutic strategies that stabilize tumor masses by
inducing an equilibrium state is a viable clinical endpoint that has not been fully
implemented by oncologists, but could greatly enhance patient survival. Another
potential strategy targeting the equilibrium phase are those that attempt to stabilize tumor
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cell genetic instability, thereby halting progression from tumor equilibrium to tumor
escape. The inhibition of tumor escape mechanisms may render tumor cells visible for
immune-mediated destruction and thus many pharmacological agents have been
generated for this end.
Targets of tumor escape mechanisms currently in clinical trials or in the pipeline
include antibody blockade of the immunosuppressive moieties CTLA-4, PD-L1, and PD1. In the case of CTLA-4 blockade, a recent Phase 3 clinical trial reported that patients
with metastatic melanoma survived longer after treatment with CTLA-4 blocking
antibodies, making this drug one of the most successful immunotherapies that targets the
immune system (206). Furthermore, strategies to inhibit immunosuppressive cytokines
such as VEGF, enzymes such as IDO and anti-apoptotic molecules such as Bcl-2 are also
being pursued. Undoubtedly, chronic inflammation contributes to both cellular
transformation and tumor progression, but less is known about what aspects specifically
induce cancer formation. Inhibitors of pro-inflammatory transcription factors may reduce
tumor development and switch the tumor microenvironment from tumor-promoting
inflammation to tumor-eliminating immunity.
Ultimately, high-throughput screening of cancer genomes and proteomes are
required to identify polymorphisms and mutations in immune pathways that limit human
cancer development and progression. Insights gained from deciphering the molecular
underpinnings of the cancer immunoediting process could lead to strategies for
manipulating the cellular and molecular microenvironment of tumors in the hope of
inducing immune-mediated eradication or stabilization of malignant disease.
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CHAPTER 2
Global Neutralization of IFN-γ Confirms its
Role in Preventing Primary Tumors and
Shaping Tumor Immunogenicity
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INTRODUCTION

IFN-γ in Tumor Immunity
IFN-γ Protects the Host from Transplantable and Primary Tumors
Over a decade ago, renewed interest in cancer immunosurveillance came from
several studies that revealed a critically important role for IFN-γ in host tumor immunity.
The first was the demonstration that endogenously produced IFN-γ protected the host
against the growth of transplanted tumors and the formation of primary chemically
induced and spontaneous tumors. Using tumor transplantation approaches, the LPSdependent rejection of the MethA fibrosarcoma was abrogated in mice treated with
neutralizing antibodies specific for IFN-γ (clone H22) (15). Second, using models of
MCA-induced tumor formation, 129/SvEv mice lacking either the IFN-γ receptor or
STAT1 were found the be approximately 10-20 times more sensitive than wild type mice
to tumor formation after carcinogen exposure. Specifically, IFN-γ insensitive mice
developed more tumors than their wild type counterparts and showed a shortened tumor
latency period (16). These results were confirmed by subsequent independent
experiments using mice on a different genetic background that lacked the gene encoding
IFN-γ itself (40). Similarly, mice lacking both the p53 tumor suppressor gene and
IFNGR1 formed a wider spectrum of tumors compared to IFN-γ-sensitive mice lacking
only p53 (16). In addition, Ifng-/- mice on a C57BL/6 background showed an increased
incidence of disseminated lymphomas despite the presence of a normal p53 tumor
suppressor gene (22). Taken together, data from transplantation approaches as well as
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chemical and spontaneous tumor induction studies clearly demonstrate a physiologically
important role for IFN-γ in host-protection against tumors.

IFN-γ Acts Directly on Tumor Cells to Exert its Antitumor Effects
The demonstration that endogenous IFN-γ is critical to protect the host from both
transplantable and primary tumors prompted a search for the physiologically important
targets of the antitumor actions of IFN-γ. Due to fact that nearly every host cell expresses
the IFN-γ receptor and that IFN-γ is very pleiotropic, there are many likely cellular
targets in vivo that are important for the direct actions of IFN-γ in the tumor rejection
process. A recently published study from our lab used bone-marrow chimera approaches
to demonstrate that IFN-γ sensitivity in both non-hematopoietic and hematopoietic host
tissues are contributing to the antitumor response of IFN-γ (25). A fellow graduate
student in lab, Sang-hun Lee, has recently generated a conditional floxed IFNGR1 mouse
to address which hematopoietic and non-hematopoietic cells of the host are targets of
IFN-γ’s antitumor effects. Future studies using this mouse will elucidate which host cells
require IFN-γ sensitivity to mediate tumor rejection, but there is also evidence that IFN-γ
acts directly on tumor cells to exert its antitumor effects. In one study, MethA tumor
cells described above were engineered to be unresponsive to IFN-γ by overexpression in
these cells of a mutant dominant-negative IFNGR1 (IFNGR1ΔIC) (15). The paralysis of
cellular IFN-γ responsiveness abrogated the LPS-dependent rejection of MethA when
transplanted into syngeneic wild type mice. In a second study, an opposite approach was
employed using a tumor generated in an Ifngr1-/- mouse. When transplanted into wild
type mice, the Ifngr1-/--derived tumor, RAD.gR28, grew progressively. However, the
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reconstitution of IFNGR1 expression in this tumor resulted in its rejection upon
transplantation into syngeneic immunocompetent mice (16). These results have
subsequently been corroborated by the observed increases in tumorigenicities of the SCK
mammary adenocarcinoma and K1735 melanoma when both tumors were significantly
impaired in their IFN-γ responsiveness using the dominant-negative IFNGR1ΔIC (207).
Taken together, these data from different tumor systems show that IFN-γ acts directly on
tumor cells to exert its antitumor effects.
Although there is a plethora of data demonstrating that IFN-γ is critical to mediate
protection against primary and transplantable tumors, there is less direct evidence of IFNγ as an immunoeditor. In this study, we globally neutralize IFN-γ in wild type mice with
an anti-IFN-γ mAb (clone H22) and treat these mice with the chemical carcinogen, MCA,
to generate sarcomas that developed in the absence of IFN-γ, but retain sensitivity to IFNγ (as opposed to tumors generated in Ifngr1-/- mice). A subset of these sarcomas are
rejected in wild type mice and thus are highly immunogenic tumors that resemble
unedited tumors derived from Rag2-/- mice (19). These results provide definitive evidence
that IFN-γ edits primary MCA sarcomas.
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MATERIALS AND METHODS
Mice. Ifngr1-/- mice (208) on a 129/Sv background were originally provided by Dr.
Michel Aguet and were bred in our specific pathogen-free animal facility. Wild type and
Rag2-/- mice were purchased from Taconic Farms. All mice were on a C57BL/6
background and were housed in our specific pathogen-free animal facility. For all
experiments, mice were 8-12 weeks of age and performed in accordance with procedures
approved by the AAALAC accredited Animal Studies Committee of Washington
University in St. Louis.

Generating primary MCA sarcomas. 3-methylcholanthrene (MCA) (Sigma) was
dissolved in corn oil at a concentration of 0.66 µg/ml by placing a polystyrene container
in a water bath that is just below boiling temperature for 3-4 hrs. Stock MCA was then
diluted with additional corn oil to desired concentration and injected into the shaved
flanks of mice in a volume of 150 µl as previously described (16).

Tumor cell lines. 3-methylcholanthrene (MCA) induced sarcomas used in this study
were generated in C57BL/6 strain wild type or Rag2-/- mice and banked as low passage
tumor cells as previously described (19). Tumor cells derived from frozen stocks were
propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10% FCS
(Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the flanks of
recipient mice. Tumor cells were >90% viable at the time of injection as assessed by
trypan blue exclusion and tumor size was quantified as the average of two perpendicular
diameters.
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Antibodies. Anti-IFN-γ (H22), anti-CD4 (GK1.5), anti-CD8α (YTS169.4) mAbs and
control immunoglobulin (PIP, a mAb specific for bacterial glutathione S-transferase)
were produced from hybridoma supernatants and purified in endotoxin-free form by
Protein G affinity chromatography (Leinco Technologies, St. Louis, MO). IFNGR1-PE,
H-2Db-PE, H-2Kb-PE and purified anti-CD16/32 were purchased from BioLegend (San
Diego, CA).

Expression vectors. The dominant negative version of the IFNGR1 subunit
(IFNGR1ΔIC) was expressed into H31m1 and d42m1 tumor cells as previously described
(15).

Measurement of MHC class I expression. Tumor cells were treated with 100U/ml IFNγ for 48-72 hrs. MHC class I expression on the cell surface was analyzed by flow
cytometry using H-2Kb or H-2Db antibodies conjugated to PE.

Flow cytometry. For flow cytometry, cells were stained for 20 minutes at 4°C with 500
ng of Fc block (anti-CD16/32) and 200 ng of H-2Kb, H-2Db, or IFNGR1 in 100 µL of
staining buffer (PBS with 1% FCS and 0.05% NaN3 (Sigma)). Propidium iodide (PI)
(Sigma) was added at 1 µg/mL immediately before FACS analysis. Events were collected
on a FACSCalibur (BD Biosciences) and analyzed using FloJo software.

Statistical Analysis. Samples were compared using an unpaired, two-tailed Student’s t
test and Mantel-Cox for tumor incidence.
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RESULTS

Global Neutralization of IFN-γ Prevents Primary MCA Sarcoma Formation
Using IFN-γ neutralizing antibodies (H22), we sought to corroborate the finding
that mice lacking IFN-γ are more susceptible to MCA-sarcoma induction. A key
distinction from the previous studies that used gene-targeted mice lacking either IFN-γ
responsiveness (Ifngr1-/-) or IFN-γ itself (Ifng-/-) is that tumors generated in anti-IFN-γ
mAb treated mice will be of wild type origin and have normal IFN-γ sensitivity. Two
cohorts of 15 female C57BL/6 mice were injected with 25 µg of the MCA chemical
carcinogen. One cohort was treated with 750 µg of anti-IFN-γ mAb (H22) on Day -1 and
then 250 µg of anti-IFN-γ mAb weekly for the duration of the experiment. The second
cohort was treated with a similar dosing schedule, but was treated with control
immunoglobulin (PIP). When wild type C57BL/6 mice injected with 25 µg of MCA
were chronically treated with the control Ig, 67% (10/15) of mice developed
progressively growing sarcomas. In contrast, wild type C57BL/6 mice chronically
treated with neutralizing anti-IFN-γ mAbs developed more MCA sarcomas (14/15; 93%)
with a shorter latency than control mice, confirming that IFN-γ protects the host from
primary carcinogenesis (Mantel-Cox p=0.0373) (Figure 1). This result verifies that IFN-γ
is a critical player in the immunosurveillance against primary MCA sarcomas.
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Figure 1. Global neutralization of IFN-γ protects against primary MCA sarcoma
formation. Two cohorts of 15 C57BL/6 mice were each treated with 25 µg of the
carcinogen MCA. One cohort received weekly injections of control antibodies (PIP)
(black) while the other cohort received weekly injections of neutralizing IFN-γ antibodies
(H22) (red). Tumor incidence was monitored weekly and compared using Mantel-Cox
(p=0.0373).
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Global Neutralization of IFN-γ Shapes MCA Sarcoma Immunogenicity
To test whether IFN-γ edits MCA sarcomas from wild type mice, tumors from
mice treated with control mAbs or anti-IFN-γ mAbs were harvested, disaggregated,
collagenase-treated, and cultured to generate tumor cell lines. All MCA-sarcoma cell
lines were frozen after four in vitro passages, subsequently thawed and injected into both
wild type and Rag2-/- recipients. All of the tumors derived from control Ig treated wild
type mice grew progressively when transplanted into both wild type and Rag2-/- hosts
(data not shown). Similarly, all tumors derived from IFN-γ-neutralized mice grew
progressively when transplanted into Rag2-/- mice (Figure 2). In contrast, 30% (3/10) of
cell lines derived from IFN-γ-neutralized mice were spontaneously rejected upon
transplantation into wild type mice, indicating that these tumors are highly immunogenic
unedited sarcomas (Figure 2) similar to MCA sarcomas generated in Rag2-/- or Ifnar1-/immunodeficient mice (19, 24). These data suggest that IFN-γ sculpts tumor
immunogenicity and, to date, is the best evidence that endogenous IFN-γ can alter tumor
immunogenicity during primary tumor development. In addition, this is the first
demonstration that unedited sarcomas can be generated using blocking monoclonal
antibodies in wild type mice.

Highly Immunogenic Sarcomas that Developed in the Absence of IFN-γ Require
CD4+ T cells, CD8+ T cells and IFN-γ for Their Rejection
Three highly immunogenic sarcomas from wild type mice chronically treated with
neutralizing IFN-γ antibodies are spontaneously rejected when transplanted into wild type
mice (Figure 2). We have designated these three tumors (H22-28027, H22-28030, and
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H22-28032) collectively as H22 regressor tumors since they display an unedited
phenotype similar to a subset of tumors derived from immunodeficient Rag2-/- mice that
we have termed Rag2 regressors (19). The fact that these H22 tumors grow progressively
in Rag2-/- mice, strongly suggests that lymphocytes are critical mediators of their
rejection. We next explored what specific components of adaptive immunity are required
to reject each of these highly immunogenic H22 regressor tumors. For the first tumor,
wild type mice were transplanted with 1x106 H22-28027 tumor cells and subsequently
treated with antibodies that neutralize IFN-γ (H22), deplete CD4+ T cells (GK1.5) or
CD8+ T cells (YTS-169.4) and were monitored for tumor growth. The unedited H2228027 tumor grows progressively in wild type mice that were treated with antibodies that
neutralize IFN-γ, deplete CD4+ T cells or CD8+ T cells, suggesting that all of these
adaptive immune components are required for tumor rejection (Figure 3). Similar results
were obtained for the other two H22 regressor tumors H22-28030 and H22-28032 (Figure
3), suggesting that IFN-γ, CD4+ and CD8+ T cells are required for the rejection of all
three immunogenic tumors derived from MCA-treated, IFN-γ-neutralized wild type mice.
The requirement of adaptive immunity to specifically target these highly immunogenic
sarcomas is identical for the subset of unedited sarcomas derived from Rag2-/- mice,
providing further evidence that these H22 regressors are unedited due to the blockade of
IFN-γ signaling in the host.
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Figure 2. Tumors from IFN-γ-neutralized mice show an unedited phenotype. In a
panel of 10 MCA sarcomas from wild type mice that were chronically treated with antiIFN-γ mAbs (H22), three (30%) tumor cell lines were spontaneously rejected upon
transplantation into wild type recipients (highlighted in blue).
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Figure 3. Highly immunogenic sarcomas require components of adaptive immunity
for their rejection in wild type hosts. a, All three highly immunogenic H22 regressors,
H22-28027, H22-28030, and H22-28032 grow progressively when transplanted (1 x 106
cells) into wild type mice that are treated with mAbs that deplete CD4+ T cells (GK1.5),
deplete CD8+ T cells (YTS-169.4), or neutralize IFN-γ. b, Percentage of mice with
progressively growing tumors from 2-3 independent tumor transplantation experiments.
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Differential Requirements for Tumor Cell and Host Cell IFN-γ Responsiveness for
the Rejection of Each Individual H22 Regressor Tumor
The finding that highly immunogenic H22 regressors grow progressively in wild
type mice treated with IFN-γ neutralizing antibodies (Figure 3) established that IFN-γ is
critical for the rejection of these tumors. However, IFN-γ can exert its antitumor effects
on both cells of the host and well as the tumor cell itself (15, 16, 25). To test whether
IFN-γ responsiveness was required at the level of the host, tumor cells were transplanted
into Ifngr1-/- recipients. Both H22-28027 and H22-28030 were mostly rejected upon
transplantation into mice lacking host IFN-γ responsiveness. In contrast, H22-28032
grew progressively when transplanted into Ifngr1-/- mice (Figure 4). These results
suggest that H22-28032 requires host IFN-γ sensitivity for its rejection while H22-28027
and H22-28030 tumors do not require IFN-γ sensitivity at the level of the host alone for
their rejection. Given that global neutralization of IFN-γ through the use of anti-IFN-γ
mAbs results in the growth of all three H22 regressors, but only H22-28032 requires IFNγ sensitivity at the level of the host for its rejection, we next addressed whether IFN-γ
sensitivity at the level of the tumor is required for tumor rejection.
To generate IFN-γ-insensitive variants of the H22 regressors, each tumor was
transduced with a dominant negative version of the IFNGR1 subunit, which lacks the
intracytoplasmic domain required for IFN-γ receptor mediated signaling (IFNGR1ΔIC)
that has been previously described (15). Each tumor cell line expressing IFNGR1ΔIC
upregulates H-2Db and H-2Kb class I proteins in response to recombinant murine IFN-α5
and IFN-β, but fails to express any class I proteins on its cell surface after treatment with
recombinant murine IFN-γ, indicating that IFNGR1ΔIC tumors are selectively and
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completely insensitive to IFN-γ (Figure 5). H22-28027 tumor cells lacking IFN-γ
responsiveness (H22-28027ΔIC) grow progressively when transplanted into wild type
mice in a manner that is indistinguishable from growth in Rag2-/- mice (Figure 6). Thus,
IFN-γ responsiveness at the level of tumor, but not the host, is necessary for the rejection
of H22-28027 tumor cells. Interestingly, H22-28030ΔIC tumor cells are rejected upon
transplantation into wild type mice suggesting that neither IFN-γ sensitivity at the level of
the host nor at the level of the tumor alone is sufficient for tumor rejection. To test
whether IFN-γ sensitivity at the level of the host and tumor are both required for tumor
rejection, H22-28030ΔIC tumor cells should be transplanted into Ifngr1-/- mice. Unlike
H22-28027 and H22-28030 tumors, which are rejected upon transplantation into Ifngr1-/mice, host IFN-γ responsiveness alone is required to mediate tumor rejection of H2228032 as this tumor grows progressively in Ifngr1-/- mice. Nevertheless, we investigated
whether IFN-γ responsiveness at the level of the tumor was also contributing to rejection
of H22-28032 tumors. H22-28032ΔIC tumor cells that are insensitive to IFN-γ display a
partial growth phenotype when transplanted into wild type mice (Figure 6). Overall, in
two independent experiments, H22-28032ΔIC tumors grew in half of wild type mice
(5/10) upon transplantation (Figure 6), suggesting that there is a role for IFN-γ sensitivity
at the level of the tumor and the host. Similar to H22-28030, IFN-γ responsiveness at the
level of the tumor and the host may both be required to achieve maximal protection from
H22-28032 tumors.
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Figure 4. H22-28032 grows progressively in Ifngr1-/- hosts. Mice deficient for
IFNGR1 and thus lack IFN-γ responsiveness in host cells were injected with 1 x 106 cells
of H22-28027, H22-28030, or H22-28032. (Experiments performed by Sang Hun Lee, a
pre-doctoral candidate in the Schreiber laboratory).
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Figure 5. H22 regressor sarcoma cells rendered insensitive to IFN-γ. H22-28027,
H22-28030, H22-28032 tumor cells were transduced with a dominant negative version of
the IFNGR1 subunit (IFNGR1ΔIC) or control retrovirus (RV) and tested for capacity to
upregulate expression of cell surface MHC class I molecules (H-2Db) using flow
cytometry after the addition of murine recombinant IFN-α5, IFN-β, or IFN-γ for 48 hrs in
vitro.
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Figure 6. H22-28027 and H22-28032 require tumor cell responsiveness to IFN-γ for
tumor rejection. a, Dominant negative versions of the IFNGR1 receptor subunit were
expressed in H22-28027, H22-28030, and H22-28032 unedited sarcomas and
transplanted into wild type mice (blue) or Rag2-/- mice (red). In addition tumors
transduced with an empty retrovirus vector were transplanted into wild type mice (black)
as a control. b, Percentage of mice with progressively growing tumors from two
independent tumor transplantation experiments.
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DISCUSSION

Several studies from our lab and others have demonstrated that IFN-γ is critical in
mediating anti-tumor immunity, especially from primary tumor formation. Mice
deficient in IFN-γ (Ifng-/-), IFN-γ responsiveness (Ifngr1-/-), or IFN-γ signaling (Stat1-/-)
all develop more chemically induced MCA sarcomas and spontaneous tumors upon aging
than their wild type counterparts (16, 19, 22, 34). Recently, a new study reported that
IFN-γ also protects from primary skin carcinomas induced by intradermal injection of
MCA (55). This study confirms earlier reports that IFN-γ is necessary for the prevention
of skin carcinomas and papillomas in the DMBA/TPA inflammatory model (23). Due to
the powerful antitumor actions of IFN-γ, one would expect that tumors would evolve
mechanisms of immune escape by rendering components of IFN-γ signaling ineffective.
Indeed, many human and mouse cancers have lost responsiveness to IFN-γ due to
mutations in signaling components downstream of the IFN-γ receptor (16, 97). For
example, JAK1 is epigenetically silenced in the human prostate cancer cell line LNCaP
and thus is unable to upregulate class I antigen processing and presentation machinery in
response to IFN-γ and IFN-α/β (103).
In addition to the tumor-preventing roles of IFN-γ, there are a few studies that
also provide evidence for the tumor-sculpting roles of IFN-γ on developing cancers. One
such study generated cell lines from MCA-treated Ifngr1-/- mice and showed that
reconstitution of these cell lines with IFNGR1 results in tumor rejection when
transplanted into naïve wild type mice (16). Subsequent studies demonstrated that these
cell lines could also be rendered immunogenic by enforcing expression of TAP1 (19) or
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H-2Db (A.T. Bruce and R.D. Schreiber, unpublished results). However, spontaneous
lymphomas that formed in C57BL/6 Ifng-/- mice were found not to be immunogenic and
grew progressively when transplanted into wild type recipients (22). In contrast,
spontaneous lymphomas from perforin-deficient mice were immunogenic and were
rejected when transplanted into wild type mice (20, 22). Thus, although there is evidence
that IFN-γ is important for sculpting tumor immunogenicity, it is mostly inferred either
from (a) already edited tumors that have lost IFN-γ sensitivity, or (b) tumors that lack
functional IFN-γ receptors rendered immunogenic by reconstitution of functional
receptors. Here, we unequivocally demonstrate that IFN-γ is involved in editing tumor
immunogenicity in a primary tumor model and confirm its actions on both host cells and
tumor cells to mediate host-protective, anti-tumor functions.
Using neutralizing antibodies against IFN-γ, we chronically treated wild type
mice exposed to MCA and documented that these mice develop more primary MCA
sarcomas than control Ig treated mice, further validating IFN-γ’s role in preventing
primary tumors. Importantly, we generated 10 tumor cell lines from these mice and
found that 3/10 (30%) sarcomas spontaneously rejected in wild type mice—a finding that
is remarkably similar to Rag2-/- mice and Ifnar1-/- mice where 40% and 36% of the MCA
sarcomas are highly immunogenic regressors, respectively (19, 24). In addition, these
highly immunogenic H22 regressors resemble typical unedited sarcomas generated in
Rag2-/- mice in that they require IFN-γ, CD4+ T cells and CD8+ T cells for their rejection.
As these tumors require IFN-γ for tumor rejection, we next explored whether host cells or
tumor cells were the critical targets for IFN-γ. In support of previous studies, we found
IFN-γ responsiveness is required on both tumor cells and host cells for tumor rejection
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(15, 16, 25). However, each of the three H22 regressors had different combinations of
host and tumor cell requirements for IFN-γ responsiveness to mediate tumor rejection, a
result that is in contrast to Rag2-/- MCA sarcomas generated on a 129/Sv background
where either IFN-γ responsiveness at the level of the host or the tumor alone is sufficient
to mediate tumor rejection (25) (C.M. Koebel and R.D. Schreiber, unpublished results).
Taken together, these data suggest that IFN-γ sculpts tumor immunogenicity and,
to date, is the best evidence that endogenous IFN-γ can alter tumor immunogenicity
during primary tumor development. In addition, this is the first demonstration that
unedited sarcomas can be generated using blocking monoclonal antibodies in wild type
mice. Although we do not yet know the host cell targets and thus the mechanisms of
action for IFN-γ, one likely mechanism is IFN-γ’s role in facilitating the recognition of
tumor-specific antigens by lymphocytes that leads to tumor cell destruction. The
remainder of this thesis dissertation will explore the role that tumor antigens play in
driving the cancer immunoediting process.
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CHAPTER 3
Exome Sequencing of the Highly
Immunogenic, Unedited d42m1 Sarcoma
Identifies its Major Rejection Antigen
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INTRODUCTION

A central tenet of tumor immunology in general, and the cancer immunoediting
process in particular, is that tumor cells express antigens that distinguish them from their
non-transformed counterparts, thus permitting their recognition by T cells and their
ultimate destruction by immunological mechanisms. Since the first human tumor antigen
was identified in 1991 (209), several tumor antigens have been cloned and can be
classified in the following five categories: 1) differentiation antigens (e.g., melanocyte
differentiation antigens, tyrosinase); 2) mutational antigens (e.g., abnormal forms of p53);
3) overexpressed/amplified normal proteins (e.g., HER2/neu); 4) cancer-testis antigens
(e.g., NY-ESO-1); and 5) viral antigens (e.g., human papilloma virus) (8). Subsequent
studies have also identified tumor antigens in the murine system (210, 211).
Inherit genomic instability of tumor cells allows some variants to acquire
additional mutations that are able to evade immunological detection. Specifically, tumor
cells may lose sensitivity to the interferons, resulting in the reduction of tumor antigen
processing and presentation (97, 101). Furthermore, numerous studies have
demonstrated that the immune system can select for tumor variants better suited for
survival in an immunologically intact environment. Specifically, when P815
mastocytoma or ultraviolet-induced 1591 fibrosarcoma cells are serially transplanted into
immunocompetent hosts, tumor variants emerge with reduced immunogenicity (211,
212).
Although a deep understanding of human and mouse tumor antigens currently
exists (32), it comes nearly entirely from analyses of tumor cells derived from
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immunocompetent hosts which were likely subjected to the sculpting forces of cancer
immunoediting. Little is known about the antigens expressed in nascent tumor cells,
whether they are sufficient to induce host-protective, anti-tumor immune responses or
whether their expression is modulated by the immune system. We realized that these
questions might be answered by defining the antigens expressed in unedited sarcoma cell
lines derived from 3’-methylcholanthrene (MCA) treated, immunodeficient Rag2-/- mice
since these tumors phenotypically resemble highly immunogenic, nascent primary tumor
cells (87). However, current methods to identify tumor antigens using expression cloning
approaches (209, 211) are time and effort intensive and are not well suited to establishing
a tumor’s antigenic profile. Recent advances in the field of genome sequencing have
made possible rapid and cost effective methods to define cancer genomes and have
established that whereas cancer cells acquire some mutations involved in the
transformation process (driver mutations), they also express many passenger mutations
that develop, in part, as a consequence of genomic instability (213). These tumor-specific
mutant proteins have been proposed, but never proven, to represent tumor-specific
antigens for T cells (214).
Herein, we use a modified from of exome sequencing to define the mutational
profile of two independent, unedited MCA sarcomas (d42m1 and H31m1). This
technique, involving cDNA capture by biotinylated mouse exome probes (Agilent)
followed by deep sequencing (hereafter referred to as cDNA Capture Sequencing or
cDNA CapSeq) showed that the two tumor cell lines display largely non-overlapping
patterns of mutations. By pipelining the cDNA CapSeq data for one of these tumors
(d42m1) into MHC class I epitope prediction algorithms, we identify a potential major
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antigen of this unedited tumor, validate its identity as the major rejection antigen using
expressing cloning techniques, and show that antigen-loss via a T cell dependent
immunoselection process represents the mechanism underlying cancer immunoediting of
this tumor. This study, thus, provides mechanistic insights into the process of cancer
immunoediting and points to the future potential that cancer genome analysis may have
on the fields of tumor immunology and cancer immunotherapy.

This study was performed in a combined and equal effort with Dr. Hirokazu Matsushita,
a post-doctoral fellow in the lab and thus, his data and my own are presented here
together for clarity.
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MATERIALS AND METHODS

Mice. Ifngr1-/- mice (208) and Ifnar1-/- mice (215) on a 129/Sv background were
originally provided by Dr. Michel Aguet and were bred in our specific pathogen-free
animal facility. Wild type and Rag2-/- mice were purchased from Taconic Farms. All
mice were on a 129/Sv background and were housed in our specific pathogen-free animal
facility. For all experiments, mice were 8-12 weeks of age and performed in accordance
with procedures approved by the AAALAC accredited Animal Studies Committee of
Washington University in St. Louis.

Tumor transplantation. 3-methylcholanthrene (MCA) induced sarcomas used in this
study were generated in 129/Sv strain wild type or Rag2-/- mice and banked as low
passage tumor cells as previously described (19). Tumor cells derived from frozen stocks
were propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10%
FCS (Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the
flanks of recipient mice. Tumor cells were >90% viable at the time of injection as
assessed by trypan blue exclusion and tumor size was quantified as the average of two
perpendicular diameters.

Isolation of normal skin fibroblasts. Skin fibroblasts were isolated from three
independent 129/Sv Rag2-/- pups by harvesting skin and incubating in 0.25% trypsin
(Hyclone) at 37°C for 30 minutes prior to washing in DMEM media (Hyclone). After
washing, chunks of skin were filtered to achieve single cell suspensions and cultured in
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vitro with DMEM media. After 3 passages, skin fibroblasts were harvested to isolate
genomic DNA and total RNA.

Extraction of genomic or complementary DNA. Genomic DNA from sarcoma cells
and normal skin fibroblasts was extracted using DNeasy Blood & Tissue Kit (Qiagen).
For cDNA isolation, total RNA from sarcoma cells and normal skin fibroblasts was
isolated using RNeasy Mini kit (Qiagen) and cDNA was synthesized using oligo (dT)
primers and SuperScript II Reverse Transcriptase (Invitrogen).

cDNA capture, sequencing, and alignment (cDNA CapSeq). cDNA samples from
each tumor (100 ng) were constructed into Illumina libraries according to the
manufacturer’s protocol (Illumina Inc, San Diego, CA) with the following modifications:
1) cDNA was fragmented using Covaris S2 DNA Sonicator (Covaris, Inc. Woburn, MA)
in 1X end-repair buffer followed by the direct addition of the enzyme repair cocktail
(Lucigen, Madison, WI). Fragment sizes ranged between 100 and 500 bp. 2) Illumina
adapter-ligated DNA was amplified in four 50 µl PCRs for five cycles using 4 µl adapterligated cDNA, 2X Phusion Master Mix and 250 nM forward and reverse primers,
5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATC and 5’	
  
CAAGCAGAAGACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTC
CGATC, respectively. 3) Solid Phase Reversible Immobilization (SPRI) bead cleanup
was used to purify the PCR-amplified library and to select for 300-500 bp fragments. 500
ng of the size-fractionated Illumina library was hybridized with the Agilent mouse exome
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reagent. After hybridization at 65°C for 24 hrs, we added 50 µl of DynaBeads M-270
Streptavidin-coated paramagnetic beads (10 mg/ml) to selectively remove the
biotinylated Agilent probes and hybridized cDNA library fragments. The beads were
washed according to manufacturer’s protocol (Agilent) and the captured library
fragments were released into solution using 50 µl of 0.125 N NaOH and neutralized with
an equal volume of neutralization buffer (Agilent). The recovered fragments then were
PCR amplified according to the manufacturer’s protocol using 11 cycles in the PCR.
Illumina library quantification was completed using the KAPA SYBR FAST qPCR Kit
(KAPA Biosystems, Woburn, MA). The qPCR result was used to determine the quantity
of library necessary to produce 180,000 clusters on a single lane of the Illumina GAIIx.
One lane of 100 bp paired-end data was generated for each captured sample (since cDNA
was used as the source for sequencing, we refer to this process as cDNA Capture
Sequencing or CapSeq). Illumina reads were aligned to the NCBI build 37 (Mm9) mouse
reference sequence using BWA (216) v0.5.5 (with –q 5 soft trimming). Alignments from
multiple lanes for the same sample were merged together using SAMtools r599, and
duplicates were marked using Picard v1.29.

Mutation detection and annotation. Putative somatic mutations were identified using
VarScan 2 (v2.2.4) (217) with the parameters “--min-coverage 3 --min-var-freq 0.08 --pvalue 0.10 --somatic-p-value 0.05 --strand-filter 1” and specifying a minimum mapping
quality of 10. Variants whose supporting reads exhibited read position bias (average read
position <10 or >90), strand bias (>99% of reads on one strand), or mapping quality
(score difference >30, or mismatch quality sum difference >100) relative to reference
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supporting reads were removed as probable false positives. We also required that the
variant allele be present in at least 10% of tumor reads and no more than 5% of normal
reads. The single nucleotide variants (SNVs) meeting these criteria were annotated using
an internal database of Genbank/Ensembl transcripts (v58_73k). In the event that a
variant was annotated using multiple transcripts, the annotation of most severe effect was
used. Non-silent coding mutations (missense, nonsense/nonstop, or splice-site) were
prioritized for downstream analysis.

Mutation rate and overlap comparisons. Mutation rates were estimated for each tumor
sample using the number of putative “tier 1” SNVs (missense, nonsense/nonstop, splice
site, silent, or noncoding RNA). To account for variability in coverage between samples,
the SNV count for each tumor sample (S) was divided by a coverage factor (F), computed
as the fraction of all tier 1 SNVs identified in any tumor sample (n=16,991) that were
covered by at least 4 reads in a given sample. For example, in the d42m1 parental sample,
15,852 of 16,991 tier 1 SNV positions were covered, for a coverage factor of 93.30%.
The number of coverage-adjusted mutations in each sample was divided by the total size
of tier 1 space in the mouse genome (43.884 Mbp) to determine the number of coding
mutations per megabase (R).
R = (S / F) / (43.884 Mbp)
For the mutation overlap comparisons and relatedness-to-parental-tumor analysis, only
high-confidence missense mutations were used (i.e., 20X or above). A mutation was
considered “shared” between two samples if both samples had a predicted mutation at the
same genomic position. For the comparison of mutated genes between d42m1 and
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H31m1 parental lines, a gene was considered “shared” if both d42m1 and H31m1
samples had a predicted missense mutation in that gene, even if the mutations did not
occur at the same position.

MHC class I epitope prediction. All missense mutations for each d42m1 tumor variant
were analyzed for the potential to form MHC class I neoepitopes that bind to either H2Db or H-2Kb molecules. The artificial neural network (ANN) algorithm provided by the
Immune Epitope Database and Analysis Resource (www.immuneepitope.org) was used
to predict epitope binding affinities (218) and the results were ultimately expressed as
“Affinity Values” (Affinity Value = 1/IC50 X 100).

Antibodies. Anti-H-2Kb (B8-24-3) and anti-H-2Db (B22/249) mAbs were generously
provided by Dr. Ted H. Hansen (Washington University School of Medicine). Anti-CD4
(GK1.5), anti-CD8α (YTS169.4) mAbs and control immunoglobulin (PIP, a mAb
specific for bacterial glutathione S-transferase) were produced from hybridoma
supernatants and purified in endotoxin-free form by Protein G affinity chromatography
(Leinco Technologies, St. Louis, MO). Purified Rat IgG was purchased from Sigma (St.
Louis, MO). CD45-FITC, CD45-PE, CD8-APC, and purified anti-CD16/32 were
purchased from BioLegend (San Diego, CA).

cDNA library construction and screening. To generate a d42m1 tumor cell cDNA
library, mRNA was isolated from parental d42m1 tumor cells using a QuickPrep mRNA
Purification kit (Amersham), converted into cDNA using SuperScript II First Strand
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Synthesis System (Invitrogen) and inserted into the EcoRI site of the expression vector
pcDNA3 (Invitrogen). The cDNA library was divided into pools of 100 bacterial
colonies with 200-300 ng of DNA from each pool transfected into 2.5 x 104 monkey COS
cells engineered to ectopically express mouse H-2Db (COS-Db) cells using Lipofectamine
2000. After 48 hr, 5 x 103 C3 CTL cells were added, and supernatants were assayed for
IFN-γ release 24 hrs later by ELISA. A single positive cDNA clone was isolated after
screening 120,000 cDNA colonies. The putative H-2Db-binding peptide VAVVNQIAL
was predicted using the algorithm available at the Immune Epitope Database and
Analysis Resource, http://www.immuneeptiope.org/. The peptides were kindly produced
by Dr. Paul Allen and Steve Horvath (Washington University School of Medicine).

Expression vectors. Full length cDNA encoding wild type spectrin-β2 and mutant
spectrin-β2 were cloned from parental d42m1 tumor cells by RT-PCR using primer pairs
5’-TGAGACAGTCAAGATGACGACCACGGTAGCCACA-3’ and 5’CGGGACAACAGGGAAGTTCACTTCTTCTTGCCGA-3’. Wild type and mutant
spectrin-β2 cDNA were subcloned from the TOPO-XL vector (Invitrogen) into the RVGFP vector (219). To generate the RV-RFP vector, full length cDNA encoding RFP was
cloned from the pTurboRFP-C vector (Evrogen) by RT-PCR using primer pairs 5'ATCTCAGAATTCATGAGCGAGCTGATCAAGGA - 3' and 5'ATCTCAGGATCCTTATCTGTGCCCCAGTTTGCTAG - 3'. RFP cDNA was then
cloned into the RV vector. To remove candidate T cell epitopes in RFP, the nucleotide A
was replaced by G at position 334 in the cDNA, resulting in amino acid substitution
N112D. Coding sequences of the constructs were verified by DNA sequencing (Big Dye
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method; Applied Biosciences). The dominant negative version of the IFNGR1 subunit
(IFNGR1ΔIC) was expressed into H31m1 and d42m1 tumor cells as previously described
(15).

Establishment of CTL lines and clones. To generate the d42m1 specific C3 CTL clone,
wild type mice were injected with 1 x 106 parental d42m1 tumor cells. Fourteen days
later, the spleen was harvested from a mouse that rejected the tumor and a CTL line was
established by stimulating 40 x 106 splenocytes with 2 x 106 parental d42m1 tumor cells
pre-treated for 48 hr with 100 U/ml of recombinant murine IFN-γ and irradiated (100
Gy). After CD8+ T cell purification using magnetic-beads (Miltenyi Biotec) and limiting
dilution, the CTL clone C3 was obtained.

Measurement of IFN-γ production. To generate target cells, tumor cells were treated
with 100U/ml IFN-γ for 48 hrs and irradiated with 100 Gy prior to use. The C3 CTL
clone was co-cultured at the indicated ratios with target tumor cells (10,000 or 5,000
cells) in 96-well round-bottomed plates overnight. IFN-γ in supernatants was quantified
using an IFN-γ ELISA kit (eBioscience). For blocking assays, 10 µg/ml of α-CD8 (YTS169.4), α-CD4 (GK1.5), or control immunoglobulin (PIP) were added to the cell culture
of effector (C3 CTL clone) and target cells (tumors).

Fluorescence-activated cell sorting analysis. For flow cytometry, cells were stained for
20 minutes at 4°C with 500 ng of Fc block (anti-CD16/32) and 200 ng of CD45, CD4, or
CD8α in 100 µL of staining buffer (PBS with 1% FCS and 0.05% NaN3 (Sigma)).
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Propidium iodide (PI) (Sigma) was added at 1 µg/mL immediately before FACS analysis.
For quantitative analysis of tumor-infiltrating lymphocytes/leukocytes (TIL) and lymph
node populations, a CD45+PI– gate was used and gated events were collected on a
FACSCalibur (BD Biosciences) and analyzed using FloJo software.

Tumor, draining lymph node, and spleen harvest. After tumor cell transplantation,
established tumors were excised from mice, minced and treated with 1 mg/ml type IA
collagenase (Sigma) in HBSS (Hyclone) for 2 hrs at room temperature. The ipsilateral
inguinal tumor-draining lymph nodes and spleen were also harvested and crushed
between two glass slides and vigorously resuspended to make single-cell suspensions.

Tetramers. H-2Db tetramers conjugated to phycoerythrin (PE) were prepared with
mutant spectrin-β2 peptides and produced by the NIH Tetramer Core Facility (Emory
University, Atlanta, GA).

Mutation specific RT-PCR and real-time RT-PCR. Total RNA from tumor cells was
isolated by RNeasy Mini kit (Qiagen) and cDNA was synthesized from the total RNA
using oligo (dT) primers and SuperScript II Reverse Transcriptase (Invitrogen). Realtime PCR specific for wild type spectrin-β2, mutant spectrin-β2 and GAPDH using the
SYBR Green Mastermix kit (Applied Biosystems) were performed on ABI 7000. The
primer sequences for used for mutant spectrin-β2 are 5’-GGTGAACCAGATTGCACT3’ and 5’-TGTCCACCAGTTCTCTGAACT-3’.
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Detection of mutation in spectrin-β 2 cDNA. The point mutation in the spectrin-β2
gene creates a PstI restriction site (CGGCAG to CTGCAG, underlined italic letters
indicate the site of mutation). To amplify spectrin-β2 cDNA we used a forward primer
(ACCCTGGCCCTGTACAAGAT) and reverse primer
(TAGACTCGATGACCTTGGTCT). The PCR conditions used were 94°C for 2 min,
followed by 35 cycles of 94°C for 30s, 55°C for 30s and 72°C for 30s. The PCR
products were digested for 2 hrs at 37°C with PstI restriction enzyme, which cleaved
mutant spectrin-β2, but not wild-type spectrin-β2, and generates a 200 bp fragment from
cDNA. The products were resolved by electrophoresis on a 1.2% agarose gel and
visualized by ethidium bromide staining.

Isolation of non-transformed cells from frozen primary d42m1 tumor chunk. A
frozen d42m1 tumor chunk from the original d42m1 tumor was thawed and treated with 1
mg/ml type IA collagenase (Sigma) in HBSS for 2 hrs at room temperature. After
filtration, single-cell suspensions were stained for 20 minutes at 4°C with 500 ng of Fc
block (anti-CD16/32) and 200 ng of CD45-PE in 100 µL of staining buffer. Propidium
iodide was added at 1 µg/mL immediately before sorting. A CD45+PI– gate was used and
the top 15% percent and the bottom 15% of gated events were collected using a
FACSAria II (BD Biosciences).

Statistical Analysis. Samples were compared using an unpaired, two-tailed Student’s t
test.
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RESULTS

cDNA CapSeq of Unedited MCA Sarcomas Reveals a Similarity to Carcinogeninduced Human Cancers
For this study, we chose two representative, highly immunogenic, unedited MCA
sarcoma cell lines, d42m1 and H31m1, that grow progressively when transplanted
orthotopically into Rag2-/- mice, but are immunologically rejected when transplanted into
naive wild type mice (19) (Figure 1 and 2). Using cDNA CapSeq, we identified 3,737
non-synonymous mutations in d42m1 cells (3,398 missense, 221 nonsense, 2 nonstop and
116 splice site mutations) and 2,677 non-synonymous mutations in H31m1 cells (2,391
missense, 160 nonsense, 3 nonstop and 123 splice site mutations) (Figure 3a and Figure
4). However, d42m1 and H31m1 share only 119 identical missense mutations when
comparing sequences with at least 20X coverage (Figure 3b), thus explaining the unique
antigenicity that each cell line displays (Figure 3c). Whereas d42m1 and H31m1 had
mutations in 73 and 42 cancer-associated genes (220), respectively, most of these do not
correspond to known activating or inactivating gene mutations in human cancers (221).
However, d42m1 and H31m1 display mutations in Kras (d42m1 Kras G12C; H31m1
Kras G12D) and in Trp53 (d42m1: Trp53 E295stop; H31m1: Trp53 S152R and S258I)
that are frequently observed in human and mouse cancers, including edited MCA
sarcomas from wild type mice (222). These same mutant proteins have been shown to
induce cancers de novo when co-expressed in transgenic mice (223, 224).
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Figure 1. d42m1 is a highly immunogenic, unedited tumor. d42m1 tumor cells were
injected at a dose of 1x106 into syngeneic wild type (a-d), Rag2-/- (a and c), Ifnar1-/- (c),
or Ifngr1-/- (d) mice. b, Groups of wild type mice injected with 1x106 d42m1 tumor cells
were treated with control IgG, anti-CD4, or anti-CD8α mAbs. d, d42m1 tumor cells
were rendered insensitive to IFN-γ (d42m1ΔIC) by expressing a dominant-negative
version of IFNGR1 (IFNGR1ΔIC) and were then transplanted (1x106 cells) into wild type
mice. Data are presented as average tumor diameter ± s.e.m. of 3-5 mice per group and
are representative of at least three independent experiments. Samples were compared
using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and ***p<0.001).
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Figure 2. H31m1 is a highly immunogenic, unedited tumor. H31m1 tumor cells were
injected at a dose of 1x106 into syngeneic wild type (a-d), Rag2-/- (a and c), Ifnar1-/- (c),
or Ifngr1-/- (d) mice. b, Groups of wild type mice injected with 1x106 H31m1 tumor cells
were treated with control IgG, anti-CD4, or anti-CD8α mAbs. d, H31m1 tumor cells
were rendered insensitive to IFN-γ (H31m1ΔIC) by expressing a dominant-negative
version of IFNGR1 (IFNGR1ΔIC) and were then transplanted (1x106 cells) into wild type
mice. Data are presented as average tumor diameter ± s.e.m. of 4-9 mice per group and
are representative of at least three independent experiments. Samples were compared
using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and ***p<0.001).
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Figure 3. d42m1 and H31m1 are distinct antigenic and immunogenic tumors. a,
Number of somatic, non-synonymous mutations (missense, nonsense, nonstop, and splice
site) in d42m1 and H31m1 tumor cells as detected by cDNA CapSeq. b, Venn diagram
comparing the number of unique and shared missense mutations expressed in d42m1 and
H31m1 tumor cells that had at least 20x sequencing coverage for each genomic site. c,
IFN-γ ELISA assay using the bulk CTL lines developed against either parental d42m1
(left panel) or H31m1 (right panel) and tested against unedited MCA sarcoma cell lines,
d42m1, H31m1, F510, 1773, 1782, and 1779 or the edited F244 MCA sarcoma derived
from a wild type 129/Sv mouse. Data are representative of at least two independent
experiments and are presented as average IFN-γ release ± s.e.m. Samples were compared
using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and ***p<0.001).
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Figure 4. Exome sequencing coverage. Percentage of exome sequence coverage (20x,
15x, 10x, 5x, 1x, 0x) is displayed for the MCA sarcoma cell lines and normal skin
fibroblasts that were isolated from three independent syngeneic 129/Sv Rag2-/- mice.
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When we compared the cDNA CapSeq data of d42m1 and H31m1 sarcoma cells
to those of human cancer genomes (225-233), two similarities were observed. First, the
overall mutation rates of d42m1 and H31m1 most closely resemble those of carcinogeninduced lung cancers from smokers, and particularly of “hypermutators” whose smoking
induced-lung cancers develop mutations in genes encoding DNA repair components
(Figure 5a). Interestingly, d42m1 and H31m1 also have mutations in DNA repair genes,
including Trp53, Atm, Brca2, Brip1, Fancd2, Fancg and Xpc. Second, 46% and 47% of
mutations in d42m1 and H31m1, respectively, are C/A or G/T transversions and thus
represent typical carcinogen signatures (229, 230) similar to those established for lung
cancers from smokers (44-46%), but distinct from those for other human cancers,
including lung cancers from individuals who never smoked (15%) (Figure 5b). Thus, the
current genomic analyses reveal the oft-proposed, but never documented similarity
between MCA sarcomas in mice and carcinogen-induced human cancers.

cDNA CapSeq of d42m1 Tumor Variants
The d42m1 sarcoma cell line displays a sporadic tendency to produce escape
variants following transplantation into naïve, syngeneic wild type mice (Figure 6a). In
fact, escape variants are observed in about 20% of naïve wild type mice injected with
parental d42m1 tumor cells (Figure 6c). Cell lines made from three such escape variants
(d42m1-es1, d42m1-es2 and d42m1-es3) consistently formed progressively growing
tumors when transplanted into naïve syngeneic recipients (Figure 6d and 7). In contrast,
parental d42m1 tumor cells passaged through immunodeficient Rag2-/- mice retained
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their immunogenicity (Figure 6b, d). Thus, unedited d42m1 tumor cells can undergo
immunoediting when transplanted into wild type mice.
To determine the basis for the heterogeneous behavior of d42m1 tumor cells in
naive immunocompetent mice, we generated single cell clones from the parental cell line
and tested the immunogenicity of each. Whereas 8 of 10 clones were rejected when
transplanted into wild type mice, two (d42m1-T3 and d42m1-T10) grew progressively
and displayed growth kinetics similar to the d42m1 escape variants (Figure 7). Thus, the
parental d42m1 cell line consisted of a disproportionate mixture of regressor and
progressor tumor cell clones.
cDNA CapSeq of d42m1 clones and escape variants revealed that all expressed
similar numbers of mutations compared to parental d42m1 tumor cells (Figure 8a).
Moreover, the missense mutations in clones and escape variants were similar to parental
d42m1 cells, but distinct from those in H31m1 parental cells (Figure 8b). However, a
greater percentage of mutations in d42m1 regressor clones were shared with parental
d42m1 tumor cells (71-78%) than those shared between parental d42m1 tumor cells and
d42m1 progressor clones (48%) or escape variants (33-35%) (Figure 8b), a result that
further supports the conclusion that the d42m1 cell line consists of a related, but
heterogeneous population of tumor cells.
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Figure 5. Unedited MCA sarcomas, d42m1 and H31m1, resemble carcinogeninduced human cancers. a, Log mutation rate/10 Mbp for d42m1 and H31m1 sarcomas
as compared to previously generated data from a panel of human cancers including acute
myelogenous leukemia (225, 226) (AML), chronic lymphocytic leukemia (232) (CLL),
breast cancer (breast-lobular (228), breast-basal (227), aromatase inhibitor (AI)-resistant,
and AI-sensitive (Ding et al., manuscript in review)), ovarian cancer (OVC1, 3, 4, 5)
(manuscript in preparation), liver cancer (Hepatitis C Virus (HCV)-positive) (231),
melanoma (ultraviolet (UV)-induced) (233), and lung cancers (non-small cell (NSC)
(229), small cell (SC) (230), Never-Smoker, Smoker, and Hypermutator (manuscript in
progress)). Only protein-coding alterations (Tier 1 SNVs) were used to calculate mutation
rates. b, Spectrum of DNA nucleotide transitions and transversions detected in d42m1
and H31m1 sarcomas and human cancers described in a.
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Figure 6. Escape variants of d42m1 display reduced immunogenicity and an edited
growth phenotype. a, d42m1 tumor cells (1x106) were transplanted into wild type (solid
lines) or Rag2-/- (dashed lines) mice. b, The escape variant d42m1-es3 (harvested from
the wild type mouse bearing an escaped d42m1 tumor in a and generated into a cell line)
(n=5, diamonds) or d42m1-RagPass (n=5, squares) were transplanted (1x106 cells) into
wild type mice. Data presented as average tumor diameter ± s.e.m of 5 mice per group
over time. c, Wild type mice or Rag2-/- mice were challenged with 1x106 d42m1 tumor
cells. Data presented as percent tumor positive from 2-4 independent experiments (n=4-6
mice per group). d, Wild type mice were challenged with 1x106 d42m1-RagPass,
d42m1-es1, d42m1-es2, or d42m1-es3 tumor cells. Data presented as percent tumor
positive from two independent experiments (n=4-5 mice per group). Samples were
compared using an unpaired, two-tailed Student’s t test (**p<0.01 and ***p<0.001)
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Figure 7. d42m1 tumor cell clones display heterogeneous growth characteristics.
d42m1 tumor clones (d42m1-T1, -T2, -T3, -T4, -T5, -T6, -T7, -T8, -T9, and -T10) and
escape variants (d42m1-es1, -es2, and -es3) were transplanted at a dose 1 x 106 cells into
wild type mice (n=5, squares). Data are presented as average tumor diameter ± s.e.m. and
are representative of two-three independent experiments.
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Figure 8. d42m1 tumor cell clones are closely related to d42m1 parental cells. a,
Number and type of non-synonymous somatic mutations (missense, nonsense, nonstop,
and splice site mutations) in d42m1 tumor variants. b, Percent of shared missense
mutations expressed in each d42m1 tumor cell variant when compared with d42m1
parental cells (left) or H31m1 parental cells (right).
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Identifying Potential d42m1 Tumor Antigens From Genomic Data
We next assessed the theoretical capacity of peptides containing each missense
mutation to bind to MHC class I proteins (i.e., to function as neoantigens) by in silico
analysis (218). As these tumors were generated on a 129/Sv genetic background, we
restricted our analysis to H-2Db and H-2Kb. Remarkably, among the large number of
potential mutant epitopes examined for binding to H-2Db or H-2Kb, only 32 (0.06%) and
138 (0.27%) displayed high affinity binding potential (IC50 < 50nM; Affinity Value > 2)
to H-2Db and H-2Kb, respectively (Figure 9).
To further simplify the pattern, we asked whether all of the d42m1 regressor
variants shared a common rejection antigen. Using a d42m1 specific CD8+ cytotoxic T
lymphocyte (CTL) clone (C3) derived from a wild type mouse that had rejected parental
d42m1 tumor cells, we observed reactivity in vitro (as evidenced by IFN-γ production)
with parental d42m1 tumor cells and with regressor d42m1 tumor cell variants, but not
with progressor d42m1 tumor cell variants or unrelated MCA sarcoma cells (Figure 10a,
b). Together, these results reveal that the regressor d42m1 tumor cell variants, indeed,
share a common rejection antigen. This conclusion was supported by the additional
finding that the original CD8+ T cell line from which the C3 clone was derived displayed
a limited oligoclonality, as evidenced by Vβ usage limited only to Vβ6 and Vβ8.1/8.2.
This result suggests that d42m1 expresses only a limited number of rejection antigens,
perhaps even a single immunodominant antigen. Therefore, we focused on the limited
number of epitopes that were common to all d42m1 regressor variants (Figure 11).
Furthermore, recognition of all d42m1 regressor variants by the C3 clone was restricted
by H-2Db (Figure 12). Based on these results, the R913L mutation in spectrin-β2
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represents the best potential rejection antigen candidate because of its high affinity for H2Db (Figure 11). The mutation in spectrin-β2 most likely represents a passenger rather
than a driver mutation since (a) spectrin-β2 is a cytoskeletal protein whose only known
role is maintaining plasma membrane integrity, (b) expression of mutant spectrin-β2 is
not required for the neoplastic phenotype of d42m1 tumor cell clones, and (c) it is not on
the list of known human cancer genes (220).

Mutant spectrin-β2 is a d42m1 Specific Tumor Antigen
To verify the predicted importance of mutant spectrin-β2 on d42m1 antigenicity,
we used a T cell based expression cloning approach (209) to independently identify the
tumor antigen recognized by the C3 CTL clone. After three rounds of screening 120,000
cDNA clones, a single positive cDNA was identified encoding a 1,722 bp fragment with
a sequence identical to spectrin-β2 except for a single G to T point mutation resulting in
an amino acid substitution of arginine to leucine at position 913. Thus, conventional
antigen expression cloning identified the same sequence that was predicted using the
cDNA capture sequencing/in silico approach.
To establish whether mutant spectrin-β2 represents a tumor-specific antigen, we
first assessed expression of mutant spectrin-β2 mRNA in the various d42m1 cell variant
populations by mutation specific qRT-PCR. Mutant spectrin-β2 mRNA was expressed in
parental d42m1 cells and d42m1 regressor clones, but not in d42m1 progressor clones or
escape variants (Figure 13). Moreover, the mutant form of spectrin-β2 was not observed
in normal tissue derived from the very same mouse as the d42m1 tumor, revealing that
the mutation was truly tumor cell specific and not due to a mouse-specific polymorphism.
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We then asked whether T cells could discriminate between the mutant and native
spectrin-β2 905-913 peptide sequences when presented on H-2Db. For this purpose, we
synthesized wild type (VAVVNQIAR) and mutant (VAVVNQIAL) 905-913 spectin-β2
peptides and tested their ability to stimulate IFN-γ production from the C3 clone when
presented on an unrelated H-2Db expressing cell line. Whereas the mutant peptide
stimulated C3 CTL cells in a dose-dependent manner, the wild type peptide did not, even
when added in 1000-fold excess (Figure 14).
To document that the anti-R913L spectrin-β2 response occurred under
physiologic conditions, we used labeled H-2Db tetramers generated with the 905-913
spectrin-β2 mutant peptide to identify CD8+ T cells in d42m1 variant tumors. Mutant
spectrin-β2 specific CD8+ T cells were detected in parental d42m1 tumors and draining
lymph nodes (DLNs) as early as 6 days after tumor injection and gradually increased in
numbers until day 11 (just prior to tumor rejection), where they reached a maximum of
5% and 0.5% of the CD8+ T cells in the tumor and DLN, respectively (Figure 15). In
contrast, no mutant spectrin-β2 specific CD8+ T cells were detected in d42m1-es3 tumors
or DLNs (Figure 15). Together these data demonstrate that a mutated gene expressed
selectively in unedited d42m1 tumor cells, gives rise to a mutant protein that evokes a
naturally occurring T cell response in naïve wild type mice. Thus mutant spectrin-β2 is
an authentic tumor-specific antigen of d42m1 sarcoma cells.
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Figure 9. Affinity value profiles of predicted MHC class I epitopes from tumorspecific mutations. All missense mutations for each d42m1 tumor variant were analyzed
for the potential to form MHC class I neoepitopes that bind to either H-2Db or H-2Kb
molecules. The artificial neural network (ANN) algorithm provided by the Immune
Epitope Database and Analysis Resource was used to predict epitope binding affinities
and the results were ultimately expressed as “Affinity Values” (Affinity Value = 1/IC50
X 100). Mutant epitopes present in each individual d42m1 tumor variant are displayed.
Arrow is pointing to one of the H-2Db epitopes created by the R913L point mutation in
spectrin-β2 that is expressed only in d42m1 cell variants that are rejected in wild type
mice.
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Figure 10. CD8+ T cells selectively recognize highly immunogenic d42m1 tumor
variants. a, b, IFN-γ ELISA assay of C3 CTL cells generated from splenocytes of a
mouse that rejected d42m1, against five different unedited sarcoma cell lines (a) or
against d42m1 tumor clones and escape variants (b). Data are representative of two
independent experiments. Samples were compared using an unpaired, two-tailed
Student’s t test (*p<0.05 and **p<0.01; n.s. is non-significant).
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Figure 11. Shared epitopes among highly immunogenic d42m1 variants. MHC class
I epitopes predicted to be shared in all of the highly immunogenic d42m1 tumor variants
(d42m1 parental, -T1, -T2, and -T9), but not in d42m1 tumor variants that display
reduced immunogenicity (d42m1-T3, -T10, -es1, -es2, and -es3) for H-2Db (top) and H2Kb (bottom). One of the H-2Db epitopes created by the R913L point mutation in
spectrin-β2 is highlighted in red.
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Figure 12. CD8+ T cell recognition of d42m1 parental tumor cells is H-2Db
restricted. IFN-γ ELISA assay of C3 CTL cells against d42m1 parental tumor cells with
the addition of antibodies that block CD4, CD8α, H-2Db, or H-2Kb. Data are
representative of two independent experiments. Samples were compared using an
unpaired, two-tailed Student’s t test (**p<0.01).
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Figure 13. Expression of mutant spectrin-β 2 is restricted to highly immunogenic
d42m1 tumor variants. qRT-PCR analyses using primer pairs specific for mutant
spectrin-β2 in d42m1 parental, d42m1 clones and escape variants and 1773, an unrelated
unedited sarcoma.
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Figure 14. C3 CTL clone recognizes mutant 905-913 spectrin-β2 peptide. a,
Estimation of IC50 (nM) for wild type and mutant spectrin-β2 epitopes on H-2Db by
Immune Epitope Database and Analysis Resource. b, IFN-γ ELISA assay of C3 CTL
cells against COS-Db cells pulsed with wild type (circles) or mutant (squares) spectrin-β2
peptides. Data are representative of two independent experiments. Samples were
compared using an unpaired, two-tailed Student’s t test (*p<0.05 and **p<0.01).
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Figure 15. Mutant spectrin-β2 specific CD8+ T cells infiltrate d42m1 parental
tumors, but not d42m1-es3 tumors. Time course of tetramer positive CD8α+ T cells in
tumors and DLNs from d42m1 or d42m1-es3 tumor-bearing mice. Tumors and DLNs
were harvested from d42m1 (n=3, circles) or d42m1-es3 (n=3, squares) -bearing mice at
days 6, 9, 11, and 13. Data includes results from 3 mice per group and is representative
of two independent experiments (left). Tumors and draining lymph nodes (DLNs) were
harvested at day 11 and CD8α+ T cells were stained with mutant spectrin-β2 tetramers
(right). Data are representative of two independent experiments. Samples were compared
using an unpaired, two-tailed Student’s t test (*p<0.05 and **p<0.01).
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Mutant spectrin-β2 is the Major Rejection Antigen of d42m1 Tumor Cells
In order to explore whether mutant spectrin-β2 represents the major rejection
antigen of parental d42m1 tumor cells, we enforced expression of either the mutant or
wild type forms of spectrin-β2 into d42m1-es3 cells (Figure 16). When injected into wild
type mice, d42m1-es3 tumor cell clones expressing GFP alone or GFP plus wild type
spectrin-β2 (WT.1 and WT.3) grew progressively and displayed similar growth kinetics
to the parental d42m1-es3 cell line (Figure 17a, c). In contrast, d42m1-es3 tumor cell
clones expressing GFP plus mutant spectrin-β2 (mu.6 and mu.14) were rejected in wild
type mice, but not in Rag2-/- mice (Figure 17b, c, d). CD8+ T cells specific for mutant
spectrin-β2 did not infiltrate d42m1-es3 tumors expressing wild type spectrin-β2 (WT.3),
but were detected by tetramer staining in rejecting d42m1-es3 tumors that had been
reconstituted with mutant spectrin-β2 (mu.14) (Figure 17e). The frequency of antigenspecific T cells infiltrating mutant spectrin-β2 expressing tumors was similar to that in
mice rejecting parental d42m1 tumors. These results demonstrate that expression of
mutant spectrin-β2 is both necessary and sufficient for the rejection of d42m1 tumors and
thus, validates it as the major rejection antigen of d42m1 sarcoma cells.

Immunoselection is the Immunoediting Mechanism for d42m1 Tumor Cells
The results presented thus far identified mutant spectrin-β2 as the major rejection
antigen of d42m1, established that the d42m1 tumor cell line is heterogeneous in its
expression of mutant spectrin-β2, and showed that loss of mutant spectrin-β2 in d42m1
cells following exposure to an intact immune system results in tumor cell variants that
escape immune control. Since our cDNA CapSeq analyses were performed on cDNA
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derived from tumor cells, we tested whether these observations could be explained by
epigenetic silencing of the mutated form of the spectrin-β2 gene. We therefore, treated
clones and escape variants of d42m1 that did not express mutant spectrin-β2 with
methyltransferase and histone deacetylase inhibitors (i.e., 5-azacytidine and trichostatin
A, respectively) alone or in combination and assessed expression of mutant spectrin-β2
mRNA. Mutant spectrin-β2 expression was not induced in d42m1 progressor clones or
escape variants (H. Matsushita and R.D. Schreiber, data not shown). We therefore
formulated the hypothesis that T cell dependent immunoselection was a likely
mechanism favoring outgrowth of tumor variants that lack strong rejection antigens. This
possibility is consistent with our finding that every d42m1 clone that expresses mutant
spectrin-β2 was rejected while every clone or variant that lacks mutant spectrin-β2
formed progressively growing tumors. To formally test this hypothesis, we assessed the
in vivo behavior of a disproportionate mixture of a highly immunogenic d42m1 tumor
cell clone expressing mutant spectrin-β2 (i.e., d42m1-T2) and a limiting amount of a
d42m1 tumor cell clone lacking mutant spectrin-β2 (i.e., d42m1-T3). To distinguish
between these two cell populations in vivo we labeled d42m1-T2 with an altered, nonimmunogenic form of RFP that lacked class I epitopes and labeled d42m1-T3 with GFP.
We first documented that the inherent in vivo growth characteristics of the two cell lines
were not altered (Figure 18a). We then tested several different ratios of the two clones
and found that we could recapitulate the tumor growth phenotype of parental d42ml at a
ratio of 95% regressor d42m1-T2RFP cells to 5% progressor d42m1-T3GFP cells (Figure
18b). At this ratio, 100% of Rag2-/- mice developed progressively growing tumors.
Similar results were obtained using wild type mice depleted of either CD4+ or CD8+ T
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cells (Figure 18c). In contrast, 5/20 (25%) wild type mice injected with the tumor cell
mixture developed escape tumors, a result that closely resembles the behavior of parental
d42m1 tumor cells in wild type recipients. Tumors harvested from Rag2-/- mice were
comprised of 84% RFP+ d42m1-T2 tumor cells and 14% GFP+ d42m1-T3 cells (Figure
18d) as detected by flow cytometry, a ratio that is very similar to the initial 95:5 mixture
that was injected. At tumor harvest, the cell mixture expressed mutant spectrin-β2 as
detected by mutation specific qRT-PCR (Figure 18e). In contrast, tumors that grew out
in wild type mice consisted of 98% GFP+ d42m1-T3 tumor cells and lacked mutant
spectrin-β2 expression. Thus, escape variants of parental d42m1 tumor cells develop as a
consequence of a T cell dependent immunoselection process that favors the outgrowth of
tumor cell clones that lack the major rejection antigen.
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Figure 16. Enforced expression of mutant spectrin-β2 in d42m1 escape variant
tumor cells. qRT-PCR analysis using a primer pair specific for mutant spectrin-β2 in
d42m1-es3 tumor cell clones that have been engineered to express either wild type or
mutant spectrin-β2. Data is displayed as relative expression after normalization to control
GAPDH expression and is representative of two independent experiments

	
  

125
	
  
	
  

	
  

126
	
  
	
  

Figure 17. Mutant spectrin-β2 is the major rejection antigen of d42m1 tumor cells.
a, b, d, d42m1-es3 tumor cell clones reconstituted with wild type or mutant spectrin-β2
and control d42m1-es3 expressing only GFP were transplanted at a dose of 1x106 cells
into five-member groups of wild type (a, b) or Rag2-/- mice (d). Data are presented as
average tumor diameter ± s.e.m. over time. c, Percent tumor positive with five wild type
mice per group from 2-3 independent experiments is shown.. e, d42m1-es3 tumors
reconstituted with wild type (WT.3) or mutant spectrin-β2 (mu.14) were harvested at day
11 (a) and CD8α+ T cells were stained with mutant spectrin-β2 tetramers. Samples were
compared using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and
***p<0.001; n.s. is non-significant).
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Figure 18. Immunoselection of d42m1 tumor cell clones that lack mutant spectrinβ2 results in tumor escape. a, d42m1-T2 clone labeled with RFP (d42m1-T2RFP)
(n=5, squares) or d42m1-T3 clone labeled with GFP (d42m1-T3GFP) (n=5, triangles)
were transplanted (1 x 106 cells) into wild type mice. Data are presented as average
tumor diameter ± s.e.m. and are representative of three independent experiments. b, A
mixture of d42m1-T2RFP (95%) and of d42m1-T3GFP (5%) was transplanted at a total
dose of 1 x 106 cells into wild type (solid lines) or Rag2-/- (dashed lines) mice. c, Rag2-/mice or wild type mice left untreated or treated with antibodies that deplete CD4+ or
CD8+ T cells were challenged with 1x106 d42m1 mixture (95% T2RFP and 5% T3GFP).
Data presented as percent tumor positive from 2-4 independent experiments (n=2-5 mice
per group. d, GFP and RFP expression was analyzed in the d42m1-T2RFP/d42m1T3GFP tumor cell mixture before injection and from tumors that grew out in Rag2-/- mice
or escaped in wild type mice by flow cytometry. Data are representative of two
independent experiments. e, Mutation specific qRT-PCR analysis for mutant spectrin-β2
in the d42m1-T2RFP/d42m1-T3GFP tumor cell mixture before injection and from tumors
that grew out in Rag2-/- mice (RagPass) or escaped in wild type mice. Data are
representative of two independent experiments. Samples were compared using an
unpaired, two-tailed Student’s t test (**p<0.01 and ***p<0.001).
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DISCUSSION

Recent advances in genome sequencing have resulted in unprecedented
opportunities to assess genetic influences on disease development. For cancer, most
genome sequencing studies have focused on identifying new driver mutations that
promote neoplastic development and metastasis in the hope of obtaining insights that lead
to novel cancer-targeted therapeutics or that provide prognostic value. However, we show
herein that this same technology, when combined with in silico epitope prediction
algorithms, can be used to identify expressed mutations in cancers that may result in
formation of tumor-specific antigens which function as targets for immune-mediated
elimination. To our knowledge, the current study is the first to use cDNA capture
sequencing (CapSeq) analysis of expressed genes to assess the spectrum of nonsynonymous mutations in unedited tumors derived from immunodeficient mice and
provide information pointing to potential antigens that may be responsible for immunemediated tumor rejection. We also demonstrate that the immunoediting of a tumor
studied here in detail is the result of T cell dependent immunoselection for tumor cell
variants that fail to express this mutation. These results thus not only provide definitive
evidence for at least one mechanism underlying the cancer immunoediting process, but
also demonstrate the key role that tumor-specific mutations play in development of a
tumor’s immunogenic phenotype and subsequent fate.
For d42m1 tumor cells, we show that an immunoselection process acting on an
oligoclonal parental tumor cell population leads to the outgrowth of tumor cell variants
that lack the major tumor rejection antigen—mutant spectrin-β2. Currently, we are
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unable to distinguish between the possibility that d42m1 clones in the parental d42m1
sarcoma line that lack mutant spectrin-β2 either never expressed this antigen or lost
expression. Nevertheless, the immunoselection that occurs upon exposure to an intact
immune system is dependent on adaptive immunity since neither parental d42m1 tumor
cells nor the mixture of regressor and progressor d42m1 tumor cell clones undergo
editing when passaged through Rag2-/- mice, but are indeed edited following
transplantation into immunocompetent wild type mice. Additional experiments involving
depletion of CD4+ or CD8+ lymphocytes point strongly to T cells as the specific effectors
of this editing. These results are consistent with the finding that both T cells and perforin
are required for editing of primary MCA sarcomas (87), primary lymphomas (22), and
UV-induced tumors (212), although the targets of editing in these earlier studies were not
defined. Thus, in the case of d42m1, the target of the immunoselection process has been
clearly identified as the major rejection antigen. However, this finding does not rule out
the possibility that similar immunoediting mechanisms might select for mutations in
other critical components of the MHC class I antigen processing and presentation
pathway such as the class I heavy chain (97), β2 microglobulin (100), or components of
IFN-γ receptor signaling (27), all of which are known to regulate tumor cell recognition
by tumor-specific CD8+ T cells.
We find it surprising that a single mutant protein functions as the sole major
rejection antigen in d42m1 tumor cells despite the fact that these tumor cells contain
thousands of mutations. Thus, the immunodominance of the mutant spectrin-β2 derived
epitope, in some ways, resembles the known immunodominance of certain viral antigens
(234). Many factors may contribute to the immunodominance of mutant spectrin-β2. On
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the basis of in silico analysis, the mutant 905-913 sequence is predicted to interact with
H-2Db with very high affinity, as opposed to the corresponding wild type sequence that is
predicted to bind only weakly. However, several other factors may also contribute to the
immunodominance of mutant spectrin-β2 including (1) antigen abundance, (2) antigen
cross-presentability, (3) T cell repertoire, or (4) presence of epitopes recognized by
regulatory T cells. Clearly, more work is needed in order to refine our capacity to
accurately predict the ultimate antigenicity of a mutated protein.
Chemically induced tumors have played a critical role in the history of tumor
immunology, providing the first unequivocal evidence for the existence of tumor-specific
antigens (235-237). It is therefore surprising that so little attention has been given to
identifying the transplantation rejection antigens of this class of tumors. Despite the
widely held assumption that mutations account for the immunogenicity of these tumors,
only one study thus far has identified a mutant protein recognized by CD8+ T cells (238).
In contrast, other studies of mouse and human tumors have chosen to focus on antigens
that are shared among different tumors and sometimes even normal tissues. With the
growing recognition of the importance of mutational antigens as tumor-specific targets
for immune recognition, there is a critical need to develop experimental systems that
facilitate their identification. The approach we have taken in this study, combining deep
sequencing, algorithm analysis, and T cell epitope cloning, provides a new use for the
powerful data that is rapidly accumulating from analyses of cancer genomes. We predict
that this approach may not only provide new insights into basic mechanisms underlying
cancer immunoediting, but also new opportunities for individualized cancer
immunotherapy. It may also be useful in identifying subsets of cancer patients whose
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tumors express antigens that can be most effectively targeted by checkpoint blockade
immunotherapy, such as that involving anti-CTLA-4 or anti-PD-1. Finally, this approach
may provide a mechanism to longitudinally evaluate changes in a tumor’s antigenic
profile as a consequence of ongoing immunotherapy.
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CHAPTER 4
Exome Sequencing of d42m1 Escape Variants
as an Approach to Identify the Antigenic
Targets of Checkpoint Blockade Therapy
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INTRODUCTION

The previous chapter in this dissertation established that exome sequencing of a
highly immunogenic, unedited sarcoma (d42m1) could be used to identify the major
rejection antigen of this tumor (R913L spectrin-β2 mutant). Nevertheless, d42m1 escape
variants that lack mutant spectrin-β2 emerge that can grow in an immunologically
unrestricted manner. In this chapter, we will explore whether the many thousands of
mutations still expressed by d42m1 escape variants and progressor clones exhibit residual
immunogenicity. Specifically, we will use antibodies that block negative co-stimulators
that have recently been very successful in human cancer patients (206) to determine
whether the potential antigens identified by exome sequencing of d42m1 escape variants
and progressor clones can be targeted by this form of cancer immunotherapy.

Checkpoint Blockade Therapy
Mechanisms of tumor escape from immune control may be directly at the level of
the tumor, whereby alterations at the tumor cell surface results in decreased recognition
(i.e. loss of MHC components) by immune cells or tumors may indirectly impede
immunosurveillance through the recruitment of cells (i.e. regulatory T cells) or the
liberation of cytokines (i.e. IL-10 or TGF-β) involved in immunosuppression. The
negative co-stimulatory molecules cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PD-1) and its ligand (PD-L1) are likely candidates that
may be facilitating tumor escape due to their potent ability to attenuate cytotoxic T cell
responses. The blockade of these negative co-stimulatory molecules to boost anti-tumor
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immunity and overcome cancer-induced immunosuppression is termed “checkpoint
blockade” therapy.

CTLA-4 in Inhibiting Tumor Immunity
These negative co-stimulatory molecules attenuate T cell responses during the
physiological contraction phase of an immune response and help maintain peripheral
tolerance. CTLA-4 is a homologue of CD28 binds to the same receptors as CD28, both
B7.1 (CD80) and B7.2 (CD86) (239, 240). The profound ability of CTLA-4 to inhibit T
cell responses is dramatically displayed by gene-targeted mice deficient for CTLA-4,
which succumb to lethal lymphoproliferative disease as a result of excessive T cell
activation (241). Subsequent studies have demonstrated that CTLA-4 expression on
regulatory T cells (Tregs) and effector T cells is critical to prevent autoimmune
lymphoproliferative disease (242, 243). There are two general mechanisms proposed to
explain how CTLA-4 is regulating immunity. The first general mechanism involves
CTLA-4 reducing the threshold of activation required for T cells to become activated in
response to stimuli (threshold model). The second general mechanism involves CTLA-4
reducing or attenuating T cell proliferation after it has become activated (attenuation
model) (244). Substantial evidence exists for both models as CTLA-4 prevents binding
of CD28 to CD80/CD86, recruits and activates phosphatases to the immunological
synapse which degrade T cell receptor mediated signaling and inhibits cell cycle
progression (245). These data formed the basis for the concept that CTLA-4 could be
blocked in the presence of an established tumor to reduce the threshold for T cell
activation, enhance T cell proliferation, and boost anti-tumor activity.
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Considerable evidence exists for both mice and humans for using CTLA-4specific blocking monoclonal antibodies to eradicate or limit the growth of established
tumors. Initial studies in mice were promising as CTLA-4 blockade resulted in tumor
rejection in a number of pre-clinical models of lymphomas, colon, renal, and prostatic
carcinomas (246-249). When CTLA-4 mAb treatment failed to lead to the rejection of
poorly immunogenic tumors, synergistic strategies proved very effective. Most often,
CTLA-4 immunotherapy was combined with irradiated tumor vaccines engineered to
secrete particular cytokines such as GM-CSF, to cause rejection of poorly immunogenic
tumors (250). In human cancer patients, both CTLA-4 monotherapy and combinatorial
therapies have been successful in reducing melanoma, prostate and renal carcinoma
tumor burdens and occasionally eliminating cancer altogether (206, 245).

PD-1/PD-L1 Axis in Inhibiting Tumor Immunity
Similar to CTLA-4, PD-1 and its ligand, PD-L1, regulate the contraction phase of
the immune response and maintain peripheral tolerance. Additionally, PD-1 expression
by antigen-specific CD8+ T cells induces exhaustion during chronic viral infections
(251). Initial studies investigating the role of PD-L1 as a mechanism of tumor escape
involved enforced expression of PD-L1 on murine tumor cell lines. In these studies it
was observed that T cell activation and tumor killing were diminished in vitro and tumors
grew more aggressively in vivo (252, 253). Using the 4T1 mammary carcinoma model,
tumor cells were found to upregulate the expression of PD-L1 in vivo, rendering the
immunotherapy with anti-4-1BB mAb ineffective (254). Furthermore, PD-L1 blockade
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using anti-PD-L1 mAb delayed the growth of a myeloma cell line known to
endogenously express PD-L1 (253).
Recent studies are now beginning to explore the use of combining PD-1, PD-L1,
and CTLA-4 antibodies to boost the anti-tumor immune response and enhance the
efficacy of these immunotherapies (255). Although it is well established that these
antibodies enhance the proliferation and cytokine secretion of both CD4+ and CD8+ T
cells, the exact mechanism of how these antibodies mediate tumor rejection remains
unknown. There is some evidence that pre-existing immunity to tumor antigens prior to
CTLA-4 therapy in human patients results in better outcomes (256). This suggests that
tumors that express antigens of moderate strength may be capable of eliciting a robust
immune response in the absence of immunosuppression or if the threshold for T cell
activation is lowered in some manner.
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MATERIALS AND METHODS

Mice. Batf3-/- mice (38) on a 129/Sv background were originally provided by Dr.
Kenneth Murphy and were bred in our specific pathogen-free animal facility. Wild type
and Rag2-/- mice were purchased from Taconic Farms. All mice were on a 129/Sv
background and were housed in our specific pathogen-free animal facility. For all
experiments, mice were 8-12 weeks of age and performed in accordance with procedures
approved by the AAALAC accredited Animal Studies Committee of Washington
University in St. Louis.

Tumor transplantation. 3-methylcholanthrene (MCA) induced sarcomas used in this
study were generated in 129/Sv strain wild type or Rag2-/- mice and banked as low
passage tumor cells as previously described (19). Tumor cells derived from frozen stocks
were propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10%
FCS (Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the
flanks of recipient mice. Tumor cells were >90% viable at the time of injection as
assessed by trypan blue exclusion and tumor size was quantified as the average of two
perpendicular diameters.

MHC class I epitope prediction. All missense mutations for each d42m1 tumor variant
were analyzed for the potential to form MHC class I neoepitopes that bind to either H2Db or H-2Kb molecules. The artificial neural network (ANN) algorithm provided by the
Immune Epitope Database and Analysis Resource (www.immuneepitope.org) was used
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to predict epitope binding affinities (218) and the results were ultimately expressed as
“Affinity Values” (Affinity Value = 1/IC50 X 100). Missense mutations were detected
using tumor cDNA exome capture and Illumina deep sequencing as previously described
in Chapter 3 of this dissertation.

Antibodies. Anti-H-2Kb (B8-24-3) and anti-H-2Db (B22/249) mAbs were generously
provided by Dr. Ted H. Hansen (Washington University School of Medicine). Anti-CD4
(GK1.5), anti-CD8α (YTS169.4), anti-IFN-γ (H22) mAbs and control immunoglobulin
(PIP, a mAb specific for bacterial glutathione S-transferase) were produced from
hybridoma supernatants and purified in endotoxin-free form by Protein G affinity
chromatography (Leinco Technologies, St. Louis, MO). Purified Rat IgG was purchased
from Sigma (St. Louis, MO). CD45-FITC, CD45-PE, CD8-APC, and purified antiCD16/32 were purchased from BioLegend (San Diego, CA). Anti-CTLA-4 (9H10), antiPD-1 (RMP1-14), and anti-PD-L1 (10F.9G2) were purchased from BioLegend (San
Diego, CA).

Establishment of CTL lines and clones. To generate the d42m1 escape variant specific
CTL lines, wild type mice were injected with 1 x 106 d42m1-T3 or d42m1-es3 tumor
cells and treated with antibodies against CTLA-4, PD-L1, or PD-1. Fourteen days after
the tumor had been rejected, the spleen was harvested and a CTL line was established by
stimulating 40 x 106 splenocytes with 2 x 106 d42m1-T3 or d42m1-es3 tumor cells pretreated for 48 hr with 100 U/ml of recombinant murine IFN-γ and irradiated (100 Gy).
CTL lines were purified using CD8+ magnetic-beads (Miltenyi Biotec).
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Measurement of IFN-γ production. To generate target cells, tumor cells were treated
with 100U/ml IFN-γ for 48 hrs and irradiated with 100 Gy prior to use. A CTL line was
co-cultured at the indicated ratios with target tumor cells (10,000 or 5,000 cells) in 96well round-bottomed plates overnight. IFN-γ in supernatants was quantified using an
IFN-γ ELISA kit (eBioscience). For blocking assays, 10 µg/ml of α-H-2Kb (B8-24-3)
and/or α-H-2Db (B22/249) were added to the cell culture of effector (CTL lines) and
target cells (tumors).

Checkpoint blockade therapy. Mice transplanted with tumors were treated with 200 µg
of anti-CTLA-4, anti-PD-1, or ant-PD-L1 on day 3, 6, 9, 12, 15, and 18 post transplant.

Tumor and spleen harvest. After tumor cell transplantation, established tumors were
excised from mice, minced and treated with 1 mg/ml type IA collagenase (Sigma) in
HBSS (Hyclone) for 2 hrs at room temperature. The spleen was also harvested and
crushed between two glass slides and vigorously resuspended to make single-cell
suspensions.

Statistical Analysis. Samples were compared using an unpaired, two-tailed Student’s t
test.
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RESULTS

d42m1 Variants Lacking Mutant Spectin-β2 Exhibit Residual Immunogenicity
To test whether d42m1 tumor variants that lack the major rejection antigen,
mutant spectrin-β2, would exhibit residual immunogenicity, we transplanted tumors into
wild type mice and treated them with blocking antibodies specific for PD-1, PD-L1, or
CTLA-4. When transplanted into wild type mice and treated with control Ig, both d42m1T3 and d42m1-es3 grew progressively (Figure 1). In contrast, d42m1-T3 and d42m1-es3
were rejected in wild type mice that were treated with anti-PD-1, anti-PD-L1, or antiCTLA-4 (Figure 1). These data reveal that antigen loss variants of the unedited sarcoma
d42m1 manifest residual immunogenicity and are rejected in wild type mice when treated
with antibodies specific for negative co-stimulatory molecules.
We next determined what are the critical immune components required to reject
d42m1 antigen loss variants in this therapeutic setting. Specifically, neutralizing
antibodies against IFN-γ, depleting antibodies against CD4+ T cells and CD8+ T cells,
and gene-targeted Rag2-/- mice that lack lymphocytes and Batf3-/- mice that lack CD8α+
(38) and CD103+ (257) dendritic cells were used for the characterization of the immune
response involved in the rejection of d42m1-T3 after anti-PD-L1 or anti-CTLA-4
treatment. As previously shown, d42m1-T3 grows progressively when transplanted into
wild type mice but is rejected when mice are treated with anti-PD-L1. In contrast,
d42m1-T3 grows progressively in wild type mice treated with anti-PD-L1 when mice are
additionally treated with anti-CD4, anti-CD8, anti-CD4/CD8 combined, or anti-IFN-γ
(Figure 2). Additionally, d42m1-T3 grows progressively when transplanted into Rag2-/-
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and Batf3-/- mice treated with anti-PD-L1 (Figure 2). Thus, CD4+ and CD8+ T cells, IFNγ and CD8α+/CD103+ dendritic cells are required to mediate d42m1-T3 rejection after
PD-L1 blockade therapy. Similar findings were obtained with d42m1-T3 after antiCTLA-4 treatment (Figure 2). Furthermore, a memory response develops against the
tumors after rejection due to checkpoint blockade therapy. Specifically, mice that
initially rejected d42m1-T3 or d42m1-es3 tumors with anti-PD-1 therapy are protected
from secondary challenge with the same tumor several weeks later without any additional
therapy (Figure 3). Secondary challenged mice reject d42m1-T3 or d42m1-es3 tumors
rapidly with tumors reaching a smaller peak size, results that are consistent with a
memory response (Figure 3). Taken together, all of these adaptive immune components
are required to detect unveiled antigens and eliminate poorly immunogenic tumor cells
after PD-L1 or CTLA-4 blockade and establish a memory response to the tumor antigens
expressed in these antigen loss variants of d42m1.
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Figure 1. d42m1-es3 and d42m1-T3 are rejected in mice treated with antibodies
that block CTLA-4, PD-L1, or PD-1. Cohorts of five mice were transplanted with 1 x
106 d42m1-T3 (left) or d42m1-es3 (right) tumor cells and subsequently were treated with
200 µg of anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14), anti-PD-L1 (10F.9G2) or control
Ig (PIP) on day 3, 6, 9, 12, 15, and 18 post transplant.
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Figure 2. Adaptive immune components are required to mediate rejection of
d42m1-T3 after checkpoint blockade therapy. Cohorts of Rag2-/-, Batf3-/-, or wild type
mice treated with control Ig (PIP), anti-CD4, anti-CD8α, or anti-IFN-γ mAbs were
transplanted with 1 x 106 d42m1-T3 tumor cells and subsequently treated with 200 µg of
anti-CTLA-4 (9H10) (top) or anti-PD-L1 (10F.9G2) (bottom) on day 3, 6, 9, 12, 15, and
18 post transplant.
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Figure 3. Checkpoint blockade therapy induces a memory immune response against
d42m1 antigen loss variants. Cohorts of wild type mice were transplanted with 1 x 106
d42m1-T3 (top) or d42m1-es3 (bottom) tumor cells and treated with 200 µg of control Ig
(PIP) or anti-PD-1 (RPM1-14) mAbs on days 3, 6, 9, 12, 15, and 18 post transplant.
Mice that rejected d42m1-T3 or d42m1-es3 tumors after anti-PD-1 therapy were
subsequently challenged with same tumor (d42m1-T3 or d42m1-es3) several weeks later.
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d42m1 Variants Confer Cross-protective Immunity to One Another
To test whether d42m1 tumor variants share similar antigens that may be cross
protective, we first transplanted d42m1-T3 into wild type treated with antibodies specific
for PD-1 to induce rejection. Several weeks later, these mice were challenged
secondarily with d42m1-T3, d42m1-es3, or F244 (Figure 4). Mice initially challenged
with d42m1-T3 tumor cells and treated with anti-PD-1 were able to reject d42m1-T3 and
d42m1-es3 upon secondary challenge, suggesting that these tumors share antigens strong
enough to mediate cross-protection (Figure 4). In contrast, secondary transplantation
with F244 resulted in tumor outgrowth. The converse was also true, where d42m1-es3
was initially transplanted into wild type mice treated with anti-PD-1 and then the same
mice were subsequently transplanted with d42m1-es3, d42m1-T3, and F244. Again,
d42m1-es3 and d42m1-T3 cells were rejected, but F244 tumor cells grew in an
unrestricted manner (Figure 4). Finally, when wild type mice that had spontaneously
rejected parental d42m1 tumor cells were challenged with d42m1-T3, d42m1-es3, or
F244 tumor cells, both d42m1-T3 and d42m1-es3, but not F244, were rejected.
Importantly, when mice that had rejected F244 after treatment with anti-PD-1 were
subsequently challenged with F244, d42m1-T3 or d42m1-es3, only F244 tumor cells
were rejected, demonstrating that d42m1-T3 and d42m1-es3 do not share antigens with
F244 (Figure 5). Taken together, these data show that the antigens expressed by d42m1T3 and d42m1-es3 that may be the targets of checkpoint blockade are most likely shared.
We previously established through exome sequencing that all of the d42m1
variants including d42m1 parental, regressor d42m1 variants (d42m1-T1, d42m1-T2, and
d42m1-T9), progressor d42m1 variants (d42m1-T3 and d42m1-10), and escape variants
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(d42m1-es1, d42m1-es2, and d42m1-es3) share a high percentage of missense mutations
with one another. Thus it is likely that these tumor variants may share similar antigens.
In serial transplantation experiments, d42m1-T3, d42m1-es3 and parental d42m1 tumor
cells appear to share antigens that can protect against secondary challenges. We sought
to extend this analysis to one additional progressor d42m1 clone (d42m1-T10) and one
additional d42m1 escape variant (d42m1-es2). Wild type mice initially transplanted with
d42m1-es3 and treated with anti-CTLA-4 to induce the rejection of d42m1-es3 cells were
subsequently challenged with d42m1-T10 or d42m1-es2 tumor cells. Both d42m1-10
and d42m1-es2 tumor cells were rejected, suggesting that d42m1-es3 cells share common
antigens with d42m1-T10 and d42m1-es2 cells that are strong enough to mediate
rejection, even when challenged several months after the initial d42m1-es3 challenge
(Figure 4). These results demonstrate the d42m1 variants express common antigens that
are strong enough to mediate protection from secondary challenges of distinct, but related
d42m1 variants.

	
  

152
	
  
	
  

Figure 4. Serial transplantation of related but distinct d42m1 tumor variants
results in cross-protective immunity. Cohorts of wild type mice were transplanted with
1 x 106 d42m1-T3 or d42m1-es3 tumor cells and treated with 200 µg of control Ig (PIP),
anti-CTLA-4 (9H10) or anti-PD-1 (RPM1-14) mAbs on days 3, 6, 9, 12, 15, and 18 post
transplant. Mice that rejected d42m1-T3 or d42m1-es3 tumors after anti-PD-1 or antiCTLA-4 therapy were subsequently challenged with d42m1-T3, d42m1-T10, d42m1-es2,
d42m1-es3, or F244 tumor cells several weeks later. Also, mice that rejected d42m1
parental tumors spontaneously were transplanted with d42m1-T3, d42m1-es3, or F244
tumor cells several weeks later.
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Figure 5. Serial transplantation of F244 does not cross-protect against d42m1
tumor variants. Cohorts of wild type mice were transplanted with 1 x 106 F244 tumor
cells and treated with 200 µg of control Ig (PIP) or anti-PD-1 (RPM1-14) mAbs on days
3, 6, 9, 12, 15, and 18 post transplant. Mice that rejected F244 tumors after anti-PD-1
therapy were subsequently challenged with d42m1-T3, d42m1-es3, or F244 tumor cells
several weeks later.
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Exome Analysis Limits the Number of Candidate Antigens Targeted by
Immunotherapy
Although we do not have direct evidence that the antigens targeted by checkpoint
blockade therapy are expressed by all the d42m1 tumor variants, the ability of d42m1
tumor variants to protect against other d42m1 tumor variants upon secondary
transplantation suggests that they do indeed share common antigens. Thus, we decided to
mine our exome sequencing data we had recently generated that catalogues all the
mutations expressed in the d42m1 tumor variants to see how many potential antigens
were shared among all the variants. When we combined all the mutations sequenced that
were found to be shared in all d42m1 variants (d42m1 parental, d42m1-T1, d42m1-T2,
and d42m1-T9 regressor variants and well as d42m1-T3, d42m1-T10, d42m1-es1,
d42m1-es2, and d42m1-es3 progressor variants), there were only a limited number of
shared mutations that may be acting as the immunotherapeutic targets of progressor
d42m1 variants (e.g., d42m1-T3 and d42m1-es3). When the shared missense mutations
were submitted to the immunoepitope database (218), very few mutations resulted in
potential H-2Kb epitopes and only three formed potential H-2Db epitopes (Figure 6a).
Since the most antigenic tumor-specific mutations most likely create peptides that bind
with higher affinity to class I molecules than the wild type form of the peptide, we
analyzed the potential antigen candidates for whether the mutant form of the peptide
created a much stronger MHC class I binder than the wild type form (Affinity Value x
Fold-Change). When this additional filter was used, only three mutations resulted in
potential H-2Kb epitopes and none formed potential H-2Db epitopes (Figure 6b). Thus,
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these results would predict that if the antigenic target of checkpoint blockade were shared
among all the d42m1 variants that it would be restricted to H-2Kb.
Next, we isolated and purified CD8+ T cells from the spleens of mice that had
rejected d42m1-T3 after treatment with anti-CTLA-4/PD-L1 to generate CTL lines that
recognize these tumor cells. To determine the MHC restriction of this bulk CTL line, we
incubated the CD8+ T cells with irradiated d42m1-T3 tumor cells in the presence of
antibodies that block H-2Db or H-2Kb. IFN-γ production was detected when CD8+ T
cells were co-cultured with d42m1, d42m1-T3, and d42m1-T3 in the presence of
blocking H-2Db antibodies. In contrast, IFN-γ production was blocked when antibodies
specific for H-2Kb were added to the culture, indicating that the putative antigen
expressed in d42m1-T3 tumor cells and recognized by this CTL line is presented on H2Kb (Figure 7). This result corroborates the finding that shared antigens among the
d42m1 tumor variants that were predicted by exome sequencing coupled to MHC class I
epitope prediction algorithms would most likely be H-2Kb restricted.
Of the limited number of H-2Kb restricted peptides common to all the d42m1
tumor variants, the three peptides with the greatest change in H-2Kb binding represent the
best candidate antigens targeted by checkpoint blockade (Figure 6b). Among the three
(Gpr108 R101L; Olfr684 D72Y; Olfr1239 C177S), one mutant peptide (Gpr108 R101L,
SVRSYRSL) is of particular interest due to its high affinity binding for H-2Kb (predicted
IC50 < 11 nM) and it resembles mutant spectrin-β2 in that it has an R to L change at the
anchoring residue (position 8 for H-2Kb) (Figure 7). Thus, we speculate that the CTL
line generated against d42m1-T3 recognizes this R101L mutation in G-protein receptor
108 (Gpr108). Additional CTL lines have been generated against both d42m1-T3 and
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d42m1-es3 using various combinations of checkpoint blockade antibodies that will be
tested first, for their capacity to recognize d42m1 tumor variant cells and secondly, for
their capacity to recognize synthesized mutant peptides (e.g. Gpr108 SVRSYRSL)
presented on an unrelated H-2Kb expressing cells.
Although exome sequencing has provided a short list of putative epitopes that
may be the targets of checkpoint blockade therapy for d42m1-T3 and d42m1-es3, more
work is needed to identify the specific antigens and demonstrate its capacity to stimulate
antigen-specific T cells in vivo. Nevertheless, the approach described herein that
combines deep sequencing of tumor exomes and class I prediction algorithms with
isolation of CD8+ T cells has greatly limited the number of potential antigens to three,
and particularly one that most likely functions as the target of immune-mediated
elimination of tumor cells by checkpoint blockade therapy.
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Figure 6. Potential antigens shared among all the d42m1 tumor cell variants. a,
Common missense mutations shared by all d42m1 tumor cell variants (d42m1 parental,
d42m1-T1, d42m1-T2, d42m1-T3, d42m1-T9, d42m1-T10, d42m1-es1, d42m1-es2, and
d42m1-es3) and detected using cDNA capture sequencing were analyzed for their
capacity to form neoantigens to H-2Db (top) or H-2Kb (bottom) using the class I
prediction algorithm available from the Immune Epitope and Analysis Resource Center.
Predicted IC50 values were expressed as “Affinity Values” (Affinity Value = 1/IC50 X
100). b, Affinity Values for H-2Db (top) and H-2Kb (bottom) were multiplied by the
fold-change of predicted IC50 values from the wild type form to mutant form of the
peptide.
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Figure 7. A CTL line generated against d42m1-T3 after checkpoint blockade
therapy is restricted to H-2Kb. CD8+ T cells isolated from a mouse that had rejected
d42m1-T3 after anti-CTLA-4 and anti-PD-L1 combination therapy were incubated with
irradiated (100 Gy) d42m1 parental, d42m1-T3, or H31m1 tumor cells pre-treated with
100 U/ml IFN-γ for 48 hrs. CTLs and target tumor cells were co-cultured overnight in
the presence or absence of antibodies that block H-2Db or H-2Kb and supernatants were
collected for IFN-γ ELISA assay.
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Figure 8. Best potential antigen candidates for H-2Kb shared among all the d42m1
tumor cell variants. The top three antigen candidates that are predicted to bind to H-2Kb
with high affinity and are shared among all d42m1 tumor cell variants are listed. For
comparison, the major rejection antigen of the regressor d42m1 variants, mutant spectrinβ2, is listed.
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DISCUSSION

These data reveal that antigen loss variants of the unedited sarcoma d42m1
manifest residual immunogenicity and are rejected in wild type mice when treated with
antibodies specific for negative co-stimulatory molecules. The rejection of d42m1
tumors that lack mutant spectrin-β2 by checkpoint blockade therapy requires CD4+ T
cells, CD8+ T cells, IFN-γ, and CD8α+/CD103+ dendritic cells. Moreover, rejection of
d42m1-T3 or d42m1-es3 by anti-PD-1 therapy establishes a long-lasting memory
response to the original tumor such that secondary tumor challenge results in spontaneous
rejection. Thus, edited d42m1 tumor cells retain expression of antigens that can serve as
functional targets for immunotherapuetically induced anti-tumor immune responses.
We next established through serial transplantation experiments that d42m1 escape
variants (d42m1-es2 and d42m1-es3), progressor d42m1 clones (d42m1-T3 and d42m1T10) and parental d42m1 tumor cells confer cross-protective immunity for one another.
Thus, both highly immunogenic d42m1 tumor cells and poorly immunogenic d42m1
tumor cells share common antigens strong enough to confer protective immunity. In
contrast, cross-protective immunity was not observed between d42m1-related cells and
an unrelated edited MCA sarcoma, F244, confirming previous exome sequencing
analyses described in Chapter 3 that d42m1 tumor variants are a closely related, but
heterogeneous group of tumor cell lines. Using the exome sequencing data, we found
that only a limited number of antigens predicted to bind to H-2Db or H-2Kb with high
affinity are shared in the d42m1 tumor variants that induce cross-protective immunity.
And when we apply an additional filter to identify those mutant proteins that form mutant
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peptides with high binding affinity to class I molecules that have very low binding
affinity as wild type peptides (i.e., neoantigens), we find only three potential antigens for
H-2Kb and none for H-2Db. In fact, a CTL line generated from a mouse that rejected
d42m1-T3 when treated with anti-CTLA-4 and anti-PD-L1 combination therapy
recognized d42m1 parental and d42m1-T3 tumor cells in a H-2Kb restricted manner.
Thus, these results point to an H-2Kb restricted mutant peptide functioning as the
antigenic target of checkpoint blockade therapy.
Among the three best antigen candidates restricted to H-2Kb, one seems very
promising based on its high affinity for H-2Kb and its point mutation creates an amino
acid substitution (R to L) at anchoring residue position 8 known to physiologically
stabilize the peptide-MHC complex. Although exome sequencing has provided a short
list of putative epitopes (one in particular – R101L mutation in G-protein receptor 108)
that may be the targets of checkpoint blockade therapy for d42m1-T3 and d42m1-es3,
more work is needed to identify the specific antigens and demonstrate its capacity to
stimulate antigen-specific T cells in vivo. To this end, additional CTLs lines have been
generated and the wild type and mutant forms of the peptides (Gpr108 R101L; Olfr684
D72Y; Olfr1239 C177S) have been synthesized. Specifically, three distinct CTL lines
have been generated from mice that rejected d42m1-T3 or d42m1-es3 tumors in response
to checkpoint blockade therapy. Next, the specificity of these CTL lines will be tested
using the synthesized candidate peptides. If any mutant peptides presented on unrelated
H-2Kb expressing cells activates one of these CTL lines, then these peptides will be used
to assemble soluble H-2Kb MHC class I tetramers to track mutation-specific CD8+ T cells
in vivo. Additionally, mutant peptides will be used to immunize wild type mice prior to
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d42m1-T3 or d42m1-es3 tumor cell challenge to test if the peptide can be used to
vaccinate against d42m1 antigen loss variants.
Although the identification of the antigens targeted by checkpoint blockade
therapy are have yet to be identified, the approach described herein that combines deep
sequencing of tumor exomes and class I prediction algorithms with isolation of CD8+ T
cells has greatly limited the number of potential antigens to three, and particularly one
that most likely functions as the target of immune-mediated elimination of tumor cells by
checkpoint blockade therapy. We predict that the additional experiments outlined above
will demonstrate which of the candidate antigens functions as the target for
immunotherapeutically induced anti-tumor immune responses.
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CHAPTER 5
Residual Immunogenicity of a Subset of
Edited Sarcomas is Revealed by Checkpoint
Blockade Therapy
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INTRODUCTION

The findings from the previous chapter provide additional support to the growing
body of evidence that checkpoint blockade can induce powerful anti-tumor responses in
both mice and humans (206, 245, 258). Although the underlying mechanism of this type
of immunotherapy remains to be elucidated, it seems likely that antigen expression by the
tumor cells is critical to allow for tumor-targeted, immune-mediated destruction of
transformed cells. In fact, human cancer patients that had the best clinical responses to
anti-CTLA-4 therapy, had pre-existing immunity to the cancer-associated antigen, NYESO-1 (259, 260). Despite dramatic reductions in tumor-burden in some cancer patients
treated with anti-CTLA-4, the majority of individuals treated do not respond to this from
of therapy for reasons that remain unknown (206).
A number of pre-clinical studies have explored whether edited tumors that
develop in immunocompetent mice can respond to checkpoint blockade therapy to
determine the quality of the immune response necessary to induce tumor rejection. For
example, one earlier study in mice demonstrated that a transplanted edited sarcoma could
be successfully treated with antibodies specific for CTLA-4 (249), and laid the
groundwork for future investigations into using these antibodies to boost anti-tumor
immunity. Many poorly immunogenic tumors studied to date require additional therapies
to be used in combination with checkpoint blockade therapy to induce host-protective
immune responses. Specifically, the experimental tumor B16 melanoma does not
respond to anti-CTLA-4 monotherapy or a GM-CSF expressing DC vaccine (GVAX)
alone, but in combination this therapy causes tumor rejection that provides long-lasting
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immunity against B16 melanoma cells (250). In this study, we sought to determine
whether a large panel of edited, poorly immunogenic tumors derived from MCA-treated
wild type mice also exhibit residual immunogenicity and respond to checkpoint blockade
therapy.
In contrast to d42m1 antigen loss variants, where all tumor variants tested
responded to checkpoint blockade therapy, only 70% (9/13) of edited MCA sarcomas
were rejected from wild type mice treated with anti-CTLA-4 therapy. Moreover, the four
different edited sarcomas that failed anti-CTLA-4 therapy also failed combinatorial
therapies with anti-CTLA-4/PD-1 mAbs and thus, appear to be non-immunogenic. These
results suggest tumor-specific mutations in edited tumors most likely arise stochastically
and therefore express different levels of antigenicity/immunogenicity. To address this
question, we used massively parallel sequencing of the exons from a panel of ten edited
sarcomas, eight of which respond to anti-CTLA-4 therapy and two of which do not, and
found that they display similar numbers of mutations. Current analysis is underway to
determine whether there are differences in the number of potential neoantigens that form
from these mutations between tumors that exhibit residual immunogenicity and tumors
that appear to be non-immunogenic and fail checkpoint blockade therapy. Thus, it is
tempting to speculate that the level of residual antigenicity remaining in a naturally
immunoedited tumor and not the mutational load plays an important role in determining
whether it can be effectively controlled by checkpoint blockade therapy.
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MATERIALS AND METHODS

Mice. Wild type and Rag2-/- mice were purchased from Taconic Farms. All mice were
on a 129/Sv or C57BL/6 background and were housed in our specific pathogen-free
animal facility. For all experiments, mice were 8-12 weeks of age and performed in
accordance with procedures approved by the AAALAC accredited Animal Studies
Committee of Washington University in St. Louis.

Tumor transplantation. 3-methylcholanthrene (MCA) induced sarcomas used in this
study were generated in 129/Sv or C57BL/6 strain wild type and banked as low passage
tumor cells as previously described (19). Tumor cells derived from frozen stocks were
propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10% FCS
(Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the flanks of
recipient mice. Tumor cells were >90% viable at the time of injection as assessed by
trypan blue exclusion and tumor size was quantified as the average of two perpendicular
diameters.

Isolation of normal skin fibroblasts from wild type mice. Skin fibroblasts were
isolated from three independent 129/Sv wild type pups by harvesting skin and incubating
in 0.25% trypsin (Hyclone) at 37°C for 30 minutes prior to washing in DMEM media
(Hyclone). After washing, chunks of skin were filtered to achieve single cell suspensions
and cultured in vitro with DMEM media. After 3 passages, skin fibroblasts were
harvested to isolate genomic DNA and total RNA.
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Extraction of genomic or complementary DNA. Genomic DNA from sarcoma cells
and normal skin fibroblasts was extracted using DNeasy Blood & Tissue Kit (Qiagen).
For cDNA isolation, total RNA from sarcoma cells and normal skin fibroblasts was
isolated using RNeasy Mini kit (Qiagen) and cDNA was synthesized using oligo (dT)
primers and SuperScript III Reverse Transcriptase (Invitrogen).

cDNA capture, sequencing, and alignment (cDNA CapSeq) with Roche NimbleGen
Exome Capture Array. cDNA samples from each tumor (100 ng) were constructed into
Illumina libraries according to the manufacturer’s protocol (Illumina Inc, San Diego, CA)
with the following modifications: 1) cDNA was fragmented using Covaris S2 DNA
Sonicator (Covaris, Inc. Woburn, MA) in 1X end-repair buffer followed by the direct
addition of the enzyme repair cocktail (Lucigen, Madison, WI). Fragment sizes ranged
between 100 and 500 bp. 2) Illumina adapter-ligated DNA was amplified in four 50 µl
PCRs for five cycles using 4 µl adapter-ligated cDNA, 2X Phusion Master Mix and 250
nM forward and reverse primers,
5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATC and 5’	
  
CAAGCAGAAGACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTC
CGATC, respectively. 3) Solid Phase Reversible Immobilization (SPRI) bead cleanup
was used to purify the PCR-amplified library and to select for 300-500 bp fragments. 500
ng of the size-fractionated Illumina library was hybridized with the Agilent mouse exome
reagent. After hybridization at 65°C for 24 hrs, we added 50 µl of DynaBeads M-270
Streptavidin-coated paramagnetic beads (10 mg/ml) to selectively remove the
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biotinylated Agilent probes and hybridized cDNA library fragments. The beads were
washed according to manufacturer’s protocol (Roche NimbleGen) and the captured
library fragments were released into solution using 50 µl of 0.125 N NaOH and
neutralized with an equal volume of neutralization buffer (Roche NimbleGen). The
recovered fragments then were PCR amplified according to the manufacturer’s protocol
using 11 cycles in the PCR. Illumina library quantification was completed using the
KAPA SYBR FAST qPCR Kit (KAPA Biosystems, Woburn, MA). The qPCR result was
used to determine the quantity of library necessary to produce 180,000 clusters on a
single lane of the Illumina GAIIx. One lane of 100 bp paired-end data was generated for
each captured sample (since cDNA was used as the source for sequencing, we refer to
this process as cDNA Capture Sequencing or CapSeq). Illumina reads were aligned to the
NCBI build 37 (Mm9) mouse reference sequence using BWA (216) v0.5.5 (with –q 5
soft trimming). Alignments from multiple lanes for the same sample were merged
together using SAMtools r599, and duplicates were marked using Picard v1.29.

Mutation detection and annotation. Putative somatic mutations were identified using
VarScan 2 (v2.2.4) (217) with the parameters “--min-coverage 3 --min-var-freq 0.08 --pvalue 0.10 --somatic-p-value 0.05 --strand-filter 1” and specifying a minimum mapping
quality of 10. Variants whose supporting reads exhibited read position bias (average read
position <10 or >90), strand bias (>99% of reads on one strand), or mapping quality
(score difference >30, or mismatch quality sum difference >100) relative to reference
supporting reads were removed as probable false positives. We also required that the
variant allele be present in at least 10% of tumor reads and no more than 5% of normal

	
  

174
	
  
	
  

reads. The single nucleotide variants (SNVs) meeting these criteria were annotated using
an internal database of Genbank/Ensembl transcripts (v58_73k). In the event that a
variant was annotated using multiple transcripts, the annotation of most severe effect was
used. Non-silent coding mutations (missense, nonsense/nonstop, or splice-site) were
prioritized for downstream analysis.

Mutation rate and overlap comparisons. Mutation rates were estimated for each tumor
sample using the number of putative “tier 1” SNVs (missense, nonsense/nonstop, splice
site, silent, or noncoding RNA). To account for variability in coverage between samples,
the SNV count for each tumor sample (S) was divided by a coverage factor (F), computed
as the fraction of all tier 1 SNVs identified in any tumor sample (n=16,991) that were
covered by at least 4 reads in a given sample. For example, in the d42m1 parental sample,
15,852 of 16,991 tier 1 SNV positions were covered, for a coverage factor of 93.30%.
The number of coverage-adjusted mutations in each sample was divided by the total size
of tier 1 space in the mouse genome (43.884 Mbp) to determine the number of coding
mutations per megabase (R).
R = (S / F) / (43.884 Mbp)

MHC class I epitope prediction. All missense mutations for edited wild type sarcoma
were analyzed for the potential to form MHC class I neoepitopes that bind to either H2Db or H-2Kb molecules. The artificial neural network (ANN) algorithm provided by the
Immune Epitope Database and Analysis Resource (www.immuneepitope.org) was used
to predict epitope binding affinities (218) and the results were ultimately expressed as
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“Affinity Values” (Affinity Value = 1/IC50 X 100). An additional analysis using Affinity
Value multiplied by the Fold Change (wild type IC50/mutant IC50) was also used.

Antibodies. Anti-CTLA-4 (9H10) was generously provided by Dr. James Allison, antiPD-1 (RMP1-14) by Dr. Hideo Yagita, and anti-PD-L1 (10F.9G2) by Drs. Arlene Sharpe
and Gordon Freeman. Subsequent quantities of these clones were purchased from
BioLegend (San Diego, CA). Distinct clones of anti-CTLA-4 (9D9), anti-PD-1 (4H2),
and anti-PD-L1 (14D8) were provided by Bristol Myers Squibb (New York, NY).

Checkpoint blockade therapy. Mice transplanted with tumors were treated with 200 µg
of anti-CTLA-4, anti-PD-1, or ant-PD-L1 on day 3, 6, 9, 12, 15, and 18 post transplant.

Statistical Analysis. Samples were compared using an unpaired, two-tailed Student’s t
test.
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RESULTS

A Subset of Edited Sarcomas from Wild Type Mice Manifest Residual
Immunogenicity
As opposed to d42m1 antigen loss variants, where all progressor clones and
escape variants are rejected with checkpoint blockade therapy, when a panel of edited
MCA sarcomas derived from wild type mice were tested for anti-CTLA-4 sensitivity,
only 70% (9/13) of sarcomas were rejected in wild type mice after transplantation of
sarcoma cells and treatment with anti-CTLA-4 mAbs (Figure 1). Specifically, 10 edited
sarcomas derived from 129/Sv strain mice (F279, F244, F236, H118m1, d4m3, d22m1,
d22m2, c20m1, c1m2, and H128m8462) (19) and three edited sarcomas derived from
C57BL/6 strain mice (9609, 9614, and 1956) (C.M. Koebel, J.D. Bui and R.D. Schreiber,
unpublished results) were transplanted into syngeneic hosts and treated with anti-CTLA4. Of the nine edited sarcomas that responded, eight were 129/Sv tumors (F244, F236,
H118m1, d22m1, d22m2, c20m1, c1m2, and H128m8462) and one was a C57BL/6
tumor (1956), leaving two edited 129/Sv tumors (F279 and d4m3) and two edited
C57BL/6 tumors (9609 and 9614) that did not respond to anti-CTLA-4 therapy (Figure
1). These results suggest that edited MCA sarcomas have varying levels of residual
immunogenicity that can be revealed by checkpoint blockade therapy.
All edited sarcomas tested that are rejected with anti-CTLA-4 therapy are also
rejected by either anti-PD-L1 mAb alone, anti-CTLA-4 mAb alone, or anti-PD-L1 and
anti-CTLA-4 mAbs in combination. Thus, F244, F236, and 1956 edited sarcomas exhibit
residual immunogenicity and are rejected when mice harboring these tumors are treated
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with any checkpoint blockade antibodies (Figure 2). On the other hand, d4m3, F279,
9614, and 9609 appear to be non-immunogenic when assayed by this method since
treatment with other checkpoint blockade antibodies did not restrain tumor growth in any
manner, even when used in combination (Figure 3). Therefore, there is a subset of edited
MCA sarcomas derived from wild type mice that appear to be non-immunogenic.

Exome Sequencing of Edited MCA Sarcomas
It is unknown whether the varying levels of residual immunogenicity remaining in
naturally immunoedited tumors is determined by varying levels of antigenicity and thus,
helps determine whether a tumor can be effectively controlled by checkpoint blockade
therapy. Therefore, we performed exome sequencing on eight edited MCA sarcoma cell
lines that respond to checkpoint blockade therapy (F244, F236, H118m1, d4m3, d22m1,
d22m2, and H128m8462) and two edited MCA sarcoma cell lines that do not respond to
checkpoint blockade therapy (F279 and d4m3) in order to characterize the mutations and
identify the array of potential antigens expressed in edited sarcomas. These ten edited
sarcomas were chosen to be sequenced among the panel of 13 edited sarcomas because
they were all derived from wild type 129/Sv mice treated with 100 µg of MCA, and thus
are genetically- and carcinogen-load–matched. In addition, three normal skin fibroblast
cell lines derived from wild type mice were generated and cDNA was isolated, exome
captured and sequenced to serve as the reference sequence for the identification of nonsynonymous mutations in the sarcoma cell lines. Specifically, cDNA was isolated from
all 10 of these sarcoma cell lines and 3 normal fibroblast lines, constructed into Illumina
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libraries, hybridized to mouse exome probes (Roche NimbleGen) and submitted for
Illumina sequencing.
Exome sequencing revealed that edited sarcomas display a range of proteincoding mutations (tier 1 SNVs). The average number of non-synonymous mutations in
all ten edited sarcomas was 2,267 with a range from 1,317 to 3,380 mutations for
individual edited sarcomas (Figure 4). As a control, d42m1 parental cells, which are
highly immunogenic and were derived in a Rag2-/- immunodeficient mouse was included
in this cDNA CapSeq experiment and found to express 2,707 non-synonymous
mutations. Thus, there does not appear to be a significant difference in the number of
mutations present in edited sarcomas when compared to those in unedited sarcomas.
However, using two rounds of exome capture with Agilent mouse exome probes with
d42m1 parental cell cDNA, we detected 3,737 non-synonymous mutations. Here we
used a single round of exome capture with Roche NimbleGen mouse exome probes and
detected nearly 1,000 fewer mutations. This discrepancy may be due in part to
differences in the percentage of genes captured by the two different commercial exome
mouse probe reagents (Agilent and Roche NimbleGen) as well as the differences in
sequencing coverage that can be minimized by repeating cDNA CapSeq. Clearly, one
approach is to perform cDNA CapSeq with the NimbleGen mouse exome probe reagent
an additional time for parental d42m1 and edited sarcoma samples to enhance exome
sequencing coverage and enhance mutation call accuracy.
Nevertheless, this preliminary sequencing data does provide some initial insight
into the mutational landscape of edited sarcomas. First, it appears that there is no
difference between edited and unedited MCA sarcomas, suggesting that the mutational
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load present in these tumor cells is not greatly influenced by the host’s immune status.
Secondly, there is a very broad range of mutations detected in edited sarcomas with some
tumors having nearly three times the number of mutations (Figure 4). For example,
1,317 mutations were detected in F279 tumor cells and 3,380 mutations were detected in
c1m2 tumor cells. Interestingly, F279 tumors cannot be controlled in immunocompetent
hosts treated with checkpoint blockade antibodies, while c1m2 tumors are rejected
following anti-CTLA-4 treatment (Figure 1). However, the other edited sarcoma that
fails checkpoint blockade, d4m3, has 2089 mutations which is comparable to the other
sarcomas that do respond to anti-CTLA-4 therapy such as F236 which has 1,606
mutations. Thus, although there is a trend for edited sarcomas that fail anti-CTLA-4
therapy (F279 and d4m3) to have fewer mutations than those that do respond to
immunotherapy, there is no statistical difference between the numbers of mutations in the
two subsets of edited sarcomas (Figure 4). Current analysis is underway to determine if
the number of potential antigens is distinct between sarcomas that respond and sarcomas
that fail to respond to checkpoint blockade therapy by pipelining the exome sequencing
data into MHC class I prediction algorithms.
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Figure 1. A subset of edited MCA sarcomas derived from immunocompetent wild
type mice respond to anti-CTLA-4 therapy. A panel of 13 edited MCA sarcomas were
transplanted into wild type mice treated with 200 µg of control Ig (PIP) (black) or antiCTLA-4 (9D9) (red) on days 3, 6, 9, 12, 15, and 18 post transplant. Ten of the 13 tumors
are 129/Sv strain tumors (F279, F244, F236, H118m1, d4m3, d22m1, d22m2, c20m1,
c1m2, and H128m8462) (19) and the remaining three edited sarcomas were derived from
C57BL/6 strain mice (9609, 9614, and 1956) (C.M. Koebel, J.D. Bui and R.D. Schreiber,
unpublished results).
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Figure 2. Edited MCA sarcomas that respond to anti-CTLA-4 therapy also respond
to anti-PD-1 and anti-PD-L1 therapy. F244, F236, and 1956 were transplanted into
wild type mice at a dose of 1 x 106 cells and treated with 200 µg of control Ig (PIP)
(black), anti-CTLA-4 (9H10) (red), anti-PD-L1 (10F.9G2) (blue), anti-PD-1 (RMP1-14)
(green) or combination of anti-CTLA-4/PD-L1 (purple) on days 3, 6, 9, 12, 15, and 18
post transplant.
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Figure 3. Edited MCA sarcomas that fail to respond to anti-CTLA-4 therapy also
fail to respond to anti-PD-1 and anti-PD-L1 therapy or anti-CTLA-4/anti-PD-L1
combination therapy. F279, d4m3, 9606, and 9614 were transplanted into wild type
mice at a dose of 1 x 106 cells and treated with 200 µg of control Ig (PIP) (black), antiCTLA-4 (9H10) (red), anti-PD-L1 (10F.9G2) (blue) or combination of anti-CTLA-4/PDL1 (green) on days 3, 6, 9, 12, 15, and 18 post transplant.
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Figure 4. Number of mutations present in edited sarcomas as detected by exome
sequencing. Number of mutations detected by exome sequencing on eight edited MCA
sarcoma cell lines that respond to checkpoint blockade therapy (“Edited Sarcomas (+)” =
F244, F236, H118m1, d4m3, d22m1, d22m2, and H128m8462) and two edited MCA
sarcoma cell lines that do not respond to checkpoint blockade therapy (“Edited Sarcomas
(+)” = F279 and d4m3). In addition, the unedited sarcoma d42m1 parental was included
as a positive control for the NimbleGen mouse exome capture reagent (“Unedited
Sarcoma”).
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DISCUSSION

In this study, we have examined a set of edited sarcomas derived from MCAtreated immunocompetent wild type mice for residual immunogenicity by using
checkpoint blockade therapy. When cohorts of wild type mice were transplanted with 13
different edited MCA sarcomas and subsequently treated with anti-CTLA-4 therapy, 9/13
(70%) sarcomas were rejected, suggesting that not all edited sarcomas exhibit residual
immunogenicity. In addition, the four sarcomas that failed anti-CTLA-4 therapy also
failed anti-PD-L1, anti-PD-1 therapy and anti-CTLA-4/PD-1 combination therapy.
Similar to this panel of edited sarcomas, it is unclear why significant clinical responses to
CTLA-4 blockade have been noted in some, but not all cancer patients (206). Perhaps
the stochastic nature of the process that gives rise to antigens derived from tumor-specific
mutations will produce edited tumors that express different levels of
antigenicity/immunogenicity.
To address this issue, the exomes of MCA sarcomas derived from
immunocompetent wild type mice were sequenced to first ask how many mutations are
present in these tumors and second, whether the number of mutations differ between
tumors generated in wild type mice (edited) versus tumors derived from Rag2-/- mice
(unedited)? First, there is a very broad range of mutations detected in edited sarcomas
with some tumors have nearly three times the number of mutations. For example, 1,317
mutations were detected in F279 tumor cells and 3,380 mutations were detected in c1m2
tumor cells. Secondly, it appears that there is no difference between the number of
mutations in edited and unedited MCA sarcomas, suggesting that the mutational load
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present in these tumor cells is not greatly influenced by host’s immune status.
Interestingly, there was a slight trend for edited sarcomas that fail anti-CTLA-4 therapy
(F279 and d4m3) to have fewer mutations than those that do respond to immunotherapy,
but there was no statistical difference between the numbers of mutations in the two
subsets of edited sarcomas.
Pipelining the mutations identified by next-generation sequencing into MHC class
I epitope prediction programs will be used to generate the antigenic profiles of tumors
that have escaped immune control. It will be very interesting to use these antigenic
profiles of edited tumors to correlate the quantity and quality of the potential antigens
with response to immunotherapy. Current analyses are in progress to generate the
antigenic profiles of all the edited sarcomas and results are pending. The ultimate test will
be to use the antigenic profiles of experimental tumors to predict which respond to
immunotherapy, which could have potential ramifications for human cancer
immunotherapy.
In future studies, we will generate CD8+ CTL lines against edited sarcomas that
respond to checkpoint blockade therapy, determine the MHC restriction of these CTL
lines and synthesize peptide epitope candidates recognized by these CTL lines to identify
the antigen(s) expressed in edited tumor cells that are putatively targeted by checkpoint
blockade therapy. To confirm whether an identified antigen candidate is targeted by
checkpoint blockade therapy in vivo, MHC class I tetramers specific for the mutant
peptide recognized by the CTL lines will be generated to track endogenous mutantspecific CD8+ T cells. Ultimately, we will enforce expression of the mutant antigen from
a susceptible tumor cell line in a tumor line that is not normally rejected by checkpoint
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blockade therapy and will assess whether it now drives rejection following anti-CTLA-4
or anti-PD-1 therapy.
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CHAPTER 6
Summary and Future Directions
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SUMMARY AND CONCLUSIONS

The research presented in this dissertation represents a significant transition in the
evolution of the cancer immunoediting concept. In the past, our efforts mostly centered
on demonstrating that the process occurs, identifying the key players in it and attempting
to define the positions that they play. We now enter a new phase in which we can begin
to elucidate the molecular mechanisms that drive the process. We shifted our focus from
the immune components that edit tumor immunogenicity, to the tumor cells themselves to
ask whether the quality or quantity of tumor antigens expressed in nascent transformed
cells determines immune-mediated elimination or sculpting. Thus, the overarching goal
of this thesis was to understand what drives the editing of highly immunogenic tumor
cells to those of reduced immunogenicity that grow in an immunologically unrestricted
manner.
In the first study, we set out to further examine the editing of tumor
immunogenicity by IFN-γ. Although other studies have shown that IFN-γ is critical to
mediate immunosurveillance against primary tumors, these tumors lacked IFNGR1 and
thus required additional manipulations to unmask their highly immunogenic character
(16, 19). In fact, lymphomas that spontaneously form in gene-targeted mice deficient in
IFN-γ do not reject when transplanted into wild type mice, suggesting that have been
edited by non-IFN-γ mechanisms (22). To unequivocally demonstrate that IFN-γ plays a
critical role in shaping tumor immunogenicity, we took the “gold standard” approach of
generating primary MCA-induced sarcomas in an environment that lacks IFN-γ,
harvested those tumors, generated cell lines, and transplanted them into wild type hosts to
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see whether any unmanipulated sarcomas spontaneously reject in immunocompetent
recipients.
Using a cohort of C57BL/6 mice exposed to MCA, we chronically treated these
mice with neutralizing IFN-γ antibodies (H22) to generate sarcomas that developed in the
absence of IFN-γ, but retained normal IFN-γ receptor signaling. These IFN-γ neutralized
mice developed more MCA-induced sarcomas than their control counterparts, confirming
previous reports that IFN-γ prevents development of primary tumors (16, 19, 55). In
addition, 3/10 (30%) of MCA-induced sarcomas from IFN-γ neutralized mice
spontaneously rejected when transplanted into naïve wild type hosts—a finding that is
remarkably similar to Rag2-/- mice and Ifnar1-/- mice where 40% and 36% of the MCA
sarcomas are highly immunogenic regressors, respectively (19, 24). These three highly
immunogenic sarcomas, termed “H22-regerssors” required CD4+ T cells, CD8+ T cells,
and IFN-γ for their rejection, providing further evidence that they phenotypically
resemble unedited tumors. Each of the three individual H22-regressors had different
requirements for IFN-γ responsiveness at the level of the host and/or tumor to mediate
tumor rejection, a result that is in contrast to Rag2-/- MCA sarcomas generated on a
129/Sv background where either IFN-γ responsiveness at the level of the host or the
tumor alone is sufficient to mediate tumor rejection (25) (C.M. Koebel and R.D.
Schreiber, unpublished results). Taken together, these data suggest that IFN-γ sculpts
tumor immunogenicity and, to date, is the best evidence that endogenous IFN-γ can alter
tumor immunogenicity during primary tumor development. In addition, this is the first
demonstration that unedited sarcomas can be generated using blocking monoclonal
antibodies in wild type mice.
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In the second study of this thesis, we show that cancer exome sequencing
technology when combined with in silico epitope prediction algorithms can be used to
identify expressed mutations in cancers that result in formation of tumor-specific antigens
which function as targets for immune-mediated elimination. Initial work revealed that
the highly immunogenic Rag2-/- unedited tumors, H31m1 and d42m1, share a similar
mutational landscape as carcinogen-induced human lung cancers. Although d42m1 and
H31m1 display largely non-overlapping mutations that helps explain their distinct
immunogenicities, they do share mutations in Kras (d42m1 Kras G12C; H31m1 Kras
G12D) and in Trp53 (d42m1: Trp53 E295stop; H31m1: Trp53 S152R and S258I) that are
frequently observed in human and mouse cancers (222-224). Next, we combined deep
sequencing, algorithm analysis, and T cell epitope cloning to identify mutant spectrin-β2
as a potential rejection antigen for d42m1 tumor cells. CD8+ T cells specific for mutantspectrin-β2 infiltrate d42m1 tumors just prior to rejection, but do not infiltrate d42m1
escape variants that lack mutant spectrin-β2 expression. However, enforced expression
of mutant spectrin-β2 into these escape variants induces the infiltration of mutant-specific
CD8+ T cells and tumor rejection, demonstrating that mutant spectrin-β2 is the major
rejection antigen of d42m1.
To our knowledge, this is the first study to identify an antigen from an unedited
tumor (d42m1) that is responsible for tumor rejection. Moreover, we show that a T celldependent immunoselection process acting on an oligoclonal parental tumor cell
population leads to the outgrowth of tumor cell variants that lack the immunodominant,
tumor-specific rejection antigen—mutant spectrin-β2. These results are consistent with
the finding that both T cells and perforin are required for editing of primary MCA
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sarcomas (87), primary lymphomas (22), and UV-induced tumors (212), although the
targets of editing in these earlier studies were not defined. Thus, in the case of d42m1,
the target of the immunoselection process has been clearly identified as the major
rejection antigen. Certainly, similar mechanisms might also produce tumor variants with
defects in MHC class I antigen processing and presentation or IFN-γ receptor signaling,
which have been observed in clinically apparent human cancers (27, 97).
The apparent singular importance of mutant spectrin-β2 in driving rejection of
d42m1 in many ways resembles the known immunodominant behavior of certain viral
antigens (234). However, preliminary analyses of other unedited MCA sarcomas (such
as H31m1) reveal that some express multiple strong antigens. Thus, it is possible that the
presence of one or more highly antigenic protein contributes to deciding whether a
nascent tumor is eliminated or undergoes editing. Our results thus not only provide
definitive evidence for at least one mechanism underlying the cancer immunoediting
process, but also demonstrate the key role that tumor-specific mutations play in
development of a tumor’s immunogenic phenotype and subsequent fate.
In the third study, we examined whether d42m1 antigen loss variants exhibit
residual immunogenicity. Since exome sequencing of d42m1 tumor variants detected
thousands of mutations that result in protein-coding alterations and since one mutant
protein (the R913L spectrin-β2 mutant) was responsible for immune-mediated
elimination of regressor d42m1 tumor cells, we asked whether these other mutations
formed antigens that conferred residual immunogenicity. To test this, we used antibodies
that block negative co-stimulatory molecules to boost anti-tumor immunity and overcome
cancer-induced immunosuppression. Currently, this form of cancer immunotherapy,
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termed “checkpoint blockade” therapy, has been the most successful form of
immunotherapy to date (245). Specifically, anti-CTLA-4 therapy is quickly becoming a
frontline therapeutic against malignant melanoma (206). When we transplanted d42m1T3 and d42m1-es3 tumor cells into wild type mice and subsequently treated these mice
with anti-CTLA-4, anti-PD-1, or anti-PD-L1 mAbs, both tumors were readily rejected.
Rejection of d42m1-T3 and d42m1-es3 in the context of checkpoint blockade therapy
required CD4+ T cells, CD8+ T cells, CD8α+/CD103+ DCs, and IFN-γ. Thus, antigen
loss variants of d42m1, indeed, express antigens that confer residual immunogenicity
and, presumably, these antigens are targeted by checkpoint blockade therapy. In
addition, distinct d42m1 tumor variants could induce cross-protective immunity in serial
transplantation experiments, suggesting that d42m1-related cells share common antigens.
In contrast, d42m1 tumor variants could not protect against secondary challenge by an
unrelated sarcoma, F244, indicating that there are unique antigens shared by the d42m1
variants capable of inducing protective immunity.
Based on these results, we mined our previous exome sequencing/in silico
analysis for mutations that form potential antigens that are shared among the d42m1
variants. We found that there were only three potential antigens for H-2Kb and none for
H-2Db. In fact, a CTL line generated from a mouse that rejected d42m1-T3 when treated
with anti-CTLA-4 and anti-PD-L1 combination therapy recognized d42m1 parental and
d42m1-T3 tumor cells in a H-2Kb restricted manner. Thus, these results point to an H2Kb restricted mutant peptide functioning as the antigenic target of checkpoint blockade
therapy. Although exome sequencing has provided a short list of putative epitopes (one
in particular – R101L mutation in G-protein receptor 108) that may be the targets of
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checkpoint blockade therapy for d42m1-T3 and d42m1-es3, more work is needed to
identify the specific antigens and demonstrate its capacity to stimulate antigen-specific T
cells in vivo. To this end, additional CTLs lines have been generated and the wild type
that rejected d42m1-T3 or d42m1-es3 tumors in response to checkpoint blockade therapy
and mutant forms of the peptides (Gpr108 R101L; Olfr684 D72Y; Olfr1239 C177S) have
been synthesized. We predict that the additional experiments outlined above will
demonstrate which of the candidate antigens functions as the target for
immunotherapeutically induced anti-tumor immune responses.
In the final study of this thesis, we explored whether edited MCA-induced
sarcomas that developed in immunocompetent wild type mice also exhibited residual
immunogenicity. Using the checkpoint blockade therapy, we found that 9/13 (70%) of
edited sarcomas respond to anti-CTLA-4 therapy. Edited sarcomas that are rejected due
to CTLA-4 therapy also rejected in mice treated with anti-PD-1 or anti-PD-L1 mAbs. In
contrast, the four edited sarcomas that fail anti-CTLA-4 therapy (F279, d4m3, 9609, and
9614) do not respond to anti-PD-1 or anti-PD-L1 mAbs, even when used in combination
with anti-CTLA-4 therapy. Thus, a subset of edited sarcomas respond to checkpoint
blockade therapy and a subset of edited sarcomas fail to respond to checkpoint blockade
therapy, a situation that resembles the clinical scenario. Currently, it is unknown why
certain human cancer patients respond or fail to respond to anti-CTLA-4 therapy, but one
study demonstrated that the patients that had the best clinical responses had pre-existing
immunity to a cancer-associated antigen, NY-ESO-1 (259, 260). This result suggests that
antigen expression by the tumor cells may be critical to allow for tumor-targeted,
immune-mediated destruction of transformed cells by checkpoint blockade therapy.
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To attempt to address this question, we sequenced the exons of ten edited wild
type sarcomas, two of which fail to respond to anti-CTLA-4 therapy (F279 and d4m3).
Although there was a trend for fewer numbers of mutations in F279 and d4m3 than the
other eight edited sarcomas that do respond to anti-CTLA-4 therapy, it was not
statistically significant. Moreover, the number of mutations in edited sarcomas was
similar to the number detected in the highly immunogenic, unedited tumors (H31m1 and
d42m1). These results suggest that the number of mutations present in MCA-induced
sarcomas is due to the carcinogen-load, location, and tissue-type involved and not due to
the immune status of the host. Thus, it is tempting to speculate that the level of residual
antigenicity remaining in a naturally immunoedited tumor plays an important role in
determining whether it can be effectively controlled by checkpoint blockade therapy. We
are currently analyzing whether the mutations present in edited sarcomas form
neoantigens using class I prediction algorithms.
Taking together, the data presented in this thesis has attempted to further our
understanding of the factors that drive the cancer immunoediting process. We show that
tumor-specific antigens of high affinity are targeted by the cancer immunosurveillance
network to eliminate tumors cells and that antigen loss variants of reduced
immunogenicity emerge due to a T-cell dependent immunoselection process.
Furthermore, residual antigenicity is unmasked in antigen loss variants of d42m1 and
edited wild type sarcomas using checkpoint blockade therapy. The approach of exome
sequencing, in silico analysis, and CD8+ T cell cloning used in this thesis may be of
beneficial use to both basic and clinical scientists. By defining the specific antigenic
targets of immunotherapeutically-induced, immune-mediated tumor cell elimination, we
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should obtain new levels of understanding of host responses to tumors during ongoing
therapy that may facilitate the development of new therapeutic opportunities to direct the
power and specificity of the immune system into controlling and/or destroying cancer. It
may also be useful in identifying subsets of cancer patients whose tumors express
antigens that can be most effectively targeted by checkpoint blockade immunotherapy
and may provide a mechanism to longitudinally evaluate changes in a tumor’s antigenic
profile as a consequence of ongoing immunotherapy. Therefore, we predict that a
genomic approach to tumor antigen identification such as the one reported here may, in
the future, facilitate the development of individualized cancer immunotherapies directed
at tumor-specific—rather than cancer-associated—antigens.
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FUTURE DIRECTIONS

What are the host targets for IFN-γ mediated tumor rejection?

We now have extensive evidence that IFN-γ is critical for preventing primary
tumor formation and for sculpting tumor immunogenicity (16, 19, 22, 55). In this thesis,
we generated three unedited sarcomas from MCA-treated wild type mice chronically
administered IFN-γ neutralizing antibodies (H22). All three of these tumors required
IFN-γ for their rejection and for one tumor, H22-28027, IFN-γ responsiveness at the level
of the tumor alone was sufficient to mediate rejection, confirming previous results from
our laboratory (15). For H22-28032 tumors, IFN-γ responsiveness at the level of the host
was sufficient to mediate tumor rejection, as H22-28032 tumor cells grew out in the
majority of Ifngr1-/- recipients. However, it has yet to be determined which host cells
stimulated by IFN-γ are critical to mediate IFN-γ’s anti-tumor effects. Currently, a
fellow graduate student in the Schreiber laboratory, Sang-hun Lee, recently generated
conditional Ifngr1 gene-targeted mice to selectively delete IFNGR1 in specific tissues to
address this issue. Unedited tumors will be transplanted into tissue-specific Ifngr1-/- mice
to determine which IFN-γ responsive host cells are required for tumor rejection. The two
unedited tumors he will use for this analysis will be H22-28032 that was generated as
part of this thesis and 1969 that, in addition to requiring host cell IFN-γ responsiveness,
also requires type I (IFN-α/β) interferon responsiveness at the level of CD11c+ cells to
mediate tumor rejection (25).
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Identifying the antigenic targets of checkpoint blockade therapy in antigen loss
variants

Although exome sequencing and class I prediction algorithms has provided a
short list of putative epitopes for d42m1-T3 and d42m1-es3, more work is needed to
identify the specific antigens that are targeted by checkpoint blockade therapy.
Specifically, CTL lines developed against d42m1-T3 and d42m1-es3 will be tested for
their capacity to recognize candidate epitopes and if so, demonstrate that the mutant
peptide stimulates antigen-specific T cells in vivo. To this end, additional CTLs lines
have been generated from wild type mice that rejected d42m1-T3 or d42m1-es3 tumors
in response to checkpoint blockade therapy and mutant forms of the peptides (Gpr108
R101L; Olfr684 D72Y; Olfr1239 C177S) have been synthesized. The synthesized
candidate peptides are currently being tested against the CTL line that recognizes d42m1
and d42m1-T3 parental cells in an H-2Kb restricted manner. If any mutant peptides
presented on unrelated H-2Kb expressing cells activates this CTL line or any of the other
CTL lines to be tested, then these peptides will be used to assemble soluble H-2Kb MHC
class I tetramers to track mutation-specific CD8+ T cells in vivo. Alternatively, mutant
peptides will be used to immunize wild type mice prior to d42m1-T3 or d42m1-es3 tumor
cell challenge to test if the peptide can be used to vaccinate against d42m1 antigen loss
variants. We predict that the additional experiments outlined above will demonstrate
which of the candidate antigens functions as the target for immunotherapeutically
induced anti-tumor immune responses.
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Do edited sarcomas that respond to anti-CTLA-4 therapy have more potential antigens
than edited sarcomas that fail to respond to anti-CTLA-4 therapy?

Recently, we sequenced the exons of ten different edited sarcomas derived from
immunocompetent 129/Sv wild type mice that were initially treated with 100 µg of the
MCA carcinogen. Two (F279 and d4m3) of the ten edited sarcomas (20%) do not
respond to checkpoint blockade immunotherapy (i.e., anti-CTLA-4, anti-PD-1, or antiPD-L1) even when used in combination, suggesting that these edited sarcomas are nonimmunogenic. Exome sequencing revealed that these tumors express slightly fewer
mutations, but the mutational load is essentially the same between edited sarcomas that
respond to anti-CTLA-4 therapy and those that do not respond to anti-CTLA-4 therapy.
In fact, there appears to be no difference in the number of mutations between highly
immunogenic, unedited sarcomas (d42m1 and H31m1) and edited sarcomas of reduced
immunogenicity. Thus, for MCA-induced sarcomas, the level of residual
immunogenicity cannot be inferred from the mutational load or the number of mutations
they express. However, it is still possible that the potential antigenic array differs
between unedited and edited sarcomas as well as between edited sarcomas that respond to
anti-CTLA-4 therapy and those that fail anti-CTLA-4 therapy. Currently, we are in the
process of submitting our exome sequencing data from edited sarcomas into class I
prediction algorithms to generate antigenic profiles for each individual tumor. In order to
correlate the quality and quantity of potential antigens of a tumor with sensitivity to
checkpoint blockade immunotherapy, additional tumors may need to be sequenced to
enhance the statistical power of the dataset.
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Identifying the antigenic targets of checkpoint blockade therapy in edited tumors

One approach to identifying the antigens expressed in transplantable, edited
tumors that respond to checkpoint blockade therapy is to use the cDNA CapSeq/in silico
analysis described in this thesis. As detailed above, we have already sequenced the exons
of a panel of edited sarcoma cell lines, some of which respond to anti-CTLA-4 therapy
and some that do not. Thus, any potential antigens predicted by class I algorithms can be
synthesized and tested for their capacity to stimulate CTL lines generated from mice that
reject edited tumors after checkpoint blockade therapy. Any mutant epitope that
positively stimulates a CTL could be used to generate soluble MHC class I tetramers to
track endogenous antigen-specific CD8+ T cells in vivo.
The second and more rigorous approach is to perform a similar analysis on
primary MCA sarcomas in wild type mice. Here, the same general principles apply in
that tumor cDNA will be sequenced, potential antigens will be predicted, and tumorspecific CTLs will be generated but, the tumor tissue will come from developing primary
tumors undergoing tumor progression or immunotherapeutically induced tumor
regression. Specifically, tumor tissue will be harvested from at least 5 primary sarcomas
that respond to checkpoint blockade therapy (as evidenced by tumor regression but before
total elimination of the tumor) and at least 5 primary MCA sarcomas that do not respond
to checkpoint blockade therapy (as evidenced by tumor progression), cDNA will be
isolated, Illumina libraries will be generated, hybridized to mouse exome probes
(Agilent) and submitted for sequencing. The study of primary MCA sarcomas as opposed
to cell lines not only has the advantage of most closely resembling the clinical scenario of
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anti-CTLA-4 therapy in terms of tumor development (autochthonous tumor model) and
in terms of anti-CTLA-4 therapeutic responses, but also provides the opportunity to
isolate normal tissue from the same individual mouse as the tumor for comparative
genome analyses. By pipelining the exome sequencing data into MHC class I epitope
prediction algorithms, we will generate antigenic profiles for each individual sarcoma and
compare whether the sarcomas that respond to immunotherapy have a greater number of
potential high- to medium-binding affinity antigens than sarcomas that fail to respond to
immunotherapy. Finally, any mouse that rejects its primary MCA sarcoma during the
course of checkpoint blockade therapy will be used to generate a CD8+ CTL line against
the primary sarcoma cells in an attempt to identify the tumor-specific antigens targeted
by this form of immunotherapy.

Potential clinical implications for cancer genome sequencing on tumor immunology

Cancer genome sequencing analyses has provided many important insights into
the nature of mutations that facilitate transformation (261). Although, the primary focus
of this field is to identify the “driver” mutations, it is becoming apparent that the vast
majority of mutations present in cancer cells are “passenger” mutations that may function
as targets for elimination by immunotherapy (213, 214). The large datasets of
information from the many cancer genome initiatives could be of extreme value to tumor
immunologists to define the “antigen landscape” as opposed to the “mutational
landscape” of human cancers (262). One application of this approach is that it could be
used to identify the subset of cancer patients whose tumors express antigens that can be
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most effectively targeted by checkpoint blockade immunotherapy. In addition, this
approach may provide a mechanism to longitudinally evaluate changes in a tumor’s
antigenic profile as a consequence of ongoing immunotherapy.
It is difficult to predict whether this type of analysis will yield prognostic value in
the clinic, as genome analysis can be costly and requires streamlined computational
analysis. Nevertheless, third-generation sequencing technologies are already
commercially available and costs for cancer genome sequencing are predicted to fall
sharply over the next decade (263), thus this type of analysis may be feasible to perform
on a individual patient’s cancer cells in the not-to-distant future. Whether it proves
useful will require extensive studies performed initially in pre-clinical models like the
ones used in this thesis as well as retrospective and longitudinal clinical studies.

	
  

206
	
  
	
  

REFERENCES

	
  

207
	
  
	
  

1.

Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V,
Cordon-Cardo C, Lowe SW. 2007. Senescence and tumour clearance is triggered
by p53 restoration in murine liver carcinomas. Nature 445: 656-60

2.

Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras
provokes premature cell senescence associated with accumulation of p53 and
p16INK4a. Cell 88: 593-602

3.

Danial NN, Korsmeyer SJ. 2004. Cell death: critical control points. Cell 116: 20519

4.

Peter ME, Krammer PH. 2003. The CD95(APO-1/Fas) DISC and beyond. Cell
Death Differ 10: 26-35

5.

Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70

6.

Janes SM, Watt FM. 2006. New roles for integrins in squamous-cell carcinoma.
Nat Rev Cancer 6: 175-83

7.

Humbert P, Russell S, Richardson H. 2003. Dlg, Scribble and Lgl in cell polarity,
cell proliferation and cancer. Bioessays 25: 542-53

8.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer
immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-8

9.

Zitvogel L, Tesniere A, Kroemer G. 2006. Cancer despite immunosurveillance:
immunoselection and immunosubversion. Nat Rev Immunol 6: 715-27

10.

Curiel TJ. 2007. Tregs and rethinking cancer immunotherapy. J Clin Invest 117:
1167-74

11.

Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell
144: 646-74

12.

Ehrlich P. 1909. Ueber den jetzigen stand der Karzinomforschung. Ned. Tijdschr.
Geneeskd. 5: 273-90

13.

Burnet FM. 1957. Cancer - a biological approach. Brit. Med. J. 1: 841-7

14.

Thomas L. 1959. Cellular and Humoral Aspects of the Hypersensitive States.
New York: Hoeber-Harper

15.

Dighe AS, Richards E, Old LJ, Schreiber RD. 1994. Enhanced in vivo growth and
resistance to rejection of tumor cells expressing dominant negative IFN gamma
receptors. Immunity 1: 447-56

	
  

208
	
  
	
  

16.

Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD.
1998. Demonstration of an interferon gamma-dependent tumor surveillance
system in immunocompetent mice. Proc Natl Acad Sci U S A 95: 7556-61

17.

Engel AM, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. 1996.
Methylcholanthrene-induced sarcomas in nude mice have short induction times
and relatively low levels of surface MHC class I expression. Apmis 104: 629-39

18.

Engel AM, Svane IM, Rygaard J, Werdelin O. 1997. MCA sarcomas induced in
scid mice are more immunogenic than MCA sarcomas induced in congenic,
immunocompetent mice. Scand J Immunol 45: 463-70

19.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD.
2001. IFNgamma and lymphocytes prevent primary tumour development and
shape tumour immunogenicity. Nature 410: 1107-11

20.

Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. 2000.
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous
lymphoma. J Exp Med 192: 755-60

21.

Korner H, Cretney E, Wilhelm P, Kelly JM, Rollinghoff M, Sedgwick JD, Smyth
MJ. 2000. Tumor necrosis factor sustains the generalized lymphoproliferative
disorder (gld) phenotype. J Exp Med 191: 89-96

22.

Street SE, Trapani JA, MacGregor D, Smyth MJ. 2002. Suppression of lymphoma
and epithelial malignancies effected by interferon gamma. J Exp Med 196: 129-34

23.

Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P,
Sutton B, Tigelaar RE, Hayday AC. 2001. Regulation of cutaneous malignancy
by gammadelta T cells. Science 294: 605-9

24.

Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond
MS, Koebel CM, Arthur C, White JM, Schreiber RD. 2005. A critical function for
type I interferons in cancer immunoediting. Nat Immunol 6: 722-9

25.

Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault
JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. 2011.
Type I interferon is selectively required by dendritic cells for immune rejection of
tumors. J Exp Med 208: 1989-2003

26.

Dunn GP, Old LJ, Schreiber RD. 2004. The immunobiology of cancer
immunosurveillance and immunoediting. Immunity 21: 137-48

27.

Dunn GP, Old LJ, Schreiber RD. 2004. The three Es of cancer immunoediting.
Annu Rev Immunol 22: 329-60

28.

Dunn GP, Koebel CM, Schreiber RD. 2006. Interferons, immunity and cancer
immunoediting. Nat Rev Immunol 6: 836-48
209
	
  
	
  

	
  

29.

Smyth MJ, Dunn GP, Schreiber RD. 2006. Cancer immunosurveillance and
immunoediting: the roles of immunity in suppressing tumor development and
shaping tumor immunogenicity. Adv Immunol 90: 1-50

30.

Swann JB, Smyth MJ. 2007. Immune surveillance of tumors. J Clin Invest 117:
1137-46

31.

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. 2011. Natural Innate and
Adaptive Immunity to Cancer. Annu Rev Immunol 29: 235-71

32.

Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: integrating
immunity's roles in cancer suppression and promotion. Science 331: 1565-70

33.

Smyth MJ, Crowe NY, Godfrey DI. 2001. NK cells and NKT cells collaborate in
host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13:
459-63

34.

Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE,
Hayday AC. 2003. The distinct contributions of murine T cell receptor
(TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically
induced skin cancer. J Exp Med 198: 747-55

35.

Swann JB, Uldrich AP, van Dommelen S, Sharkey J, Murray WK, Godfrey DI,
Smyth MJ. 2009. Type I natural killer T cells suppress tumors caused by p53 loss
in mice. Blood 113: 6382-5

36.

Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T,
Pelikan SB, Crowe NY, Godfrey DI. 2000. Differential tumor surveillance by
natural killer (NK) and NKT cells. J Exp Med 191: 661-8

37.

Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita
H, Okumura K. 2001. Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) contributes to interferon gamma-dependent natural killer cell protection
from tumor metastasis. J Exp Med 193: 661-70

38.

Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M,
Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL,
Murphy KM. 2008. Batf3 deficiency reveals a critical role for CD8alpha+
dendritic cells in cytotoxic T cell immunity. Science 322: 1097-100

39.

Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, Smyth
MJ, Parish CR. 2007. Regulation of carcinogenesis by IL-5 and CCL11: a
potential role for eosinophils in tumor immune surveillance. J Immunol 178:
4222-9

40.

Street SE, Cretney E, Smyth MJ. 2001. Perforin and interferon-gamma activities
independently control tumor initiation, growth, and metastasis. Blood 97: 192-7

	
  

210
	
  
	
  

41.

Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog
P, Smyth MJ. 2007. Type I IFN contributes to NK cell homeostasis, activation,
and antitumor function. J Immunol 178: 7540-9

42.

Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ.
2008. Demonstration of inflammation-induced cancer and cancer immunoediting
during primary tumorigenesis. Proc Natl Acad Sci U S A 105: 652-6

43.

Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. 2002.
Increased susceptibility to tumor initiation and metastasis in TNF-related
apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-61

44.

Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura
K. 2002. Critical role for tumor necrosis factor-related apoptosis-inducing ligand
in immune surveillance against tumor development. J Exp Med 195: 161-9

45.

Smyth MJ, Taniguchi M, Street SE. 2000. The anti-tumor activity of IL-12:
mechanisms of innate immunity that are model and dose dependent. J Immunol
165: 2665-70

46.

Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S,
Yasui T, Kikutani H, Shibuya K, Shibuya A. 2008. Accelerated tumor growth in
mice deficient in DNAM-1 receptor. J Exp Med 205: 2959-64

47.

Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. 2005.
NKG2D function protects the host from tumor initiation. J Exp Med 202: 583-8

48.

Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S,
Cado D, Greenberg NM, Raulet DH. 2008. NKG2D-deficient mice are defective
in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-80

49.

Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. 2010.
Tumor immunoediting by NKp46. J Immunol 184: 5637-44

50.

Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. 2000. TAP
expression provides a general method for improving the recognition of malignant
cells in vivo. Nat Biotechnol 18: 515-20

51.

Fallarino F, Gajewski TF. 1999. Cutting edge: differentiation of antitumor CTL in
vivo requires host expression of Stat1. J Immunol 163: 4109-13

52.

Zhang B, Karrison T, Rowley DA, Schreiber H. 2008. IFN-gamma- and TNFdependent bystander eradication of antigen-loss variants in established mouse
cancers. J Clin Invest 118: 1398-404

53.

Qin Z, Kim HJ, Hemme J, Blankenstein T. 2002. Inhibition of
methylcholanthrene-induced carcinogenesis by an interferon gamma receptordependent foreign body reaction. J Exp Med 195: 1479-90
211
	
  
	
  

	
  

54.

Liu J, Xiang Z, Ma X. 2004. Role of IFN regulatory factor-1 and IL-12 in
immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T
lymphoma. J Immunol 173: 1184-93

55.

Wakita D, Chamoto K, Ohkuri T, Narita Y, Ashino S, Sumida K, Nishikawa H,
Shiku H, Togashi Y, Kitamura H, Nishimura T. 2009. IFN-gamma-dependent
type 1 immunity is crucial for immunosurveillance against squamous cell
carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 30: 1408-15

56.

Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski
TF. 2011. Host type I IFN signals are required for antitumor CD8+ T cell
responses through CD8{alpha}+ dendritic cells. J Exp Med 208: 2005-16

57.

Johansen C, Vestergaard C, Kragballe K, Kollias G, Gaestel M, Iversen L. 2009.
MK2 regulates the early stages of skin tumor promotion. Carcinogenesis 30:
2100-8

58.

Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H,
Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F. 1999. Mice deficient in
tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5: 82831

59.

Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, MullerDecker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P. 2008.
RAGE signaling sustains inflammation and promotes tumor development. J Exp
Med 205: 275-85

60.

Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson
BA, 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL.
2008. Chronic inflammation that facilitates tumor progression creates local
immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad
Sci U S A 105: 17073-8

61.

Yusuf N, Nasti TH, Katiyar SK, Jacobs MK, Seibert MD, Ginsburg AC, Timares
L, Xu H, Elmets CA. 2008. Antagonistic roles of CD4+ and CD8+ T-cells in
7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res 68: 392430

62.

Gasser S, Orsulic S, Brown EJ, Raulet DH. 2005. The DNA damage pathway
regulates innate immune system ligands of the NKG2D receptor. Nature 436:
1186-90

63.

Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi
M, Hayday AC. 2005. Sustained localized expression of ligand for the activating
NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor
immunosurveillance. Nat Immunol 6: 928-37

	
  

212
	
  
	
  

64.

Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, Kaplan DH,
Hayday AC, Girardi M. 2008. Acute upregulation of an NKG2D ligand promotes
rapid reorganization of a local immune compartment with pleiotropic effects on
carcinogenesis. Nat Immunol 9: 146-54

65.

Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok
AI, Schutz G, Greiner EF, Kemp CJ, Walczak H. 2008. TRAIL-R deficiency in
mice enhances lymph node metastasis without affecting primary tumor
development. J Clin Invest 118: 100-10

66.

Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B,
McClanahan T, Kastelein RA, Oft M. 2006. IL-23 promotes tumour incidence
and growth. Nature 442: 461-5

67.

Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Moller A,
Hill GR, Iwakura Y, Oft M, Smyth MJ. 2010. IL-23 suppresses innate immune
response independently of IL-17A during carcinogenesis and metastasis. Proc
Natl Acad Sci U S A 107: 8328-33

68.

Xiao M, Wang C, Zhang J, Li Z, Zhao X, Qin Z. 2009. IFNgamma promotes
papilloma development by up-regulating Th17-associated inflammation. Cancer
Res 69: 2010-7

69.

Norbury KC, Kripke ML. 1978. Ultraviolet carcinogenesis in T-cell-depleted
mice. J Natl Cancer Inst 61: 917-21

70.

Ward PL, Koeppen HK, Hurteau T, Rowley DA, Schreiber H. 1990. Major
histocompatibility complex class I and unique antigen expression by murine
tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res 50:
3851-8

71.

Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM,
Diefenbach A, Yagita H, Godfrey DI, Smyth MJ. 2004. Innate immune
surveillance of spontaneous B cell lymphomas by natural killer cells and
gammadelta T cells. J Exp Med 199: 879-84

72.

Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, Smyth MJ.
2005. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J
Immunol 175: 5586-90

73.

Davidson WF, Giese T, Fredrickson TN. 1998. Spontaneous development of
plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp
Med 187: 1825-38

74.

Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. 2009.
Temperature sensitivity of human perforin mutants unmasks subtotal loss of

	
  

213
	
  
	
  

cytotoxicity, delayed FHL, and a predisposition to cancer. Proc Natl Acad Sci U S
A 106: 9809-14
75.

Stutman O. 1975. Immunodepression and malignancy. Adv Cancer Res 22: 261422

76.

Gershwin ME, Ohsugi Y, Castles JJ, Ikeda RM, Ruebner B. 1983. Anti-mu
induces lymphoma in germfree congenitally athymic (nude) but not in
heterozygous (nu/+) mice. J Immunol 131: 2069-73

77.

Hayashi T, Faustman DL. 2002. Development of spontaneous uterine tumors in
low molecular mass polypeptide-2 knockout mice. Cancer Res 62: 24-7

78.

Airoldi I, Di Carlo E, Cocco C, Sorrentino C, Fais F, Cilli M, D'Antuono T,
Colombo MP, Pistoia V. 2005. Lack of Il12rb2 signaling predisposes to
spontaneous autoimmunity and malignancy. Blood 106: 3846-53

79.

Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M,
Dranoff G. 2003. Deficiencies of GM-CSF and interferon gamma link
inflammation and cancer. J Exp Med 197: 1213-9

80.

Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420: 860-7

81.

Bolitho P, Street SE, Westwood JA, Edelmann W, Macgregor D, Waring P,
Murray WK, Godfrey DI, Trapani JA, Johnstone RW, Smyth MJ. 2009. Perforinmediated suppression of B-cell lymphoma. Proc Natl Acad Sci U S A 106: 2723-8

82.

Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. 2004. Enhanced
tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma.
Blood 104: 3305-11

83.

Finnberg N, Klein-Szanto AJ, El-Deiry WS. 2008. TRAIL-R deficiency in mice
promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest
118: 111-23

84.

Bellone M, Ceccon M, Grioni M, Jachetti E, Calcinotto A, Napolitano A, Freschi
M, Casorati G, Dellabona P. 2010. iNKT cells control mouse spontaneous
carcinoma independently of tumor-specific cytotoxic T cells. PLoS One 5: e8646

85.

Willimsky G, Blankenstein T. 2005. Sporadic immunogenic tumours avoid
destruction by inducing T-cell tolerance. Nature 437: 141-6

86.

Aguirre-Ghiso JA. 2007. Models, mechanisms and clinical evidence for cancer
dormancy. Nat Rev Cancer 7: 834-46

87.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ,
Schreiber RD. 2007. Adaptive immunity maintains occult cancer in an
equilibrium state. Nature 450: 903-7
214
	
  
	
  

	
  

88.

Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, Street NE.
1999. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma
in establishing and maintaining the tumor-dormant state. J Immunol 162: 2842-9

89.

Saudemont A, Quesnel B. 2004. In a model of tumor dormancy, long-term
persistent leukemic cells have increased B7-H1 and B7.1 expression and resist
CTL-mediated lysis. Blood 104: 2124-33

90.

Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T, Beissert
S, Melief CJ, Penninger JM. 2007. Spontaneous tumor rejection by cbl-b-deficient
CD8+ T cells. J Exp Med 204: 879-91

91.

Schumacher K, Haensch W, Roefzaad C, Schlag PM. 2001. Prognostic
significance of activated CD8(+) T cell infiltrations within esophageal
carcinomas. Cancer Res 61: 3932-6

92.

Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong
LC, Jin Y, Kato M, Prevost-Blondel A, Chow P, Yang H, Abastado JP. 2010.
Tumor cells disseminate early, but immunosurveillance limits metastatic
outgrowth, in a mouse model of melanoma. J Clin Invest 120: 2030-9

93.

Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE, Jr. 1996.
Transcriptionally active Stat1 is required for the antiproliferative effects of both
interferon alpha and interferon gamma. Proc Natl Acad Sci U S A 93: 7673-8

94.

Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R. 1998. Interferon-induces
expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that
prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK).
Oncogene 16: 217-25

95.

Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak
K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M,
Forster I, Huss R, Weber WA, Kneilling M, Rocken M. 2008. TNFR1 signaling
and IFN-gamma signaling determine whether T cells induce tumor dormancy or
promote multistage carcinogenesis. Cancer Cell 13: 507-18

96.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM,
Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries
CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. 2006. Cancer
regression in patients after transfer of genetically engineered lymphocytes.
Science 314: 126-9

97.

Khong HT, Restifo NP. 2002. Natural selection of tumor variants in the
generation of "tumor escape" phenotypes. Nat Immunol 3: 999-1005

98.

Kyewski B, Klein L. 2006. A central role for central tolerance. Annu Rev
Immunol 24: 571-606

	
  

215
	
  
	
  

99.

Schell TD, Knowles BB, Tevethia SS. 2000. Sequential loss of cytotoxic T
lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen
transgenic mice developing osteosarcomas. Cancer Res 60: 3002-12

100.

Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR,
Rosenberg SA. 1996. Loss of functional beta 2-microglobulin in metastatic
melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:
100-8

101.

Khong HT, Wang QJ, Rosenberg SA. 2004. Identification of multiple antigens
recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape
by antigen loss and loss of MHC expression. J Immunother 27: 184-90

102.

Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. 1996. Inverse
relationship of melanocyte differentiation antigen expression in melanoma tissues
and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigenloss variants in vivo. Int J Cancer 66: 470-6

103.

Dunn GP, Sheehan KC, Old LJ, Schreiber RD. 2005. IFN unresponsiveness in
LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 65: 3447-53

104.

Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N,
Mandelboim M, Mandelboim O. 2008. Human microRNAs regulate stressinduced immune responses mediated by the receptor NKG2D. Nat Immunol 9:
1065-73

105.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R,
Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. 2004.
Regulation of the innate and adaptive immune responses by Stat-3 signaling in
tumor cells. Nat Med 10: 48-54

106.

Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, Froelich CJ,
Tschopp J. 1998. FLIP prevents apoptosis induced by death receptors but not by
perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol
161: 3936-42

107.

Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H,
Kalthoff H, Ungefroren H. 2000. Bcl-XL protects pancreatic adenocarcinoma
cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19:
5477-86

108.

Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, Lee JH, Lee SK, Lee
SN, Jung SS, Han JY, Kim H, Lee JY, Yoo NJ. 2001. Mutations of tumor
necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and
receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61: 4942-6

	
  

216
	
  
	
  

109.

Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC,
Shipp MA. 2006. FAS death domain deletions and cellular FADD-like interleukin
1beta converting enzyme inhibitory protein (long) overexpression: alternative
mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large Bcell lymphoma subtypes. Clin Cancer Res 12: 3265-71

110.

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu
J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. 2002. Tumor-associated B7H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat
Med 8: 793-800

111.

Tripathi P, Agrawal S. 2006. Non-classical HLA-G antigen and its role in the
cancer progression. Cancer Invest 24: 178-86

112.

Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A,
Jotereau F, Gervois N. 2006. Expression and release of HLA-E by melanoma
cells and melanocytes: potential impact on the response of cytotoxic effector cells.
J Immunol 177: 3100-7

113.

Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA.
2005. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine
protection against autochthonous mammary carcinomas. J Immunol 174: 4228-36

114.

Radoja S, Rao TD, Hillman D, Frey AB. 2000. Mice bearing late-stage tumors
have normal functional systemic T cell responses in vitro and in vivo. J Immunol
164: 2619-28

115.

Groh V, Wu J, Yee C, Spies T. 2002. Tumour-derived soluble MIC ligands impair
expression of NKG2D and T-cell activation. Nature 419: 734-8

116.

Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, Sanvito F,
Ponzoni M, Valentinis B, Bregni M, Prinetti A, Steffensen KR, Sonnino S,
Gustafsson JA, Doglioni C, Bordignon C, Traversari C, Russo V. 2010. Tumormediated liver X receptor-alpha activation inhibits CC chemokine receptor-7
expression on dendritic cells and dampens antitumor responses. Nat Med 16: 98105

117.

Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A,
Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC,
Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI. 2010. Lipid
accumulation and dendritic cell dysfunction in cancer. Nat Med

118.

Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. 1999. Antibodies to
vascular endothelial growth factor enhance the efficacy of cancer immunotherapy
by improving endogenous dendritic cell function. Clin Cancer Res 5: 2963-70

	
  

217
	
  
	
  

119.

Wrzesinski SH, Wan YY, Flavell RA. 2007. Transforming growth factor-beta and
the immune response: implications for anticancer therapy. Clin Cancer Res 13:
5262-70

120.

Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. 1997. Type
1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in
vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 159: 66473

121.

Fujii S, Shimizu K, Shimizu T, Lotze MT. 2001. Interleukin-10 promotes the
maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 98: 214351

122.

Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A,
Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA. 2004. Targeted inhibition
of galectin-1 gene expression in tumor cells results in heightened T cell-mediated
rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5: 24151

123.

Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T,
Van den Eynde BJ. 2003. Evidence for a tumoral immune resistance mechanism
based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:
1269-74

124.

Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. 2009. Inhibitors of
indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the
trees? Nat Rev Cancer 9: 445-52

125.

Terabe M, Berzofsky JA. 2004. Immunoregulatory T cells in tumor immunity.
Curr Opin Immunol 16: 157-62

126.

Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. 2009. Regulatory
T cells: how do they suppress immune responses? Int Immunol 21: 1105-11

127.

Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, McLaughlin N,
Yamaguchi T, Sakaguchi S, Darcy PK, Smyth MJ. 2010. Multiple antitumor
mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res
70: 2665-74

128.

DiLillo DJ, Matsushita T, Tedder TF. 2010. B10 cells and regulatory B cells
balance immune responses during inflammation, autoimmunity, and cancer. Ann
N Y Acad Sci 1183: 38-57

129.

Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI,
Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA. 2005. A nonclassical nonValpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for downregulation of tumor immunosurveillance. J Exp Med 202: 1627-33

	
  

218
	
  
	
  

130.

Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators
of the immune system. Nat Rev Immunol 9: 162-74

131.

Li H, Han Y, Guo Q, Zhang M, Cao X. 2009. Cancer-expanded myeloid-derived
suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
J Immunol 182: 240-9

132.

Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. 2010.
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine
and cysteine. Cancer Res 70: 68-77

133.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL,
Schneck J, Gabrilovich DI. 2007. Altered recognition of antigen is a mechanism
of CD8+ T cell tolerance in cancer. Nat Med 13: 828-35

134.

Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH.
2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development
of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.
Cancer Res 66: 1123-31

135.

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C,
Beschin A, De Baetselier P, Van Ginderachter JA. 2008. Identification of discrete
tumor-induced myeloid-derived suppressor cell subpopulations with distinct T
cell-suppressive activity. Blood 111: 4233-44

136.

Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou
W. 2005. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human
ovarian carcinoma. Cancer Res 65: 5020-6

137.

Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A,
Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D,
Caroll R, Coukos G. 2004. Tumor-infiltrating dendritic cell precursors recruited
by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.
Nat Med 10: 950-8

138.

Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. 2010. Induction of
lymphoidlike stroma and immune escape by tumors that express the chemokine
CCL21. Science 328: 749-52

139.

Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas
SK, Allavena P, Mantovani A. 2008. Macrophage polarization in tumour
progression. Semin Cancer Biol 18: 349-55

140.

Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi
D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D,
Cerottini JC, Romero P, Pittet MJ. 2004. Effector function of human tumor-

	
  

219
	
  
	
  

specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
Cancer Res 64: 2865-73
141.

Boshoff C, Weiss R. 2002. AIDS-related malignancies. Nat Rev Cancer 2: 373-82

142.

Frisch M, Biggar RJ, Engels EA, Goedert JJ. 2001. Association of cancer with
AIDS-related immunosuppression in adults. JAMA 285: 1736-45

143.

Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. 2007.
Elevated risk of lung cancer among people with AIDS. AIDS 21: 207-13

144.

Kirk GD, Merlo C, P OD, Mehta SH, Galai N, Vlahov D, Samet J, Engels EA.
2007. HIV infection is associated with an increased risk for lung cancer,
independent of smoking. Clin Infect Dis 45: 103-10

145.

Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law
M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. 2006. Cancer incidence
before and after kidney transplantation. JAMA 296: 2823-31

146.

Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. 2006.
A population-based study of skin cancer incidence and prevalence in renal
transplant recipients. Br J Dermatol 154: 498-504

147.

Penn I. 1996. Malignant melanoma in organ allograft recipients. Transplantation
61: 274-8

148.

Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, Liso V. 2009.
Spontaneous remission of "methotrexate-associated lymphoproliferative
disorders" after discontinuation of immunosuppressive treatment for autoimmune
disease. Review of the literature. Med Oncol 26: 1-9

149.

Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ. 1976. Cell surface
antigens of human malignant melanoma: mixed hemadsorption assays for
humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U
S A 73: 3278-82

150.

Ueda R, Shiku H, Pfreundschuh M, Takahashi T, Li LT, Whitmore WF, Oettgen
HF, Old LJ. 1979. Cell surface antigens of human renal cancer defined by
autologous typing. J Exp Med 150: 564-79

151.

Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. 2009. A systematic
review of humoral immune responses against tumor antigens. Cancer Immunol
Immunother 58: 1535-44

152.

Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter
G, Old LJ, Knuth A. 1999. Humoral immune responses of cancer patients against
"Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer
84: 506-10
220
	
  
	
  

	
  

153.

Soussi T. 2000. p53 Antibodies in the sera of patients with various types of
cancer: a review. Cancer Res 60: 1777-88

154.

Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend
T. 1993. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes
from a human regressive melanoma. Evidence for in situ T cell clonal expansion.
J Clin Invest 91: 1183-90

155.

Zorn E, Hercend T. 1999. A natural cytotoxic T cell response in a spontaneously
regressing human melanoma targets a neoantigen resulting from a somatic point
mutation. Eur J Immunol 29: 592-601

156.

Knuth A, Danowski B, Oettgen HF, Old LJ. 1984. T-cell-mediated cytotoxicity
against autologous malignant melanoma: analysis with interleukin 2-dependent Tcell cultures. Proc Natl Acad Sci U S A 81: 3511-5

157.

Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki
RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ. 2003. Survey of naturally
occurring CD4+ T cell responses against NY-ESO-1 in cancer patients:
correlation with antibody responses. Proc Natl Acad Sci U S A 100: 8862-7

158.

Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee
SY, Jungbluth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT,
Old LJ, Knuth A. 2000. Monitoring CD8 T cell responses to NY-ESO-1:
correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A
97: 4760-5

159.

Griffioen M, Borghi M, Schrier PI, Osanto S. 2001. Detection and quantification
of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides
by the IFN-gamma-ELISPOT assay. Int J Cancer 93: 549-55

160.

Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F,
Fleischhauer K, Cerundolo V, Cerottini JC, Romero P. 1999. High frequencies of
naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human
histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190: 70515

161.

Albert ML, Darnell RB. 2004. Paraneoplastic neurological degenerations: keys to
tumour immunity. Nat Rev Cancer 4: 36-44

162.

Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. 1998.
Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4:
1321-4

163.

Mathew RM, Cohen AB, Galetta SL, Alavi A, Dalmau J. 2006. Paraneoplastic
cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up
with FDG-PET. J Neurol Sci 250: 153-5

	
  

221
	
  
	
  

164.

Darnell RB, DeAngelis LM. 1993. Regression of small-cell lung carcinoma in
patients with paraneoplastic neuronal antibodies. Lancet 341: 21-2

165.

Horino T, Takao T, Yamamoto M, Geshi T, Hashimoto K. 2006. Spontaneous
remission of small cell lung cancer: a case report and review in the literature.
Lung Cancer 53: 249-52

166.

Clark WH, Jr., Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D,
Synnestvedt M, Halpern AC. 1989. Model predicting survival in stage I
melanoma based on tumor progression. J Natl Cancer Inst 81: 1893-904

167.

Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N.
1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth
phase of primary cutaneous melanoma. Cancer 77: 1303-10

168.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G,
Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G.
2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N
Engl J Med 348: 203-13

169.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina
D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT,
Ohtani H, Old LJ, Odunsi K. 2005. Intraepithelial CD8+ tumor-infiltrating
lymphocytes and a high CD8+/regulatory T cell ratio are associated with
favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-43

170.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. 1998.
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human
colorectal cancer. Cancer Res 58: 3491-4

171.

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B,
Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH,
Trajanoski Z, Fridman WH, Galon J. 2005. Effector memory T cells, early
metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-66

172.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc
PH, Trajanoski Z, Fridman WH, Pages F. 2006. Type, density, and location of
immune cells within human colorectal tumors predict clinical outcome. Science
313: 1960-4

173.

Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal
J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza
LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G,
Connors JM, Staudt LM, Chan WC, Gascoyne RD. 2010. Tumor-associated
macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:
875-85

	
  

222
	
  
	
  

174.

Scanlan MJ, Simpson AJ, Old LJ. 2004. The cancer/testis genes: review,
standardization, and commentary. Cancer Immun 4: 1

175.

van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp
BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ, Oudejans
JJ. 2008. Favorable outcome in clinically stage II melanoma patients is associated
with the presence of activated tumor infiltrating T-lymphocytes and preserved
MHC class I antigen expression. Int J Cancer 123: 609-15

176.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan
M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B,
Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 2004.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune
privilege and predicts reduced survival. Nat Med 10: 942-9

177.

Hiraoka N, Onozato K, Kosuge T, Hirohashi S. 2006. Prevalence of FOXP3+
regulatory T cells increases during the progression of pancreatic ductal
adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-34

178.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta
B. 2009. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic
significance in colorectal cancer. J Clin Oncol 27: 186-92

179.

Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri
V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E. 2006.
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and
neck cancers. Clin Cancer Res 12: 465-72

180.

Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel
Doeberitz M, Kloor M. 2005. Microsatellite instability in colorectal cancer is
associated with local lymphocyte infiltration and low frequency of distant
metastases. Br J Cancer 92: 1746-53

181.

Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N,
Macri E, Fornasarig M, Boiocchi M. 1999. High prevalence of activated
intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in
colorectal carcinomas with microsatellite instability. Am J Pathol 154: 1805-13

182.

Nakata B, Wang YQ, Yashiro M, Nishioka N, Tanaka H, Ohira M, Ishikawa T,
Nishino H, Hirakawa K. 2002. Prognostic value of microsatellite instability in
resectable pancreatic cancer. Clin Cancer Res 8: 2536-40

183.

Callaway MP, Briggs JC. 1989. The incidence of late recurrence (greater than 10
years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast
Surg 42: 46-9

	
  

223
	
  
	
  

184.

Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G,
Schlimok G. 2001. Disseminated cytokeratin positive tumor cells in the bone
marrow of patients with prostate cancer: detection and prognostic value. J Urol
166: 699-703

185.

Karrison TG, Ferguson DJ, Meier P. 1999. Dormancy of mammary carcinoma
after mastectomy. J Natl Cancer Inst 91: 80-5

186.

Sagalowsky AI, Molberg K. 1999. Solitary metastasis of renal cell carcinoma to
the contralateral adrenal gland 22 years after nephrectomy. Urology 54: 162

187.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD,
Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D,
Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. 2004. Circulating
tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10: 8152-62

188.

Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza
AM. 2002. Transplant tumor registry: donor related malignancies.
Transplantation 74: 358-62

189.

MacKie RM, Reid R, Junor B. 2003. Fatal melanoma transferred in a donated
kidney 16 years after melanoma surgery. N Engl J Med 348: 567-8

190.

Dhodapkar MV. 2005. Immune response to premalignancy: insights from patients
with monoclonal gammopathy. Ann N Y Acad Sci 1062: 22-8

191.

Dhodapkar MV, Krasovsky J, Osman K, Geller MD. 2003. Vigorous
premalignancy-specific effector T cell response in the bone marrow of patients
with monoclonal gammopathy. J Exp Med 198: 1753-7

192.

Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. 1998. Anti-idiotype
antibodies can induce long-term complete remissions in non-Hodgkin's
lymphoma without eradicating the malignant clone. Blood 92: 1184-90

193.

Medzhitov R. 2008. Origin and physiological roles of inflammation. Nature 454:
428-35

194.

Balkwill F, Mantovani A. 2001. Inflammation and cancer: back to Virchow?
Lancet 357: 539-45

195.

Bui JD, Schreiber RD. 2007. Cancer immunosurveillance, immunoediting and
inflammation: independent or interdependent processes? Curr Opin Immunol 19:
203-8

196.

Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M,
Iwakura Y, Segal S, Dinarello CA, Apte RN. 2007. Interleukin-1beta-driven
inflammation promotes the development and invasiveness of chemical
carcinogen-induced tumors. Cancer Res 67: 1062-71
224
	
  
	
  

	
  

197.

Betts G, Twohig J, Van den Broek M, Sierro S, Godkin A, Gallimore A. 2007.
The impact of regulatory T cells on carcinogen-induced sarcogenesis. Br J Cancer
96: 1849-54

198.

Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M.
2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent
IL-6 production. Science 317: 121-4

199.

Rakoff-Nahoum S, Medzhitov R. 2007. Regulation of spontaneous intestinal
tumorigenesis through the adaptor protein MyD88. Science 317: 124-7

200.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G,
Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ,
Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, ClavelChapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L.
2007. Toll-like receptor 4-dependent contribution of the immune system to
anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-9

201.

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo
M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P,
Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. 2007. Calreticulin exposure
dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61

202.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K,
Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl
M, Genin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, Andre F, Lidereau R,
McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L. 2009.
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat Med 15: 1170-8

203.

Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW,
Ohashi PS. 2007. TNF-alpha is critical for antitumor but not antiviral T cell
immunity in mice. J Clin Invest 117: 3833-45

204.

Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG,
Robinson SC, Balkwill FR. 2008. "Re-educating" tumor-associated macrophages
by targeting NF-kappaB. J Exp Med 205: 1261-8

205.

Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner
R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L,
Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S,
McCoon P, Cao ZA, Yu H, Jove R, Zinda M. 2009. The JAK2 inhibitor
AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Cancer Cell 16: 487-97

206.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh

	
  

225
	
  
	
  

AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH,
Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ,
Nichol GM, Hoos A, Urba WJ. 2010. Improved Survival with Ipilimumab in
Patients with Metastatic Melanoma. N Engl J Med
207.

Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G,
Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM.
1998. Tumor cell responses to IFNgamma affect tumorigenicity and response to
IL-12 therapy and antiangiogenesis. Immunity 9: 25-34

208.

Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilcek J,
Zinkernagel RM, Aguet M. 1993. Immune response in mice that lack the
interferon-gamma receptor. Science 259: 1742-5

209.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den
Eynde B, Knuth A, Boon T. 1991. A gene encoding an antigen recognized by
cytolytic T lymphocytes on a human melanoma. Science 254: 1643-7

210.

Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C,
Reddehase MJ, Lejeune J, Boon T. 1989. Structure of the gene of tumtransplantation antigen P91A: the mutated exon encodes a peptide recognized
with Ld by cytolytic T cells. Cell 58: 293-303

211.

Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. 1991. The gene
coding for a major tumor rejection antigen of tumor P815 is identical to the
normal gene of syngeneic DBA/2 mice. J Exp Med 173: 1373-84

212.

Urban JL, Holland JM, Kripke ML, Schreiber H. 1982. Immunoselection of tumor
cell variants by mice suppressed with ultraviolet radiation. J Exp Med 156: 102541

213.

Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P,
Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L,
Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B,
Kinzler KW, Velculescu VE. 2006. The consensus coding sequences of human
breast and colorectal cancers. Science 314: 268-74

214.

Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B,
Allison JP. 2008. Epitope landscape in breast and colorectal cancer. Cancer Res
68: 889-92

215.

Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M.
1994. Functional role of type I and type II interferons in antiviral defense. Science
264: 1918-21

	
  

226
	
  
	
  

216.

Li H, Durbin R. 2009. Fast and accurate short read alignment with BurrowsWheeler transform. Bioinformatics 25: 1754-60

217.

Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER,
Weinstock GM, Wilson RK, Ding L. 2009. VarScan: variant detection in
massively parallel sequencing of individual and pooled samples. Bioinformatics
25: 2283-5

218.

Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S,
Brunak S, Lund O. 2003. Reliable prediction of T-cell epitopes using neural
networks with novel sequence representations. Protein Sci 12: 1007-17

219.

Ranganath S, Ouyang W, Bhattarcharya D, Sha WC, Grupe A, Peltz G, Murphy
KM. 1998. GATA-3-dependent enhancer activity in IL-4 gene regulation. J
Immunol 161: 3822-6

220.

Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N,
Stratton MR. 2004. A census of human cancer genes. Nat Rev Cancer 4: 177-83

221.

Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A,
Teague J, Futreal PA, Stratton MR, Wooster R. 2004. The COSMIC (Catalogue
of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-8

222.

Chen AC, Herschman HR. 1989. Tumorigenic methylcholanthrene transformants
of C3H/10T1/2 cells have a common nucleotide alteration in the c-Ki-ras gene.
Proc Natl Acad Sci U S A 86: 1608-11

223.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL,
Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA,
Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. 2004. Endogenous
oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and
developmental defects. Cancer Cell 5: 375-87

224.

Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP,
Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT,
Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T. 2007.
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat
Med 13: 992-7

225.

Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D,
Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE,
Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner
T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X,
Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE,
Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon
WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK.

	
  

227
	
  
	
  

2008. DNA sequencing of a cytogenetically normal acute myeloid leukaemia
genome. Nature 456: 66-72
226.

Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt
DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ,
Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael
L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE,
Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis
JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J,
Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J,
Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA,
DiPersio JF, Wilson RK, Ley TJ. 2009. Recurring mutations found by sequencing
an acute myeloid leukemia genome. N Engl J Med 361: 1058-66

227.

Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan
MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC,
Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF,
Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K,
Davies S, Guintoli T, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF,
Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS,
Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert
ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE,
O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson
DM, Jr., Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson
M, Ley TJ, Wilson RK, Mardis ER. 2010. Genome remodelling in a basal-like
breast cancer metastasis and xenograft. Nature 464: 999-1005

228.

Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A,
Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G,
Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol
R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA,
Aparicio S. 2009. Mutational evolution in a lobular breast tumour profiled at
single nucleotide resolution. Nature 461: 809-13

229.

Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP,
Bhatt D, Ha C, Johnson S, Kennemer MI, Mohan S, Nazarenko I, Watanabe C,
Sparks AB, Shames DS, Gentleman R, de Sauvage FJ, Stern H, Pandita A,
Ballinger DG, Drmanac R, Modrusan Z, Seshagiri S, Zhang Z. 2010. The
mutation spectrum revealed by paired genome sequences from a lung cancer
patient. Nature 465: 473-7

230.

Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin
ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR,
Ordonez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy
C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA,
McLaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD, Gazdar
A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal PA, Campbell PJ.
228
	
  
	
  

	
  

2010. A small-cell lung cancer genome with complex signatures of tobacco
exposure. Nature 463: 184-90
231.

Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsutsumi S,
Sonoda K, Totsuka H, Shirakihara T, Sakamoto H, Wang L, Ojima H, Shimada
K, Kosuge T, Okusaka T, Kato K, Kusuda J, Yoshida T, Aburatani H, Shibata T.
2011. High-resolution characterization of a hepatocellular carcinoma genome. Nat
Genet 43: 464-9

232.

Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis
G, Jares P, Bea S, Gonzalez-Diaz M, Bassaganyas L, Baumann T, Juan M, LopezGuerra M, Colomer D, Tubio JM, Lopez C, Navarro A, Tornador C, Aymerich M,
Rozman M, Hernandez JM, Puente DA, Freije JM, Velasco G, GutierrezFernandez A, Costa D, Carrio A, Guijarro S, Enjuanes A, Hernandez L, Yague J,
Nicolas P, Romeo-Casabona CM, Himmelbauer H, Castillo E, Dohm JC, de
Sanjose S, Piris MA, de Alava E, San Miguel J, Royo R, Gelpi JL, Torrents D,
Orozco M, Pisano DG, Valencia A, Guigo R, Bayes M, Heath S, Gut M, Klatt P,
Marshall J, Raine K, Stebbings LA, Futreal PA, Stratton MR, Campbell PJ, Gut I,
Lopez-Guillermo A, Estivill X, Montserrat E, Lopez-Otin C, Campo E. 2011.
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic
leukaemia. Nature 475: 101-5

233.

Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ,
Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J,
Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, KokkoGonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T,
Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce
T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J,
Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton
MR. 2010. A comprehensive catalogue of somatic mutations from a human
cancer genome. Nature 463: 191-6

234.

Yewdell JW. 2006. Confronting complexity: real-world immunodominance in
antiviral CD8+ T cell responses. Immunity 25: 533-43

235.

Foley EJ. 1953. Antigenic properties of methylcholanthrene-induced tumors in
mice of the strain of origin. Cancer Res 13: 835-7

236.

Prehn RT, Main JM. 1957. Immunity to methylcholanthrene-induced sarcomas. J
Natl Cancer Inst 18: 769-78

237.

Old LJ, Boyse EA. 1964. Immunology of Experimental Tumors. Annu Rev Med
15: 167-86

238.

Ikeda H, Ohta N, Furukawa K, Miyazaki H, Wang L, Kuribayashi K, Old LJ,
Shiku H. 1997. Mutated mitogen-activated protein kinase: a tumor rejection
antigen of mouse sarcoma. Proc Natl Acad Sci U S A 94: 6375-9

	
  

229
	
  
	
  

239.

Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. 1991.
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:
561-9

240.

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG,
Golstein P. 1987. A new member of the immunoglobulin superfamily--CTLA-4.
Nature 328: 267-70

241.

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP,
Thompson CB, Griesser H, Mak TW. 1995. Lymphoproliferative disorders with
early lethality in mice deficient in Ctla-4. Science 270: 985-8

242.

Ise W, Kohyama M, Nutsch KM, Lee HM, Suri A, Unanue ER, Murphy TL,
Murphy KM. 2010. CTLA-4 suppresses the pathogenicity of self antigen-specific
T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 11: 129-35

243.

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z,
Nomura T, Sakaguchi S. 2008. CTLA-4 control over Foxp3+ regulatory T cell
function. Science 322: 271-5

244.

Egen JG, Kuhns MS, Allison JP. 2002. CTLA-4: new insights into its biological
function and use in tumor immunotherapy. Nat Immunol 3: 611-8

245.

Peggs KS, Quezada SA, Allison JP. 2008. Cell intrinsic mechanisms of T-cell
inhibition and application to cancer therapy. Immunol Rev 224: 141-65

246.

Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. 1999. In vivo
blockade of CTLA-4 enhances the priming of responsive T cells but fails to
prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S
A 96: 11476-81

247.

Shrikant P, Khoruts A, Mescher MF. 1999. CTLA-4 blockade reverses CD8+ T
cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
Immunity 11: 483-93

248.

Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM,
Burg MB, Allison JP. 1997. Manipulation of T cell costimulatory and inhibitory
signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 94:
8099-103

249.

Leach DR, Krummel MF, Allison JP. 1996. Enhancement of antitumor immunity
by CTLA-4 blockade. Science 271: 1734-6

250.

van Elsas A, Hurwitz AA, Allison JP. 1999. Combination immunotherapy of B16
melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and
granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines

	
  

230
	
  
	
  

induces rejection of subcutaneous and metastatic tumors accompanied by
autoimmune depigmentation. J Exp Med 190: 355-66
251.

Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ,
Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral
infection. Nature 439: 682-7

252.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement
of PD-L1 on tumor cells in the escape from host immune system and tumor
immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99: 12293-7

253.

Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D,
Cheville J, Hirano F, Lin W, Kasperbauer JL, Ballman KV, Chen L. 2003. B7-H1
blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Cancer Res 63: 6501-5

254.

Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies
DB, Lau JS, Zhu G, Tamada K, Chen L. 2005. Blockade of B7-H1 and PD-1 by
monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:
1089-96

255.

Curran MA, Montalvo W, Yagita H, Allison JP. 2010. PD-1 and CTLA-4
combination blockade expands infiltrating T cells and reduces regulatory T and
myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107: 427580

256.

Zang X, Allison JP. 2007. The B7 family and cancer therapy: costimulation and
coinhibition. Clin Cancer Res 13: 5271-9

257.

Edelson BT, Kc W, Juang R, Kohyama M, Benoit LA, Klekotka PA, Moon C,
Albring JC, Ise W, Michael DG, Bhattacharya D, Stappenbeck TS, Holtzman MJ,
Sung SS, Murphy TL, Hildner K, Murphy KM. 2010. Peripheral CD103+
dendritic cells form a unified subset developmentally related to CD8alpha+
conventional dendritic cells. J Exp Med 207: 823-36

258.

Chambers CA, Kuhns MS, Egen JG, Allison JP. 2001. CTLA-4-mediated
inhibition in regulation of T cell responses: mechanisms and manipulation in
tumor immunotherapy. Annu Rev Immunol 19: 565-94

259.

Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA,
Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood
M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. 2008. CTLA-4
blockade enhances polyfunctional NY-ESO-1 specific T cell responses in
metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105:
20410-5

	
  

231
	
  
	
  

260.

Callahan MK, Wolchok JD, Allison JP. 2010. Anti-CTLA-4 antibody therapy:
immune monitoring during clinical development of a novel immunotherapy.
Semin Oncol 37: 473-84

261.

Stratton MR. 2011. Exploring the genomes of cancer cells: progress and promise.
Science 331: 1553-8

262.

Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM,
Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T,
Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J,
Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH,
Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh
E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW,
Velculescu VE, Vogelstein B. 2007. The genomic landscapes of human breast and
colorectal cancers. Science 318: 1108-13

263.

Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458:
719-24

	
  

232
	
  
	
  

